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Abstract 
 
A novel lipid modifying enzyme, lysophosphatidylcholine acyltransferase (LPCAT), 
has been shown to regulate pro-inflammatory cytokine responses to 
lipopolysaccharide (LPS), a key molecule in initiating sepsis. Current research has 
shown that phospholipid metabolism may influence cell signalling, since that is 
dependent on the clustering of the receptor molecules into membrane microdomains 
(lipid rafts). LPCAT therefore, may be a target for novel anti-sepsis therapies.  
 
This study aimed to determine if LPCAT is essential in the regulation of pro-
inflammatory cytokine responses to Gram-positive cell bacterial components, such as 
peptidoglycan (PG), lipoteichoic acid (LTA) and synthetic tripalmitoylated 
lipopeptide Pam3CSK4 in monocytes and lung epithelial cells. Inhibition of LPCAT 
activity consistently reduced TNF-α, IL-6 and IL-8 protein and mRNA levels in 
monocytes stimulated with all microbial ligands tested. Furthermore, cytokine 
production observed in monocytes primed with IFN-γ prior to ligand stimulation was 
twice that seen in unprimed cells, yet still inhibition of LPCAT significantly 
decreased the amplified inflammatory response. Lung epithelial cells, BEAS-2B, 
were more immunologically responsive to Pam3CSK4 where it consistently induced a 
high secretion of IL-8 and IL-6. However, whilst inhibition of LPCAT demonstrated 
a reduction in cytokine secretion, it was not a predominant as observed in monocytes 
indicating that LPCAT may have a lesser role in these cells. 
 
The secondary aim was to characterise the expression levels of 5 LPCAT enzymes in 
diverse cell types to ascertain if there is differential expression of the LPCATs, which 
may help to explain the altered effects that LPCAT inhibition produces on 
inflammatory cytokine production between cell types. Data in this report did not 
demonstrate one particular LPCAT iso-form to be highly expressed by monocytes, 
however literature has suggested that LPCAT2 might be the enzyme to modulate the 
inducible phospholipid remodeling pathways in innate immune cells. Further studies 
on inducible LPCAT expression in human cell lines is required to support these ideas. 
 
Previous studies have observed LPCAT to regulate translocation of TLR4 into 
membrane lipid raft domains and subsequent down-stream inflammatory responses. 
Although the translocation of TLR2 into membrane lipid rafts has been researched, its 
regulation by LPCAT has not, thus it was investigated in this study. Complications 
with experiments, however, did not allow this to be adequately assessed but, literature 
suggests this is the likely mechanism that LPCAT elicits its immuno-regulatory effect 
in response to microbial stimuli. 
 
The present study provided evidence that LPCAT influences the complex network of 
cell signalling involved in microbial responses, underlying it’s importance in 
inflammatory responses and potentially offering a target for novel anti-sepsis 
therapies.   
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1.1 A Summary of the Innate and Adaptive Immune Systems 
The human body is under constant attack from foreign invaders, such as microbes and 
multicellular organisms, yet encounters with these infectious agents rarely result in 
disease. The body has evolved a sophisticated mechanism known as immunity, to 
protect itself from such invaders, including disease causing microbes termed 
pathogens. The immune system is the collection of cells, tissues and molecules that 
protects the body from numerous pathogenic microbes and toxins in the environment. 
This defence against pathogens has been divided into two types of responses: innate 
immunity and adaptive immunity. The innate immune system is the first line of 
defence against pathogens and consists of cells and proteins that are always present 
and ready to mobilize and fight microbes at the site of infection. The main 
components of innate immunity are physical epithelial barriers, phagocytic 
leukocytes, dendritic cells (DCs), natural killer cells (NK) and circulating 
complement proteins and lysozymes (Akira et al., 2006). The adaptive immune 
system is very dependent upon the innate immune system to receive guidance on 
what to respond against and what not to respond against thus is involved in the 
elimination of pathogens in the later phases of infection. Components of the adaptive 
immune system are normally dormant, however, when activated these components 
“adapt” to the presence of infectious agents by activating, proliferating and creating 
potent mechanisms for neutralizing or eliminating pathogens (Riedemann et al., 
2003). 
 
The innate immune system has a major role to recognise pathogens for removal via 
phagocytic cells, such as monocytes, macrophages and neutrophils. For over 50 years 
immunologists have based views, experiments and clinical treatments on the theory 
that the immune system functions by discriminating between “self” and “non-self”, 
with leukocytes responding to any molecules they identify as foreign and no immune 
response triggered against self-constituents (Burnet and Fenner, 1949; Burnet, 1969; 
Tauber, 1994). This model has assisted the area of research well and helped to 
characterise pattern-recognition receptors (PRRs) present on phagocytes for the 
identification of microbial components, known as pathogen-associated molecular 
patterns (PAMPs) (Janway, 1989, 1992). However, years of detailed examination 
have revealed a number of inherent problems with the self-non-self theory and 
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questions, such as how does the immune system tolerate commensal microorganisms 
or why do some self-derived molecules trigger immune responses, arose? 
 
Aside from infection, there is a growing recognition that tissue damage, leading to 
non-physiological cell death, can also provoke activation of the immune system. 
More recently, Polly Matzinger suggested an opposing theory, called the “danger 
theory” (Matzinger, 1994, 2001, 2002). The danger model suggests that the immune 
system will respond to molecules that enter the body and cause damage, activating the 
damaged tissues to release immune-stimulating alarm signals. These danger or alarm 
signals, termed danger-associated molecular patterns (DAMPs), are self-derived 
molecules normally found within healthy cells, but are detected in extracellular space 
when they are released by cells that die via an uncontrolled mode of cell death, called 
necrosis. Thus the model proposes that self-constituents can trigger an immune 
response if they are dangerous (e.g. cellular stress) and non-self constituents can be 
tolerated if they are not dangerous (e.g. commensal bacteria). HMGB1, a chromatin-
binding prtein, interleukin-1α (IL-1α) and interleukin-33 (IL-33) are DAMPs known 
to activate the immune system (Matzinger, 2012). The scientific community has now 
accepted that recognition of both PAMPs and DAMPs may act synergistically to 
provoke more robust and effective immune responses than would occur in response to 
either alone (Pradeu and Cooper, 2012).  
 
A major player in the initiation of innate immune responses is the macrophage. These 
cells are relatively abundant in most tissues and patrol the environment around them, 
looking for infectious agents through an array of pattern recognition receptors 
(PRRs). PRRs such as Toll-like receptors (TLRs) recognize both small, conserved 
structural components of pathogens (PAMPs) and self-derived DAMPs (Batista and 
Harwood, 2009). When activated, these receptors cause the stimulating PAMP to be 
endocytosed and cause multiple changes within the macrophage. Firstly the 
macrophage increases its ability to engulf and kill any microorganism it encounters. 
Secondly it begins to secrete cytokines and chemokines that have immediate effect on 
nearby endothelial cells lining the blood capillaries to make them more permeable. 
The increased vascular permeability allows plasma proteins and neutrophils that are 
normally restricted to the blood (due to their potentially destructive behaviour) to 
infiltrate the tissue at the site of infection (Harwood and Batista, 2010).  
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Dendritic cells (DCs) also express PRRs on their surface to recognise invading 
microorangisms, but unlike macrophages, DCs do not stand and fight pathogens 
directly. Instead DCs play a key role in awakening the adaptive immune systems as 
antigen presenting cells (APCs) (Janeway, 2001). Activated DCs endocytosed the 
PAMP, break it down into peptides and display the antigen on its surface via MHC II 
molecules. The APC then synthesizes additional surfaces molecules that will act as 
co-stimulators for the activation of T lymphocytes in the adaptive immune system 
(Kinashi, 2005).  
 
The adaptive immune system is characterized by specificity and can develop humoral 
and cell-mediated responses, as well as the generation of immunological memory 
(Remick, 2003). The main components of adaptive immunity are B cells which 
mature into antibody secreting plasma cells that target antigens for destruction 
(humoral response) and T cells which mature into effector helper cells and cytotoxic 
T cells (cell-mediated response). Effective communication and coordination between 
innate and adaptive immunity, facilitated through multiple intermediaries and 
complex pathways, is vital for maximal protection against invading pathogens. 
Activated cytotoxic T cells (and NK cells) directly kill infected cells but helper T 
cells secrete cytokines that help plasma cells to mount potent antibody responses and 
assist macrophages in killing phagocytosed microbe (Smith-Garvin et al., 2009). 
Thus non-lymphoid leukocytes such as macrophages participate in the elimination of 
microbes in both the innate and adaptive immune responses. 
 
1.2 A Summary of Inflammatory Responses 
Inflammation is a term given to the series of events that surround an immune 
response and display a number of characteristics. In the early stages of an immune 
response, neutrophils are the predominant cell type infiltrating the tissue. Neutrophils, 
like macrophages, are capable of phagocytising invading pathogens through their 
PRRs, attacking and engulfing any microorganism it encounters with gusto (Van der 
Poll and Opal, 2008). An influx of activated macrophages, neutrophils and mast cells, 
further amplify the immune response through the release of cytokines, chemokines, 
complement fragments, histamine and prostaglandins. Release of these inflammatory 
mediators activate the coagulation and complement cascades, which in turn promote 
localised edema, increased capillary permeability, blood flow and vasodilation to the 
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affected area of injury and trigger the influx of more leukocytes to the site of injury to 
kill pathogens and remove cellular debris (Cohen, 2002). But subsequently this tissue 
trauma results in an elevated temperature, swelling, redness and painful area on the 
skin that is characteristic of an inflammatory response. The features of inflammation 
are the collective consequence of the actions of the inflammatory mediators that 
trigger vascular permeability and chemotaxis, with the extra fluid that gathers at the 
site of an infection contributing to the swelling seen and increasing redness of the 
skin tone (Carlet et al., 2008). 
 
Whilst inflammatory mediators orchestrate a complex network of immune responses 
designed to limit the spread of infection, they can also trigger localised tissue 
damage. The vasoactive amino acid histamine, released by activated mast cells, is 
instrumental in provoking increased permeability of blood vessels, which in turn 
causes the subsequent migration of neutrophils.  Histamine also up-regulates platelet-
activating factor and P-selectin expression on vascular endothelial cells, which 
instigates downstream diapedesis of neutrophils into the tissue (Van der Poll and 
Opal, 2008). Activation of neutrophils and macrophages release a number of 
cytokines, such as interleukin-1β (IL-1β), interleukin-6 (IL-6) interleukin-8 (IL-8) 
and tumour necrosis factor-alpha (TNF-α) that cause neutrophils to actively produce a 
host of cytotoxic substances, including reactive oxygen species, such as superoxide 
anions, hypochloride, and nitric oxide (NO) (Akira et al., 2006).  
 
Small peptide components from the complement cascade, C3a and C5a, also act 
directly on neutrophils and macrophages to stimulate respiratory burst during 
phagocytosis and the subsequent release of more reactive oxygen intermediates, 
including hydrogen peroxide via activation of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (Bosmann and Ward, 2013). These factors all lead to up 
to damaged vascular endothelium which triggers the blood coagulation and 
fibrinolysis pathways, promoting tissue factor expression that enhances the 
production of thrombin and fibrin. However, if fibrin production is increased 
significantly, clots can be deposited in small blood vessels and deprive vital organs of 
oxygen (Glauser et al., 1991; Cohen, 2002). 
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Although the inflammatory response is a normal, protective part of immunity that 
helps to prevent infection, if the duration and intensity are not effectively regulated 
and tissue damage is not limited, it can lead to a response that is more harmful than 
protective. Complement regulatory proteins, transforming growth factor-β (TGF-β) 
and glucocorticoids, to name just a few are powerful regulators that prevent 
inflammation from getting out of hand. However, the case in chronic inflammatory 
responses such as sepsis, inflammation becomes amplified and dysregulated, where 
the response leads to systemic rather than localised effects. 
 
1.3 Sepsis and the dysregulation of the inflammatory responses  
Sepsis is a complicated clinical syndrome arising as a consequence of a 
predominantly cytokine-mediated hyper-inflammatory state, referred to as systemic 
inflammatory response syndrome (SIRS), which can lead to multiple organ failure 
and ultimately death (Heumann et al., 1996). Microbial PAMPs such as Gram-
negative bacterial lipopolysaccharide (LPS) activate macrophages, neutrophils and 
endothelial cells to release excessive quantities of tumour necrosis factor-alpha (TNF-
α), interleukin-1 (IL-1β) and interleukin-6 (IL-6) (Cavaillon, 2003). Whilst release of 
these pro-inflammatory cytokines would normally enhance host defences by initiating 
multiple cascades, in sepsis, the homeostatic mechanisms controlling these 
inflammatory pathways become dysregulated and result in an accumulation of 
neutrophils in tissues, systemic inflammation and unwanted pathophysiological states 
at locations away from site of injury (Akira et al., 2006).  
 
A major contribution of elevated LPS-induced inflammatory responses may be the 
priming of Interferon-gamma (IFN-γ) to enhance the activation state in monocytes 
and macrophages (Silva & Cohen 1992; Heinzel, 1990; Doherty et al., 1992). IFN-γ 
has shown to sensitise macrophages to become hyper-activated upon subsequent 
exposure to LPS and produce excessive inflammatory mediators including TNFα and 
IL-1β (Figure 1.1) (Katschinski et al., 1992; Billiau et al., 1987). Increased plasma 
levels of IL-1, TNF-α and IFN-γ correlate highly with rates of mortality, illustrating 
the detrimental effect generated by overexpression of these cytokines (Remick, 2003). 
 
Although during normal inflammatory responses, activated neutrophils and 
macrophages generate substantial amounts of reactive oxygen species (ROS) which 
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can react with a variety of targets, in sepsis, additional amounts of ROS are released 
and can be damaging to cells and organs. Excessive ROS are known to induce 
biochemical changes that lead to an imbalance in the redox system, resulting in the 
formation of an oxidant state (Glauser et al., 1991). There is evidence that the 
production of antioxidant enzymes required to regulate these pathways is impaired 
during sepsis, which appears to intensify SIRS and the downstream events (Bosmann 
and Ward, 2013). In sepsis, the coagulation pathways are also enhanced inducing 
increased tissue factor that leads to amplified production, but reduced removal of 
fibrin (Philippart and Cavaillon, 2007). The accumulation of fibrin and the disturbed 
homeostatic balance between procoagulant and anticoagulant mechanisms, causes the 
deposition of fibrin clots in small blood vessels, that in turn deprives vital organs of 
an adequate oxygenated blood supply (Ward, 2004).  
 
In the later stages of sepsis there is evidence of progressive functional deterioration 
and dysfunction of activated phagocytes and dendritic cells (DCs), which results in 
degraded innate immune functions such their ability to kill phagocytized pathogens. 
This also results in diminished adaptive immune responses as macrophages and DCs 
have impaired antigen presentation to T cells. Thus the hyper-inflammatory state, 
together with impaired innate immune functions of phagocytes and 
immunosuppression is not adequate enough to contain commensal bacterial which 
contributes further to pathogenesis of sepsis (Bosmann and Ward, 2013). 
 
In this manner, complement activation products together with the release of excessive 
pro-inflammatory cytokines by macrophages, neutrophils and dendritic cells 
contribute to poor myocardial contractility, impaired peripheral vascular tone, 
microvascular occlusion, tissue hypoperfusion and inadequate organ oxygenation and 
potentially leads to multiple systemic organ failure and lethality of sepsis (Figure 
1.2). 
  
   
Jenny Hughes    Chapter 1: Introduction 
 8 
 
 Pleiotropic activity of Interferon gamma Figure 1.1
Interferon gamma (IFN-γ) is secreted by TH1 cells, NK cells and TC cells and acts on numerous cell types. The activation of macrophages 
induced by IFN-γ plays a critical role in chronic inflammation. [Adapted from Research News, 1993, Science 259:1693] (Remick, 2003).
Redacted due to copyright
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 Macrophage activation and pathophysiology of sepsis Figure 1.2
Lipopolysaccharide (LPS) and other microbial components simultaneously activate 
multiple parallel cascades that contribute to the pathophysiology of sepsis. The 
combination of poor myocardial contractility, impaired peripheral vascular tone and 
microvascular occlusion leads to tissue hypoperfusion and inadequate oxygenation, 
and thus to organ failure. (Figure adapted from Cohen, 2002). 
 
  
Redacted due to copyright
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1.4 Sepsis epidemiology and mortality rates 
Currently, there are no specific therapeutic interventions to treat sepsis as no single 
treatment strategy has effectively managed the condition, thus it has a high mortality 
rate (Glauser, 2000). Severe sepsis (sepsis associated with acute organ dysfunction) is 
a huge and expensive medical problem throughout the world. In North America, it is 
estimated that there are more than 600,000 cases of severe sepsis annually, with 
mortality rate ranging between 30 % and 50 % (Angus and Linde-Zwirble, 2001). 
 
Current estimates of severe sepsis in the UK are derived from adult critical-care units 
in the Intensive Care National Audit & Research Centre (ICNARC) Case Mix 
Programme (CMP) Database (National Collaborating Centre for Cancer, 2012). 
These indicate an increasing treated incidence of severe sepsis in critical care, rising 
from 50 to 70 cases per 100,000 population per year over the last decade. This now 
represents approximately 31,000 critical-care unit patient episodes per year. Similarly 
high incidence rates have been reported elsewhere (Linde-Zwirble and Angus, 2004; 
Padkin et al., 2003). The increase in these estimates is indicative that more 
immunocompromised people are being kept alive rather than fatally succumbing to 
the infection. 
 
In critical care units in England, Wales and Northern Ireland in 2004, hospital 
mortality for admissions with severe sepsis was 44.7 % and the total number of 
deaths was 14,000 (Harrison et al., 2006) (Figure 1.3a). In 2003, Sepsis had the 
highest mortality rate of 36,800 deaths (Daniels, 2007), therefore claiming more lives 
than lung cancer, and more than breast and bowel cancer combined (Figure 1.3b).  
 
Even these figures are likely to be an underestimate as diagnosis of sepsis can be 
difficult and deaths are frequently attributed to the underlying condition (for example, 
pneumonia) rather than to the resulting systemic inflammation (Van der Poll and 
Opal, 2008). The extremely high degree of mortality and morbidity associated with 
sepsis makes the study of the underlying contributory inflammatory mechanisms of 
great importance for the informed development of new therapeutic strategies. 
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(a) 
 
(b) 
 
 
 Sepsis mortality rates in the U.K. Figure 1.3
(a) Changes in outcomes for admissions with severe sepsis to the critical care unit 
outcomes over time, 1996 to 2004, in England, Wales and Northern Ireland hospitals 
(Harrison et al., 2006). (b) Comparison of annual mortality rates in 2003 between 
severe sepsis and lung, bowel and breast cancer in the UK (Daniels, 2007).  
Redacted due to copyright
Redacted due to copyright
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1.5 Bacterial pathogen-associated molecular patterns associated with sepsis 
Gram-negative bacteria are well recognised to play a significant role in the 
pathogenesis of sepsis because of one notorious immune-stimulatory structural 
component of the bacterial cell wall; lipopolysaccharide (LPS), or endotoxin. LPS is a 
powerful inflammatory stimulant, capable of inducing the production of inflammatory 
mediators in many leucocytes and thus is highly associated with induction of bacterial 
sepsis (Bosmann and Ward, 2013). The predominant causative agent of meningitis 
and severe sepsis in young adults worldwide, for example, is Neisseria meningitides, 
of which LPS is crucial to its pathogenicity (Brouwer et al., 2010). 
 
LPS is a unique and abundant glycolipid found in the Gram-negative bacteria outer 
membrane, classified within a group of structural components termed pathogen-
associated molecular patterns (PAMPs). LPS structure is composed of three domains: 
a membrane-distal hydrophilic polysaccharide (specific O-antigen region) attached to 
a basal core oligosaccharide and a highly conserved hydrophobic lipid moiety termed 
lipid A that anchors the structure to the outer bacterial membrane (Figure 1.4) (Lu et 
al., 2008).  The composition of the O-antigen varies from strain to strain, 
characterizing specific species of bacterium, however, the lipid A anchor is highly 
conserved across bacterial species. The structure of lipid A is responsible for the 
endotoxic activity of LPS and exerts an immune stimulatory effect via toll-like 
receptor 4 (TLR4) signalling in diverse types of immune cells. It activates antigen 
presenting cells by inducing cytokine secretion, co-stimulatory molecule expression, 
and antigen presentation, which links innate immune response to adaptive response 
(Dobrovolskaia, 2002). Thus lipid A derivatives with reduced toxicity have been 
targets for the development of human vaccine adjuvant (Han, et al., 2014). 
 
Initially, Gram-negative bacteria were considered to be the predominant causative 
agents of sepsis, but the incidence of Gram-positive bacterial sepsis is now reported 
to be at equivalent levels (Riedemann et al., 2003). The Gram-positive bacterium 
Staphylococcus aureus is one of the bacteria most commonly isolated from patients 
with sepsis (Wang et al., 2003). Peptidoglycan (PG) and lipoteichoid acid (LTA) are 
two major cell walls components in Gram-positive bacteria and have been shown to 
stimulate inflammatory responses and like LPS are recognised by Toll-like receptors 
(TLRs) present on phagocytes (Seam and Suffredini, 2007; Triantafilou et al., 2012). 
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 Diagrammatic representation of the structure of lipopolysaccharide. Figure 1.4
General structure of Gram-negative bacterial lipopolysaccharides (LPS). LPS also 
known as endotoxin, are found in the outer membrane of Gram-negative bacteria and 
elicit strong immune responses. LPS are large molecules consisting of a lipid and a 
polysaccharide composed of O-antigen, outer core and inner core joined by a covalent 
bond. The lipid A anchor is highly conserved across bacterial species, however 
composition of the O-antigen side chain varies from strain to strain, characterizing 
specific species of bacteria. The presence or absence of O-antigen determines whether 
the LPS are considered smooth or rough. Full-length O-chains would render the LPS 
smooth, whereas the absence or reduction of O-chains would make the LPS rough.   
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Gram-positive bacteria also produce membrane bound lipopeptides and some secrete 
exotoxins, such as staphylococcal enterotoxin B (SEB) and toxic shock syndrome 
toxin-1 (TSST-1) (Cohen, 2002). Such exotoxins have the properties of superantigens 
and have also demonstrated to induce fatal hypersensitivity to LPS (Dinges and 
Schlievert, 2001), thus supporting the dominant role LPS may play in all types of 
sepsis. Although the bacterial load and expression of virulence factors such as 
exotoxins can contribute to the outcome of severe infections, much of the damage 
inflicted during sepsis is attributable to the host’s amplified inflammatory response to 
microbial PAMPs (Van der Poll and Opal, 2008). 
 
1.6 Pattern recognition receptors (PRRs) 
Pattern recognition receptors (PRRs) are a diverse group of receptors that can either 
be cell-associated or soluble and are divided into at least five distinct families based 
upon structural features; Toll-like receptors (TLRs), C-type lectin receptors (CTLRs), 
NOD-like receptors (NLRs), RIG-like helicase receptor (RLRs) and scavenger 
receptors (Akira et al., 2006). Multiple receptors also exist in each class of PRRs with 
the result that in excess of 50 distinct PRRs may be expressed by a phagocyte at any 
given time, enabling the immune system to detect PAMPs and DAMPs and 
instigating a range of responses upon encounter with their appropriate ligands (Pradeu 
& Cooper 2012). 
 
Phagocytes display CTLRs, one of which, macrophage mannose receptor (CD206), 
generates intracellular activation signals that facilitate macrophage phagocytosis of 
microorganisms, on encounter with its respective microbial PAMP (Kawai and Akira, 
2010). NLRs are soluble proteins that reside in the cytoplasm of phagocytes where 
they act as receptors for pathogen-derived molecular patterns and typically recruit 
proteases or kinases, such as NFκB-activating kinase, upon activation (Janeway, 
2002). RLRs also reside in the cytoplasm, acting as intracellular sensors for viral-
derived products and are capable of activating NFκB in response to double-stranded 
RNA. Scavenger receptors represent yet another class of phagocytic receptors that 
recognise a variety of anionic polymers and low-density proteins (Le Roy, 2001). The 
role of the CD14 scavenger receptor will be described in later sections. 
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1.7 Toll-like receptors (TLRs) 
The Toll-like receptors (TLRs) are a major subset of PRRs, able to detect a diverse 
range of PAMPs and DAMPs and are called so because of their similarity to the Toll 
receptor in the fruit fly. Research on TLRs began with the discovery of interleukin-1 
receptor (IL-1R) (Sims et al., 1988). IL-1 activates many cell types and induces many 
pro-inflammatory genes, thus the necessity to map its signalling pathway prompted 
the cloning of its receptor, IL-1R. In 1991, its homology to the Drosophila 
melanogaster fruit fly protein Toll was first reported (Gay and Keith, 1991). 
Subsequent research demonstrated its implication in host fly defences and proved that 
adult flies lacking the toll gene would succumb to fungal infections. Thus Toll had a 
role of sensing fungal pathogens (Lemaitre et al., 1996). Importantly, at around the 
same time that similarities between Drosophila Toll and IL-1R were being identified, 
speculation that Toll might perform a similar role in human fungal infections was 
being investigated (Sims and Dower, 1994). In 1997, a mammalian Toll homogue, 
which was termed hToll, was cloned and studied (Medzhitov et al., 1997). Soon after, 
five mammalian Toll homologues were described and named Toll-like receptors 
(TLRs) - these included hToll which was renamed as TLR4 (Rock et al., 1998).  To 
date, 10 functioning TLRs have been described in humans and 13 in mice (O’Neill et 
al., 2013). TLRs 1, 2, 4, 5 and 6 are expressed on the cell surface but TLRs 3, 7, 8 
and 9 are almost exclusively expressed in intracellular compartments such as 
endosomes. 
 
The TLR family of PPRs are characterized by three domains: leucine-rich repeats 
(LRR), a transmembrane region and the intracellular Toll/IL-1 receptor (TIR) domain 
(O’Neill et al., 2013). The TIR domain of TLRs is shared by the IL-1R family, which 
enabled its discovery, but small differences in the extracellular and intracellular 
regions of TLRs give rise to the specificity of recognising precise microbial products 
(Jin and Lee, 2008). Each TLR has demonstrated to detect a specific type of microbial 
PAMP and to signal the presence of infections (Iwasaki and Medzhitov, 2004). TLR4 
has been definitively identified as the signalling receptor for LPS (Poltorak et al., 
1998: Qureshi et al., 1999: Hoshino et al., 1999) and TLR2 has shown to sense Gram 
positive bacterial lipopeptides (Jin et al., 2007: Kang et al., 2009). For the purpose of 
this study, a summary of the key PAMPs recognised by only TLR4 and TLR2 are 
given in Figure 1.5.  
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 Key bacterial cell wall PAMPs recognised by TLR 4 and TLR2 Figure 1.5
The TLR family of PPRs are characterized by three domains: leucine-rich repeats 
(LRR), a transmembrane domain and the intracellular Toll/IL-1 receptor (TIR) 
domain. Toll-like receptors (TLR) mediate immune responses to a range of cell wall 
based microbial stimuli. Recognition of Gram negative (G-) LPS is via the TLR4 
homodimer and is aided by two accessory proteins: CD14 and MD-2. TLR2 
recognizes Gram positive (G+) bacterial ligands and functions as a heterodimer with 
either TLR1 or TLR6 (TLR2/TLR1 or TLR2/TLR6). Lipoteichoic acid (LTA) 
activates cells via the TLR2/TLR6 heterodimer, whereas Synthetic tripalmitoylated 
lipopeptide Palmitoyl-3-cysteine-serine-lysine-4 (Pam3CSK4) activates the cells via 
the TLR2/TLR1 heterodimer. Some Gram positive bacterial PG has shown to activate 
through TLR2, forming a heterodimer with TLR6, but these observations remain 
controversial as PG has also been shown to stimulate independent of TLRs through 
NODs. For the purpose of this study, other TLRs expressed on the cell surface (such 
as TLR5) or TLRs expressed in intracellular compartments (such as TLRs 3, 7, 8 and 
9) are not included in the figure.  
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1.8 TLR2 bacterial PAMP recognition 
TLR2 has been shown to recognize a broad range of Gram positive bacterial ligands 
and functions as a heterodimer with either TLR1 or TLR6 (TLR2/TLR1 or 
TLR2/TLR6), which appear to be involved in the discrimination of subtle changes in 
the lipid portion of lipoproteins (Figure 1.5.) (Takeuchi, 1999). Lipoteichoic acid 
(LTA) contains a diacylated moiety and activates the cells via the TLR2/TLR6 
heterodimer (Jin and Lee, 2008). Synthetic tripalmitoylated lipopeptide Palmitoyl-3-
cysteine-serine-lysine-4 (Pam3CSK4) contains a triacylated moiety and activates the 
cells via the TLR2/TLR1 heterodimer (Jin et al., 2007: Triantafilou et al., 2006).  
 
TLR2 has also been reported to recognize Gram positive peptidoglycan (PG) 
(Tapping, 2009). In a study conducted by Ozinsky and colleagues, S. aureus PG was 
shown to induce TNF-α production in mouse macrophage cell line, RAW-TT10 
(Ozinsky, et al., 2000). TLR2 was reported to physically associate with TLR6 on 
encountering PG and both receptors were recruited to phagosomes, leading to the 
constitutive activation of nuclear factor-κB (NF-κB) to induce TNF-α production. 
Other in vitro models have also shown that PG induced NF-κB activation and 
cytokine production is mediated by TLR2 and TLR6 (Abrahams et al., 2008: 
Triantafilou et al., 2006) although this observation remains controversial. 
 
Studies using PG components that have been biochemically purified from bacteria are 
often inconclusive due to the possibility of contaminating LTA. A report in 2004, 
used a range of highly purified PGs and showed that PG was not sensed through 
TLR2, TLR2/1 or TLR2/6 (Travossos et al., 2004). Instead the report revealed that 
PG sensing was lost after removal of lipoteichoic acids from Gram-positive cell walls 
and implied that research linking PG with TLR2 recognition have relied mainly on 
the use of commercial S.aureus PG that was contaminated with LTA. In contrast, the 
report showed that peritoneal murine macrophages did not produce TNF-α or IL-6 in 
response to purified PGs and suggested that PG detection is more likely to occur 
independently of TLRs through intracellular NODs (Nod1/Nod2). Further research 
also indicated that PG signalling can occur via NLRs (O’Neill, 2004), thus the 
identification of the universal signalling receptor for most types of PG has remained 
elusive.  
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1.9 PAMP induced activation clusters 
In addition to the involvement of TLRs, which function as central sensors for Gram-
negative and Gram-positive bacterial products, other accessory molecules have found 
to be involved in establishing cellular activation (Hoshino et al., 1999). Serum 
proteins, such as lipopolysaccharide-binding protein (LBP) have been observed to 
bind LPS or LTA and deliver it to its cellular target (Figure 1.6a) (Schumann, et al., 
1990; Wright, et al., 1990). CD14 a glycosylphosphatidylinositol (GPI)-anchored 
protein, is also believed to act as a transfer molecule for both Gram-negative and 
Gram-positive bacteria (Passon-McDermott and O’Neill, 2004). In the case of LPS 
recognition, it has been further shown that a soluble accessory molecule myeloid 
differentiation protein 2 (MD-2), is recruited to the site of CD14–LPS ligation (Figure 
1.6b) (Triantafilou, et al., 2001) and possibly additional receptor components are 
required. Chemokine receptor 4 (CXCR4), heat shock proteins (Hsps) 70 and 90 or 
CD55 have been suggested to be part of this activation cluster (Triantafilou et al. 
2004). In the case of LTA recognition, TLR2 seems to form receptor clusters, 
comprising of at least CD14, TLR2, TLR6, and CD36 (Figure 1.6b) (Tapping, 2009: 
Triantafilou and Triantafilou, 2002). Cell activation via the TLR2/TLR1 heterodimer 
by Pam3CSK4, however, is not CD36 dependent (Travossos et al., 2004). 
 
CD14 lacks a transmembrane domain and thus require TLRs to act as a signal 
transducing molecule to associate with. It is widely accepted that TLRs pre-exist as 
homodimers (in the case of TLR4) or heterodimers (TLR2/1 or TLR2/6) and are not 
induced by the ligand (Akira et al., 2004: Kawai & Akira, 2011). However, 
expression levels of TLRs are modulated rapidly in response to pathogens, a variety 
of cytokines and environmental stress. Recently it had been proposed that receptor-
receptor association of the extracellular TLR domains forced a series of protein 
conformational changes and initiated dimerization of the cytoplasmic domains as well 
(Motshwene et al., 2009). Upon ligand engagement, TLRs are recruited into lipid 
bilayer microdomains termed ‘lipid rafts’, where they associate with lipid raft resident 
protein CD14 to form an activation cluster (Figure 1.6c). Binding of appropriate 
microbial ligand leads to clustering of receptors and triggers activation of multiple 
intracellular signalling cascades that lead, via NF-κB, to production and secretion of 
pro-inflammatory cytokines and IFNs (Passon-McDermott and O’Neill, 2004: 
Triantafilou and Triantafilou, 2004).  
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 Receptor cluster complex  on cell membrane Figure 1.6
This schematic figure represents the events involved in detecting and responding to 
lipopolysaccharide (LPS) and Lipotechoic acid (LTA). (a) products released from 
bacteria bind to the serum protein, LPS-binding protein (LBP), and forms a complex. 
LBP catalyzes the transfer of LPS or LTA to membrane-bound. (b) CD14 requires the 
formation of trimolecular receptor cluster with the toll-like receptor homodimer 
(TLR4) or heterodimer (TLR2/TLR6). The accessory molecule myeloid 
differentiation protein 2 (MD-2) or CD36 are required to mediate a transmembrane 
signal in response to LPS and LTA, respectively. (c) clusters of activated receptors 
concentrate in lipid raft domains and their intracellular machinery clusters as well, 
forming a signalling platform that is crucial for the activation of downstream TLR 
signalling pathways. Model adapted from Triantafilou et al. (2011). 
 
Redacted due to copyright
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1.10 TLR2 and TLR4 Intracellular signalling Pathway 
Identifying the ligand specificity and downstream pathways of each TLR dimer has 
been the subject of intense research for the last 15 years (Vandenbon et al., 2012). 
Recent data suggests that multiple membrane-based and intracellular molecules 
interact upon activation and additional serum proteins are needed to mount an ideal 
response against the invading pathogen (Triantafilou et al., 2012). Two main TLR 
signalling pathways have been identified: the myeloid differentiation factor 88 
(MyD88)-dependent and the TIR domain-containing adaptor protein inducing IFN-β 
(TRIF)-dependent pathways. The MyD88-dependent pathway is activated by all 
known TLRs except TLR3, and leads to the production of pro-inflammatory 
cytokines. TLR3 and TLR4 can activate the TRIF-dependent pathway, which leads to 
the production of type I interferons (IFNs) against viral infection (Figure 1.7). 
 
In the case of the MyD88-dependent signalling pathway, the Toll/IL-1 receptor (TIR) 
domain of the TLR dimer engages directly with TIR domain-containing adaptor 
proteins: MyD88 and MyD88-adaptor-like protein (MAL; also known as TIRAP) 
found in the cell cytoplasm (Kawai & Akira, 2011). MAL in turn localizes to the 
plasma membrane, where it serves to bridge the interaction between MyD88 and TLR 
upon ligand engagement. The MyD88 then recruits IL-1R-associated kinases 
(IRAKs), TNF receptor-associated factor 6 (TRAF6) and the Transforming growth 
factor-beta–activated kinase 1 (TAK1) complex, leading to the downstream activation 
of nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs) 
(O’Neill et al., 2013). A major consequence of TLR signalling is the induction of pro-
inflammatory cytokines and IFN. 
 
TLR4, which is expressed on the cell surface, initially transmits signals for the early-
phase activation of NF-κB via MyD88-dependant pathways, but is then endocytosed 
and moves from the plasma membrane to endosomes, allowing the switch to TRIF-
dependant signalling pathways. In phagosomes, TLR4 forms a complex with TIR 
domain-containing adaptor protein inducing IFN-β (TRIF) and TRIF-related adaptor 
molecule (TRAM). The complex then recruits TRAF3 and the protein kinases 
TANK-binding kinase 1 (TBK1) and inhibitor of NF-κB kinase (IKKi), which 
catalyse the phosphorylation of interferon regulatory factor 3 (IRF3), leading to late-
phase activation of NF-κB for the induction of type I IFN (Kawai & Akira, 2011).   
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 TLR trafficking and signalling pathways Figure 1.7
PAMP engagement induces conformational changes of TLRs expressed on the cell 
surface of macrophages and dendritic cells, which allow homo- or heterodimer 
interactions of TLRs.  Heterodimers of TLR1-TLR2 and TLR2-TLR6 induce NF-κB 
activation through recruitment of MAL and MyD88 (MyD88-dependent signalling 
pathway).  Homodimers of TLR4 can signal through the MyD88-dependent pathway 
(as above) or through TRIF-dependent pathway, via recruitment of adaptor proteins 
TRIF and TRAM. Both pathways for NF-κB activation is required for the induction 
of the signalling cascade that leads to the activation of synthesis of pro-inflammatory 
cytokines and effector molecules. Model adapted from Kawai & Akira (2011) and 
O’Neill et al. (2013).  
Redacted due to copyright
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1.11 Experimental trials for the treatment of sepsis 
The clinical therapy of sepsis presents the difficult task of removing the infection 
while simultaneously controlling the excessive inflammatory response to infection 
without compromising host immunity. Whilst many key factors, including patient 
group, length of stay in ITU, pathogen load and antibiotic resistance, are crucial to 
treatment, there is no specific therapy for sepsis and it is often difficult to obtain a 
rapid microbial diagnosis before treatment begins. The current best available 
therapeutic approach is centred on supportive therapy, by such means as mechanical 
ventilation, administration of fluids, drainage of the source of infection, appropriate 
support for organ dysfunction and empirical treatment with antimicrobials (Cohen, 
2002). However such treatment strategies are not always effective and thus sepsis 
carries a high mortality rate (Carlet et al., 2008). Numerous potential targets and 
compounds for the treatment of sepsis have been examined within a clinical trials 
setting and are summarised in Figure 1.1Table 4.1. 
 
TLR4 represents a potential target for treatment strategies of Gram-negative mediated 
sepsis. Anti-TLR4 antibodies have been shown to inhibit intracellular signalling, 
markedly reducing cytokine production, and subsequently protecting mice from lethal 
endotoxic shock and Escherichia coli sepsis when administered as a prophylactic 
agent (Roger, et al., 2009). TLR4 and MyD88 knockout mice were fully resistant to 
E. coli-induced septic shock, strongly supporting the concept of TLR4-targeted 
therapy for management of Gram-negative sepsis (Wittebole et al., 2010). 
 
More recently, a phase II trial in patients with severe sepsis has shown that Eritoran 
tetrasodium may be a useful contender in the treatment of sepsis (Tidswell et al., 
2010). Eritoran tetrasodium (E5564) is a synthetic lipopolysaccharide analogue that 
acts as a TLR4 antagonist and interferes with signalling responses to endotoxin. The 
structure of the molecule is based on the lipid A portion of a naturally occurring, 
weakly agonistic endotoxin found in Rhodobacter sphaeroides. E5564 is a potent in 
vitro antagonist of endotoxin that directly binds to the hydrophobic pocket of MD-2, 
competitively inhibits the lipid A component of endotoxin from binding to the same 
site, and thereby prevents dimerization of TLR4 and intracellular signalling. In this 
trial, E5564 did not appear to have an adverse effect on immune protection and 
consistently had a favourable (but not statistically significant) trend toward a lower  
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Table 4.1 Targets in clinical trials for treatment of sepsis 
 
 (Modified from Riedemann et al., 2003 and updated with Wittebole et al., 2010). Target Treatment for Clinical trials 
Immune modulation 
Glucocorticoids (inhibition of over-activation of the immune 
system) 
Intravenous IgG (improvement of host defense) 
Endotoxin (LPS) 
Anti-endotoxin antibodies: 
polyclonal human antiserum 
human monoclonal anti-lipid A (HA-1A) 
murine monoclonal anti-lipid A (E5) 
human monoclonal antibodies 
Bactericidal / permeability-increasing protein 
LPS elimination (hemofiltration) 
TNF-α 
TNF-α antibodies: 
murine monoclonal antibodies 
F(ab)2 anti-TNF-α 
Soluble TNF receptors (TNF inhibition) 
IL-1 IL-1 receptor antagonist 
PAF 
Phospholipase A2 antagonist (reduction of PAF) 
PAF antagonist 
PAF-acetylhydrolase (PAF inactivation) 
Bradykinin Bradykinin antagonist 
Arachidonic acid 
metabolites 
Prostaglandin (PG) E1 and liposomes containing PGE1 (anti-
inflammatory) 
Thromboxane inhibitors (anti-inflammatory) 
Ketoconazole (thromboxane synthetase inhibition) 
Ibuprofen (COX inhibition) 
Reactive oxygen species 
N-acetylcysteine (restoration of cellular antioxidant potential) 
Selenium has been used to bolster selenium-dependent 
glutathione peroxidise, which is a scavenger for oxygen. 
NO 
L-NAME (NOS inhibition) 
L-NMMA (iNOS inhibition)  
Methylene blue (guanylyl cyclise inhibition) 
PHP (NO scavenger) 
Phosphodiesterase Pentoxifylline (phosphodiesterase inhibition, cAMP increase) 
Neutrophil activity 
IFN- (reactivation of neutrophil immune functions) 
G-CSF, GM-CSF (increase of immune-competent blood cells) 
PGG-glucan (increase of phagocytosis and bacterial killing) 
Complement system C1 inhibition (inhibition of classical  and lectin pathway activation) 
Coagulation 
Antithrombin III (inhibition of thrombin, factors IXa, Xa, XIa and 
XIIa) 
TFPI (inhibition of factors X and IX) 
APC (inactivation of factors Va and VIIIa) 
TLR-4 
Molecules interfering with TLR4 and TLR4-mRNA expression 
Molecules interfering with TLR4-related intracellular signalling 
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mortality rate in subjects. However, Eritoran tetrasodium treatment was only 
beneficial to some subsets of the study population; namely those patients presenting a 
high risk of death, thus limiting its application (Wittebole et al., 2010). 
 
One major problem with treatments targeting TLR4 is activation of the inflammatory 
system via mechanisms independent of TLR4, such as those demonstrated in 
meningococcal studies (Brouwer et al., 2010; Prins et al., 1998). Neisseria hia 
homologue (NhhA), a meningococcal outer membrane protein, was found to trigger 
release of proinflammatory cytokines from RAW 264.7 macrophages via two distinct 
pathways; Interleukin-6 (IL-6) secretion was dependent on activation of TLR4 and 
required MyD88. In contrast, release of tumor necrosis factor (TNF) was TLR4- and 
MyD88-independent (Sjölinder et al., 2012). Since Neisseria meningitides represents 
the leading cause of meningitis and severe sepsis in young adults worldwide, success 
with treatment targeted at TLR4 would be limited. 
 
Recombinant human activated protein C (rhAPC) is an alternative anti-sepsis 
treatment as it has anti-thrombotic, anti-inflammatory and anti-fibrinolysis properties. 
In previous studies, rhAPC has produced dose-dependent reductions in the levels of 
markers of coagulation and inflammation in patients with severe sepsis (Bernard et 
al., 2001).  A 6.1 % decrease in mortality was noted in the rhAPC group compared 
with the placebo group. Based on these data, in 2008, the International Surviving 
Sepsis Campaign Guidelines Committee reviewed the available literature on rhAPC 
trials. It was concluded that rhAPC was of benefit to those patients with severe sepsis 
and a high risk of death, most of whom had multiple organ failure. Subsequently, in 
2009, the British Committee for Standards in Haematology (BCSH) guideline 
recommended the use of APC in patients with severe sepsis.  
 
Results, however, consistently fail to show benefits for the subgroup of patients at 
lower risk of death and consistently showed increases in serious bleeding (Dellinger 
et al., 2008). The BCSH therefore concluded that there was likely to be no benefit in 
treating patients at a low risk of death and also recommended against the use of 
rhAPC in children. Consequently, with the increasing uncertainty surrounding 
efficacy and concerns over the bleeding risk, rhAPC was recently withdrawn from the 
Jenny Hughes       Chapter 1: Introduction 
 25 
 
market worldwide pending the results of a phase II trial focusing on the use of rhAPC 
in combination with low-dose corticosteroids (Thachil et al., 2012).  
 
An alternative concept is the use of drugs that increase activated protein C, a natural 
anticoagulant which breaks down blood clots, which may lead to improve survival 
rates (Fisher and Yan, 2000; Looney and Matthay, 2001). Activated protein C has 
been shown to inhibit TNF amplification in response to endotoxin in several animal 
models and in vitro, noticeably reducing the rate of death due to severe sepsis 
(Bernard et al., 2001). Initial data suggests this to be a promising approach which 
continues to be assessed in clinical trials (Esmon, 2002).  
 
Long courses of low-dose corticosteroids (LDC) have also shown to improve 
systemic symptoms of sepsis and reduce the time on vasopressor treatment (Beale et 
al., 2010). As with other clinical trials, however, a debate remains on how best to 
characterise the patient population that is most likely to benefit from the treatment, 
the optimum dose and duration. Thus the use of rhAPC, E5564 and LDC remain of 
limited application. 
 
Despite the crucial role for TNF-α and IL-1 in mediating sepsis, studies have 
demonstrated only limited success with treatments for sepsis based on antibodies 
directed at these pro-inflammatory cytokines (Glauser et al., 1991; Tracey et al., 
1987). So far blocking the actions of pro-inflammatory cytokines has only proven 
successful if antibodies to TNF or IL-1 are given at specific time points before 
bacterial challenge (Hinshaw et al., 1990; Bagby et al., 1991; McIntyre, 1991). 
However, both TNF and IL-1 can also mediate anti-inflammatory responses that may 
protect against tissue injury. TNF, for example, up-regulates the cytolytic activity of 
lymphocytes, complement receptors, oxidative burst and stimulates the proliferation 
of B and T cells, all of which participate in the host’s defence against infection 
(Wakabayashi, 1991). Hence, the use of anti-TNF/IL-1 in the treatment of human 
sepsis may in fact interfere with the cytokine concentrations that are required for an 
appropriate control of infection and worsen the very infection responsible for sepsis 
Ozinsky et al., 2000). 
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An alternative strategy to cytokine control is the use of antibodies to block endotoxins 
(Natanson et al., 1994; Ziegler et al., 1991). Synthetic antibodies to the specific O-
oligosaccharide side chain of LPS have complement-dependent bactericidal activity; 
however the O-side chain of LPS is structurally and antigenically diverse between 
different Gram-negative bacterial genera, species and strains. An antibody to a 
specific O-side chain would therefore only be likely to be able to target one bacterial 
species, hugely limiting its potential clinical application. This problem has led to 
investigation of antibodies directed at the core glycolipid or lipid A structures of 
endotoxin, which are more highly conserved and retain structural similarities amongst 
common Gram-negative bacterial pathogens. Antibodies directed at lipid A or the 
core glycoprotein could, in theory, provide cross-protection against a wide and 
diverse range of Gram-negative bacteria. A murine anti-lipid A monoclonal antibody, 
E5, was tested in a clinical trial and gave no significant benefit to patients with Gram-
negative septic shock (Greenman et al., 1991). Those treated that entered the trial 
with the infection but not in shock, conversely, had statistically significant lower 
mortality (Greenman, et al., 1991), though this has not been replicated among all 
trials performed with E5 (Bone et al., 1995). As yet studies blocking specific 
components of pathogenic bacteria have proved inconclusive meaning that alternative 
approaches must also be explored. 
 
Though many trials have been performed for the treatment for sepsis, all have arisen 
from work in animal models and have only achieved limited success. Differences 
between animal and human TLRs also exist implying the response to a bacterial 
stimulus may differ between species (Passon McDermott and O’Neill, 2004). Perhaps 
the lack of success in clinical trials to date may be partly attributed to the differences 
between animal experiments and the disease process in humans. Sepsis results from a 
complex interplay between bacterial and host factors. The regulation of inflammatory 
mediators is known to be crucial in preventing a detrimental outcome. This, and the 
lack of effective treatment options necessitates further elucidation of the underlying 
inflammatory mechanism in order that novel targets, compounds and strategies might 
be identified.  Understanding the role of membrane-bound PRRs and their recruitment 
into receptor-signalling complexes by lipid rafts represents one such novel approach 
for the development of therapeutic options. 
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1.12 Membrane structure and dynamics 
Cells of all organisms are enclosed by a plasma membrane, which for over 40 years, 
scientists have based views and experiments on the fluid mosaic membrane model of 
Singer and Nicolson (1972). According to the Singer-Nicolson fluid mosaic model, 
biological membranes can be considered as a two-dimensional liquid in which lipid 
and protein molecules diffuse more or less easily. Although the lipid bilayers that 
form the basis of the membranes do indeed form two-dimensional liquids by 
themselves, the plasma membrane also contains a large quantity of proteins, which 
provide more structure (Munro, 2003). In recent years, new models of the structure of 
the plasma membrane of mammalian cells has helped understand membrane 
dynamics and function and has suggested that the fluid mosaic model is greatly 
oversimplified (Olsson and Sundler, 2006). It has been demonstrated that the plasma 
membrane consists of lipids, cholesterol and proteins with lateral heterogeneities, 
patches and microdomains, often called lipid or membrane rafts. Lipid rafts are 
enriched in cholesterol and sphingolipids and appear as highly ordered, detergent-
insoluble microdomains and are proposed to represent sites of cellular signalling 
(Koseki et al., 2007). 
 
1.13 The role of membrane regulation in inflammatory response 
Accumulating evidence suggests that an important feature in LPS recognition is the 
clustering of the receptor molecules within lipid rafts (Munro, 2003; Triantafilou and 
Triantafilou, 2004). LPS has been observed to cause the translocation of several 
signalling molecules into lipid rafts including; translocation of TLR4 into human 
A549 lung epithelial cell (Abate, et al., 2010) and human monocytic MM6 cell  lipid 
rafts (Triantafilou, et al., 2002),  and  translocation of CD-14 and MAP kinases into 
macrophage cell RAW264.7 lipid rafts (Olsson and Sundler, 2006).  
 
Translocation into lipid rafts enhances LPS-mediated signalling by allowing co-
localisation of receptors which co-operate to provide a signalling event. CD14, hsp70 
and hsp90, are found to localise in lipid rafts constitutively, whereas TLR4 and 
CXCR4 are recruited into the lipid rafts only after LPS binding (Triantafilou, et al., 
2002). Signalling molecules, such as MyD88, are also recruited into lipid rafts 
following microbial stimulation (Triantafilou, et al., 2011). To allow recruitment of 
molecules into lipid rafts, modifications to the plasma membrane phospholipid 
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microenvironment through incorporation of unsaturated fatty acids must occur 
(Darmani et al., 1993). 
 
1.14 Lipid metabolism and membrane phospholipid re-modelling 
Phospholipids are the major component of the plasma membrane. Cellular 
membranes are comprised of several different classes of phospholipids which have 
numerous structural and functional roles. An important phospholipid component of 
many membranes is phosphatidylcholine (PC) (Figure 1.8) (Choy and Arthur, 1989). 
The distribution of fatty acids within phospholipids results from remodelling of newly 
synthesized PC rather than de novo biosynthesis (Arthur and Choy, 1984). 
 
Phospholipids are first formed by the de novo pathway (Kennedy pathway) and 
subsequently undergo modification in the remodelling pathway. The pathway for the 
remodelling of PC was first identified by Lands (1960) and involves the deacylation 
of PC to a lyso-PC and its subsequent re-acylation back to PC with a different acyl 
chain composition. The Lands Cycle, that is the acylation and deacylation of 
membrane phospholipids, provides a mechanism for the incorporation of unsaturated 
fatty acids, mainly arachidonic acid, into different phospholipids to provide a range of 
lipid mediators and to generate a mature membrane with asymmetry and diversity 
(Yamashita et al., 1997).   
 
Fatty acids are cleaved from phospholipids by the action of phospholipase A2 and re-
incorporated by acyltransferases (Lands, 2000) (Figure 1.9). Studies have revealed 
that arachidonic-acid is first incorporated into phospholipids containing a 1-acyl 
linkage by Coenzyme A (CoA)-dependent enzymes (Lands 1960; Chilton et al., 
1996). Arachidonic acid is subsequently transferred by CoA-independent 
transacylases from 1-acyl linked phospholipids to 1-alkyl and 1-alk-1-enyl 
lysophospholipids to form 1-alkyl and 1-alk-1-enyl-2-arachidonyl, which are 
important for the synthesis of platelet activating factor (PAF). Reacylation of lysoPC 
to PC is catalysed by the action of lysophosphatidylcholine acyltransferase (LPCAT). 
Thus LPCAT plays a significant role in the remodelling of membrane PC. 
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 Basic structure of Phosphatidylcholine  Figure 1.8
The basic structure of phosphatidylcholine (PC) comprising of a saturated fatty acyl chain at the sn-1 position (palmitoyl) and an unsaturated fatty 
acyl chain at the sn-2 position (oleoyl). Saturated fatty acids have no double bonds between the individual carbon atoms of the fatty acid chain, 
unsaturated fatty acids contain carbon-carbon double bonds or triple bonds. Adapted from Jackson and Parton (2004). 
Redacted due to copyright
Jenny Hughes       Chapter 1: Introduction 
 30 
 
 
 
 
 LPCAT modulates PC acyl composition via substitution of Figure 1.9
unsaturated fatty acids 
Land’s cycle: (a) Phospholipase A2 (PLA2) cleaves the fatty acyl chain at the sn-2 
position, releasing a free fatty acid such as arachidonic acid. (b)  
Lysophosphatidylcholine (lysoPC) is then reacylated by Coenzyme A dependent 
lysophosphatidylcholine acyltransferase (LPCAT), which incorporates an unsaturated 
fatty acid (donor acyl-CoA) such as oleoyl, to yield a remodeled phosphatidylcholine 
(PC). 
  
 
Table 4.2 Summary of saturated and unsaturated fatty acids 
Type Carbon:double 
bond ratio 
Systematic name Common name 
Saturated 2:0 
12:0 
14:0 
16:0 
18:0 
Ethanoic acid 
dodecanoic acid 
tetradecanoic acid 
hexadecanoic acid 
octadecanoic acid 
Acetic acid 
lauric acid 
myristic acid 
palmitic acid 
stearic acid 
    
Unsaturated 18:1 cis-9-octadecenoic acid oleic acid 
 18:2 cis-6-octadecadienoic acid  linoleic acid 
 18:3 cis-6-octadecatrienoic acid linolenic acid 
 20:4 cis-6-eicosatetraenoic acid arachidonic acid 
 22:6 cis-3-docosahexaenoic acid cervonic acid 
  
(b) 
 
(b) 
(a) 
 
(a) 
Jenny Hughes       Chapter 1: Introduction 
 31 
 
1.15 Evidence of enzymes with LPCAT-like activity 
The LPCAT enzyme was first described in rat liver microsomes (Lands, 1960) and 
has since been identified in a diversity of species ranging from bacteria (Proulx and 
Van Deenen, 1966), plants (Devor et al., 1971), insects (Heckman et al., 1977) and 
fish (Holub et al., 1976) to mammals (Choy and Arthur, 1989). The current literature 
supports the identification of 5 human acyltransferases with LPCAT activity; i.e. they 
have all been shown to incorporate an acyl-CoA into lysoPC, reacylating it to PC 
(Shindou et al., 2009). This includes several enzymes from the 1-acylglycerol-3-
phosphate O-acyltransferase (AGPAT) and membrane bound O-acyltransferases 
(MBOAT) families that have been reported to reacylate lysoPC to PC. LPCAT1, 
LPCAT2 and LPEAT2 are members of the AGPAT family, whereas LPCAT3 and 
LPCAT4 are members of the MBOAT family. These enzymes are characterized in 
terms of their substrate specificity, donor fatty acid preference and lysoPC acceptor 
(Table 4.2 and Figure 1.10). Research has demonstrated sequence homology between 
mouse, rat and human LPCATs and expression patterns in a variety of tissue and 
cultured cell-lines, indicating these genes are conserved across several species 
(Shindou et al., 2008).  
 
1.15.1 LPCAT1 
LPCAT1, formerly AGPAT7 and AYTL2, was discovered idependantly by two 
groups in 2006 and was observed to be highly expressed in the lung, especially in 
alveolar type II cells, responsible of the secretion of surfactant components (Chen et 
al., 2006; Nakanishi et al., 2006). Pulmonary surfactant is a lipoprotein complex that 
coats the surface of alveoli, reducing surface tension and preventing alveolar collapse. 
Deficiencies and/or dysfunction of the surfactant system are known to contribute to 
the pathogenesis of several pulmonary diseases and can lead to severe respiratory 
failure (Nakanishi et al., 2006). Thus the production of surfactant lipids is highly 
regulated. The phospholipid content in pulmonary surfactant is thought to be 
predominantly synthesized by LPCAT1, suggesting a critical role for this enzyme 
within respiratory physiology. In fact when Lpcat1 mRNA levels were reduced in 
newborn mice it could be directly correlated with low PC content, LPCAT1 activity, 
and survival (Bridges et al., 2010).   
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 Characterisation of lysophospholipid acyltransferases (LPLATs) Figure 1.10
(a) Phylogenetic tree of mouse lysophospholipid acyltransferases (LPLATs). (b) 
Summary of functionally identified LPLATs and their preference for donor fatty acyl  
chain (defined in ) incorporation into the sn-2 position of phospholipids such as 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), 
phosphatidic acid (PA), phosphatidylglycerol (PG) and phosphatidylinositol (PI). 
Darker colors indicate higher enzymatic activity for acyl-CoAs. Additional LPLATs 
that may exist are indicated with question marks. Reproduced from Hishikawa et al. 
(2008) © the National Academy of Sciences.  
  
Redacted due to copyright
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LPCAT1 is principally involved in catalysing disaturated-PC and disaturated-PG 
synthesis, specifically utilising linoleic acid (18:2)-CoA or linolenic acid (18:3)-CoA 
as donor fatty acids in vitro (Nakanishi et al., 2006). Disaturated phospholipids, 
mainly dipalmitoyl- phosphatidylcholine (DPPC), are major components of 
pulmonary surfactant. Studies found that 55-75 % of DPPC in alveolar type II cells 
was formed by the remodelling pathway (Chen et al., 2006; Nakanishi et al., 2006). 
 
In 2008 Soupene et al. (2008) reported the characterization of the product of the 
Aytl2 gene in adult human red blood cells (RBCs). Mammalian RBCs lack de novo 
lipid synthesis but maintain membrane composition by rapid turnover of acyl 
moieties at the sn-2 position of phospholipids. The authors suggested that AYTL2 is 
the reacylating enzyme for lysoPC in the RBC membrane and identified it to have the 
function of a LPCAT protein. As more sequences became available, multiple 
sequence alignment of AYTL2 and LPCAT1 revealed that they were in fact identical 
(Harayama et al., 2009).  
 
Interestingly, Agarwal et al., (2007) reported that human AGPAT9/LPCAT1 had a 
similar cDNA sequence to the mouse LPCAT1 reported by Chen et al. (2006) and 
Nakanishi et al. (2006). Notably, Agarwal, et al. (2007) did not observe any LPCAT 
activity when LPCAT1 was overexpressed in Chinese hamster ovary (CHO) cells. 
Instead of favoring lysoPC as a substrate in the in vitro studies, LPCAT1 exhibited a 
preference for lysophosphatidic acid (lysoPA), which could argue for LPCAT1’s role 
in lung physiology. Conversely, when hLPCAT1 was overexpressed in human 
embryonic kidney cells (HEK293), ample LPCAT activity was obtained (Zhao et al., 
2008). This discrepancy may have resulted from a problem related to the location of 
the epitope tag in the plasmid construction used to overexpress LPCAT1 in CHO 
cells as suggested by Mansilla et al. (2009). It may however, also be possible that 
each LPCAT performs a unique function within different cell types, either 
maintaining cellular membrane structure and /or producing specific phospholipid 
molecules (Harayama et al., 2009). 
 
Recent findings implicate a role for LPCAT1 within colorectal cancer (CRC). A 
common characteristic in cancer cells and solid tumours has revealed to be the 
elevation of PC. This elevation has been observed in almost every single cancer type 
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studied by NMR spectroscopy and is employed as an endogenous biomarker of 
cancer (Ackerstaff et al., 2003). When 168 colorectal adenocarcinomas were 
examined, LPCAT1 mRNA was shown to be upregulated 2.5-fold in CRC tissues as 
compared to normal mucosa (Mansilla et al., 2009). The hLPCAT1 protein in a colon 
cancer cell-line (SW480) was found to predominately have LPCAT, rather than 
AGPAT, enzyme activity. hLPCAT1 activity was associated with an increased 
reacylation of lysoPC and correlated with a significantly increased the growth rate of 
the cancer cells. By altering the specific lipid profile, LPCAT1 contributes to the total 
choline metabolite accumulation found in CRC - a process that may consequentially 
influence potential therapies due to the membrane structure affecting drug delivery 
(Mansilla et al., 2009). During the progression of human mammary epithelial cells to 
a malignant phenotype, an increase in PC and total choline containing compounds has 
been observed, as well as altered ratios of  glycerophosphocholine (GPC) to PC 
(Glunde et al., 2006). 
 
1.15.2 LPCAT2 
AGPAT11 cDNA has recently been identified as LPCAT2, lyso-platelet-activating 
factor acyltransferase (Lyso-PAF-AT), previously named acyltransferase-like 1 
(AYTL1) (Shindou et al., 2007).  As the names would suggest, this enzyme utilises 
the same precursor (lyso-PAF) to synthesise both PAF and PC in inflammatory cells, 
although the mechanism(s) as to how the two activities are differentially regulated 
remains unknown. 
 
Protein sequence alignments have revealed hLPCAT2 to be 58 % homologous to 
hLPCAT1, with 41.5 % identical amino acids (Agarwal and Garg, 2010). These 
isoforms are more similar than any other two human ATs within the AGPAT family 
and share comparable expression patterns for most human tissue types. Like 
LPCAT1, LPCAT2 is largely expressed in the lung, spleen and leukocytes, except 
LPCAT2 is expressed one or two fold less. Since the overexpression of hLPCAT1 
protein has been detected in CRC tissue (Mansilla et al., 2009), an investigation into 
the expression of LPCAT2 in human tumour tissues has been reported (Agarwal and 
Garg, 2010). Like LPCAT1, AGPAT11/LPCAT2 expression is significantly 
increased in colorectal, breast and cervical cancer tissue compared to normal tissues 
in these anatomical sites. Expression of LPCAT2 was found to be reflective of the 
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degree of tumour tissue present. In normal colon tissue LPCAT2 is naturally 
expressed, but in CRC tissue expression is amplified considerably. 
 
Agarwal and Garg (2010) also determined LPCAT2’s acyl-CoA and 
lysophospholipid specificity for AGPAT activity. LPCAT2 appears to have a broad 
preference for lysophosphatidic acid (lysoPA) -containing saturated fatty acids. 
Lysophosphatidylserine (lysoPS) was the only other lysophospholipid for which 
LPCAT2 retained some activity. This group did not publish their lysoPC data and 
stated only that LPCAT activity did not reach statistical significance, in contrast to 
other groups who have shown LPCAT activity with this cDNA  (Shindou et al., 2007: 
Harayama et al., 2008). 
 
Mouse LPCAT2 shows 48.2 % amino acid sequence similarity to mouse LPCAT1 
and 88.4 % sequence homology to human LPCAT2, therefore, in vitro and in vivo 
studies are frequently performed using murine models (Shindou et al., 2007; 
Harayama et al., 2008). In mouse peritoneal macrophages treated with LPS, the 
LPCAT2 mRNA was upregulated (Shindou et al., 2005). However only the lyso-
PAF-AT activity of LPCAT2 was activated; the LPCAT activity of LPCAT2 was not 
shown to be elevated. When hLPCAT2 siRNA was transfected into HEK293 cells, 
not only did it considerably reduce the mRNA level of hLPCAT2 by 70-80 %, but 
also significantly decreased lyso-PAF-AT activity by 50-60 % (Shindou et al., 2007). 
Thus hLPCAT2 appears to be the principal enzyme for PAF production in HEK293 
cells providing an inducible remodelling pathway for PAF synthesis.  
 
1.15.3 LPCAT3 / MBOAT5 
LPCAT3, a member of the MBOAT family, has been found abundantly in liver, 
pancreas and adipose tissue and is thought to be primarily responsible for hepatic 
LPCAT activity (Shindou et al., 2008). The latter is shown by LPCAT3 siRNA 
transfection into human hepatoma Huh7 cells, where a 90 % reduction in LPCAT 
activity was observed relative to the control (Zhao et al., 2008).  This suggests that 
LPCAT3 is the major enzyme contributing to LPCAT activity in hepatocytes in vivo. 
When hLPCAT3 was overexpressed in HEK293 cells, it displayed LPCAT activity 
equivalent to that of LPCAT1 (Zhao et al., 2008) and in these cells, LPCAT3 
Jenny Hughes       Chapter 1: Introduction 
 36 
 
exhibited substrate specificity only for lysoPC and lysoPS (Hishikawa et al., 2008; 
Zhao et al., 2008; Matsuda et al., 2008). 
 
In 2008, Kazachkov et al. (2008) concluded that hLPCAT3 expressed in a yeast strain 
exhibited a dramatic increase in LPCAT activity compared to the control. mLPCAT3 
expressed in CHO-K1 cells provided further evidence that LPCAT3 preferred mono- 
or polyunsaturated fatty acyl-CoAs and played a major role in LPCAT activity in 
these cells (Hishikawa et al., 2008). It was also noted that LPCAT3 expression was 
not influenced by innate immune agonists, confirming that it contributes to membrane 
biogenesis in a constitutive manner (Gijón et al., 2008; Jain et al., 2009). LPCAT3 
has been shown to be widely distributed in human tissues further indicating that this 
is a principal enzyme in the regulation of the remodelling pathway. 
 
1.15.4 LPCAT4 / MBOAT2 
MBOAT2, also known as LPCAT4, has shown both LPCAT and LPEAT activities in 
mice (Gijón et al., 2008). mLPCAT4 mRNA is highly expressed in epididymis, brain, 
tesis and ovary  tissue and has demonstrated a clear preference for lysoPC or lysoPE. 
mLPCAT4 also exhibited higher LPCAT activity with 1-acyl-lysoPC than 1-O-alkyl-
lysoPC or 1-O-alkenyl-lysoPC as acceptors, suggesting it may recognise differences 
between the ester and ether bond at the sn-2 position of lysoPC. Localisation of this 
enzyme was also examined and found to mainly reside in the endoplasmic reticulum, 
rather than the Golgi or mitochondria in CHO-K1 cells (Hishikawa et al., 2008). Toll-
like receptor 3, 4, or 9 agonists did not induce mRNA expression of mLPCAT4 in 
macrophages, indicating that like LPCAT3, mLPCAT4 may play a constitutive role 
in membrane biogenesis, as opposed to an inducible remodelling pathway in response 
to external stimuli (Hishikawa et al., 2008).  
 
1.15.5 LPEAT2 
LPEAT2, also known as acyltransferase-like 3 (AYTL3) and AGPAT7, shares a high 
degree of protein sequence homology with both LPCAT1 and LPCAT2 (Ye et al., 
2005) and is predominantly expressed in brain and inflammatory cells (Cao et al., 
2008). Similarly to both these LPCATs, LPEAT2 shows high LPEAT and moderate 
LPCAT and LPGAT activity, with preference toward C18:1 and C16:0-CoAs. The 
mouse ortholog of LPEAT2 was found to share 93 % amino acid identity with the 
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human gene (Cao et al., 2008). mLPEAT2 mRNA was detected in erythroleukemic 
mouse Friend cells (as was LPCAT1 and 2), but was not detected in reticulocytes or 
adult RBCs unlike LPCAT1 (Soupene et al., 2008).  In contrast to LPCAT1 and 
LPCAT2, mRNA expression levels were very low in both mouse and human liver 
and lung tissues.  
 
Whilst some research suggests dominant LPEAT activity and a small increase in 
LPCAT activity when mLPEAT2 was overexpressed in E.coli (Cao et al., 2008), 
other group’s have found only weak LPCAT and undetectable LPEAT activity 
(Soupene et al., 2008). This apparent contrast may be the result of intrinsic 
differences between E.coli and mammalian expression systems. However, when 
LPEAT2 was depleted by siRNA in HEK293 cells, only LPEAT activity significantly 
decreased. Neither LPGAT nor LPCAT activity was affected in these cells, 
suggesting LPEAT2 mainly contributes to phosphatidylethanolamine (PE) formation 
in these cells. Since LPEAT2 is also primarily expressed in brain tissue, it may 
suggest a possible role for LPEAT2 in modulating brain PE composition.  
 
1.16 LPCAT’s role in cell signalling  
An alteration to fatty acid or acyl composition of the plasma membrane, facilitated by 
LPCAT, subsequently modifies not only membrane structure but also its function 
(Shindou et al., 2008). It is suggested that by altering the plasma membrane 
properties to become more fluid, LPCAT enzymes allow the membrane to modulate 
movement of proteins for the assembly of receptor complexes (Schmid et al., 2003). 
In previous studies, (Neville et al., 2005; Jackson et al., 2008) LPCAT has shown to 
alter the phospholipid composition of the plasma membrane in monocytes and 
macrophages and findings also confirmed that lysophospholipid metabolism 
facilitates TLR4 membrane translocation in A549 epithelial cells, after LPS challenge 
(Abate et al., 2010). LPCAT could therefore potentially be involved in the activation 
of TLR4 in response to LPS and hence may play a role in the control of subsequent 
inflammatory cytokine signalling events associated with sepsis. However it is not 
clear which cytokine signalling processes are regulated in this way and the role of 
LPCAT during inflammatory responses to other microbial stimuli, such as TLR2 
ligands, is not clearly understood. 
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Further studies have shown that inflammatory cytokine interferon (IFN)-γ can 
directly up-regulate the activity of LPCAT in monocytes (Neville et al., 2003). 
Furthermore, IFN-γ primes monocytes for subsequent challenge with LPS through, a 
process that involves changes in the plasma membrane fatty acid composition, 
generating increased inflammatory responses to LPS (Schmid et al., 2003). The 
control of the consequential amplified release of cytokines by IFN-γ primed 
monocytes is important in the pathogenesis of sepsis, but how LPCAT may regulate 
these inflammatory responses to microbial stimuli, are poorly understood. Under such 
conditions the inhibition of LPCAT represents a potential method to better understand 
these processes. 
 
1.17 Inhibitors of LPCAT 
In 2003, Schmid and colleagues identified inhibitors for LPCAT by high-throughput 
screening. A promising candidate that emerged from this study is 5 hydroxyethyl 5,3′ 
thiophenyl pyridine (HETP), a noncompetitive specific inhibitor of CoA-dependent 
LPCAT which has since been synthesized by a method adapted from Yamada et al. 
(2005). In the cell systems used, HETP was found to have an IC50 of 10 μM for the 
inhibition of LPCAT and demonstrated a subsequent reduction in the production of 
two key inflammatory cytokines TNF-α and IL-6, in LPS-stimulated monocytes 
(Schmid et al., 2003).  
 
In 2004, Chambers and Brown identified a novel acyl-CoA cholesterol 
acyltransferase inhibitor, 2,2-methyl-N-(2,4,6-trimethoxyphenyl) dodecanamide (CI-
976). Studies utilising this inhibitor demonstrate that CI-976 inhibits multiple 
membrane trafficking steps, including ones found in the endocytic and secretory 
pathways, and it has been suggested to non-specifically inhibit LPCAT (Brown et al., 
2008). Both LPCAT inhibitors were investigated during this study. 
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1.18 Rationale and aims of the present study 
LPCAT describes the activity of enzymes which catalyse the reacylation of lysoPC to 
PC in the plasma membrane. This activity serves to alter membrane properties and 
modulate the movement of proteins for assembly of receptor complexes and may 
therefore be important in the regulation of inflammatory responses and hence the 
pathogenesis of sepsis. As such it would be beneficial to study the immnuo-regulatory 
properties of LPCAT in response to diverse microbial stimuli, in monocytes and 
airway epithelial cells that regularly come into contact with pathogenic components. 
 
Previous studies have indicated that LPCAT plays a crucial role in monocyte 
inflammatory responses to TLR4 ligand, LPS (Schmid et al., 2003: Abate et al., 
2010). Furthermore, TLR2 associated PAMPs arising from Gram-positive bacterial 
cell components, including peptidoglycan and lipoteichoic acid, have shown to be of 
similar importance in the induction of bacterial sepsis (Seam and Suffredini, 2007). 
Studies of LTA-induced inflammatory responses have shown that the TLR 
heterodimer TL2/TLR6 translocates into the lipid raft domain of monocytes upon 
encounter with LTA and initiates the downstream signalling cascades, producing pro-
inflammatory cytokine TNF-α (Triantafilou et al., 2004). However the effect of 
LPCAT in LTA-induced inflammatory responses has not yet been studied. 
 
This study aims to determine if LPCAT has a key role in the regulation of TLR2 
ligand induced inflammatory responses and consequently Gram-positive bacterial 
sepsis and to identify if a correlation between the expression of specific LPCAT 
isoforms and the inflammatory response regulatory mechanisms exists in 
inflammatory cells to elucidate if LPCAT could be a potential target in the treatment 
of sepsis. 
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1.18.1 Objectives 
The objectives of this study were: 
 To use a specific LPCAT inhibitor (HETP) to demonstrate the role of LPCAT 
in the production of an array inflammatory cytokines, TNF-α, IL6 and IL8, 
with TLR2 ligands LTA, PG and Pam3CSK4 in monocytic cell line, MM6, 
primary blood derived monocytes and epithelial cells, BEAS-2B.  
 To determine if IFN-γ primes monocytes for subsequent challenge with TLR2 
ligands LTA, PG and Pam3CSK4 whilst using the specific HETP to 
investigate the role of LPCAT in IFN-γ priming. 
 To ascertain if LPCAT2 is the major remodelling enzyme involved in 
inflammatory pathways through detecting the intrinsic mRNA expression 
level of 5 LPCATs in monocytic (MM6) and epithelial (BEAS-2B) cell lines. 
 To determine how LPCAT activity is regulated during an inflammatory 
immune response, by examining LPCAT mRNA and protein expression and 
LPCAT activity before and after IFN-γ stimulation. 
 To determine if LPCAT is involved in TLR2 translocation into the lipid rafts 
of MM6 cells during stimulation with TLR2 ligands LTA and Pam3CSK4. 
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1.19 Hypothesis: 
The hypothesis of this study was that inhibition of LPCAT with HETP will suppress 
secretion of pro-inflammatory cytokines, TNF-α, IL-6 and IL-8, in response to LPS, 
LTA, PG and Pam3CSK4 stimulation, as previously demonstrated with LPS 
stimulation in the MM6 cell line and primary blood monocytes (Schmid et al., 2003; 
Jackson and Parton, 2004). Thus it was also predicted that LPCAT will play a crucial 
role in the translocation of TLR2 into the lipid raft domain of monocytes upon 
stimulation, as previously seen with TLR4 (Jackson et al., 2008; Abate et al., 2010). 
As lung tissues are delicate and have designated functions to perform, they cannot 
allow themselves to be overly infiltrated with immune cells that might destroy them 
or their function in the process of fighting infection, it was anticipated that 
inflammatory responses to LPS, LTA, PG and Pam3CSK4 in lung epithelial cells, 
BEAS-2B, would be less than seen in monocytes. 
 
It was expected that LPCAT would play a role in IFN-γ priming of monocytes for 
subsequent challenge with TLR2 ligands, due to an up-regulation in LPCAT activity, 
generating an amplified production of inflammatory cytokines as seen with LPS 
stimulation (Schmid et al., 2003). It was hypothesized that LPCAT isoforms are 
unique to particular cell types and expression levels of individual LPCATs will reflect 
this. Additionally, it was anticipated that one LPCAT, most likely LPCAT2, (Shindou 
et al., 2007) will be predominately expressed in monocytes, where inflammatory 
responses are initiated and that LPCAT mRNA and protein expression will be 
amplified after IFN-γ stimulation in monocytes as seen with LPCAT activity (Neville 
et al., 2003). 
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2.1 Reagents 
All reagents were obtained from Sigma (Poole, UK), unless stated otherwise. 
Palmitoyl-3-cysteine-serine-lysine-4 (Pam3CSK4) hydrochloride was supplied by 
Merck Chemicals Ltd. (Nottingham UK). ELISA DuoSet kits were obtained from 
R&D Systems (Oxford, UK). Precast gels were from Invitrogen (Paisly, UK), 
antibodies for Western blotting were from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA), and antibodies for flow cytometry were from e-Bioscience (San Diego, 
CA, USA). ECL Plus detection kit was from Amersham Biosciences 
(Buckinghamshire, UK). 
 
2.2 Cell Lines 
All cell lines were seeded at a density recommended by the respective supplier and 
grown at 37°C in humidified air and 5 % CO2. 
 
2.2.1 MonoMac6 cells  
A human acute monocytic leukemia cell line, established from the peripheral blood of 
a 64-year-old man, obtained from German Cell Collection (DSMZ, Braunschweig, 
Germany). MonoMac6 cells (MM6) were maintained in RPMI-1640 medium, 
supplemented with 10 % (v/v) foetal bovine serum, 2 mM L-glutamine, 1 mM 
Sodium pyruvate, 1 % (v/v) non-essential amino acids and 1 % (v/v) penicillin/ 
streptomycin. 
 
2.2.2 A549 cells 
A human lung carcinoma cell line, established from an explanted lung tumour which 
was removed from a 58-year-old Caucasian man, obtained from American Type 
Culture Collection (Manassas, VA, USA). A549 cells were maintained in RPMI-1640 
medium, supplemented with only 5 % (v/v) foetal bovine serum (or without if serum 
free), 2 mM L-glutamine and 1 % (v/v) penicillin/ streptomycin. 
 
2.2.3 BEAS-2B cells 
A transformed human bronchial epithelial cell line, obtained from autopsy of non-
cancerous individuals, infected with an adenovirus 12-SV40 virus hybrid 
(Ad12SV40) and cloned. The cells were a kind donation from Dr Amanda Tonks 
(Cardiff University, Cardiff, UK). BEAS-2B cells were maintained in F-12 Kaighn’s 
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modification medium, supplemented with 5 % (v/v) foetal calf serum (or without if 
serum free) and 1 % (v/v) penicillin/ streptomycin. 
 
2.2.4 HEPG2 
A human liver epithelial cell line established from a hepatocellular carcinoma of a 15 
year old adolescent male. HEP G2 cells were maintained in EMEM, supplemented 
with 10 % (v/v) foetal bovine serum, 2 mM L-glutamine, 1 % (v/v) non-essential 
amino acids and 1 % (v/v) penicillin/ streptomycin. 
 
2.2.5 HEK 293 
A human embryonic kidney cell line transformed with adenovirus 5 DNA in the early 
70s (Graham et al., 1977). HEK 293 cells were maintained in EMEM, supplemented 
with 10 % (v/v) foetal bovine serum and 1 % (v/v) penicillin/ streptomycin. 
 
2.2.6 RAW 264.7  
A murine macrophage cell line, established from a tumour induced by Abelson 
murine leukemia virus. RAW 264.7 cells were maintained in 4.5 g/L glucose DMEM, 
supplemented with 10 % (v/v) foetal bovine serum, 1 % (v/v) non-essential amino 
acids and 1 % (v/v) penicillin/ streptomycin. 
 
2.3 Inhibitors of LPCAT Activity 
Initially a range of inhibitor concentrations were tested to determine the appropriate 
concentration to use for a significant reduction in cytokine secretion, without 
affecting cell viability. HETP: 5-Hydroxyethyl 5,3’thiophenyl pyridine (HETP), a 
non-competitive, specific inhibitor of CoA-dependent LPCAT, was synthesized by a 
collaborator Simon Jones, (University of Sheffield, UK), using a method adapted 
from Yamada et al.  (2005).  
 
To analyse the dose response of HETP, a range of concentrations (0-100 µM) was 
added to cells for 30 minutes prior to co-culture with or without LPS. In experiments 
conducted after this preliminary test, cells were routinely treated with 0 µM or 50 µM 
HETP for 30 minutes prior to ligand stimulation. 
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Another inhibitor, 2,2-methyl-N-(2,4,6-trimethoxyphenyl) dodecanamide (CI-976): a 
novel acyl-CoA cholesterol acyltransferase inhibitor (GlaxoSmithKline 
pharmaceuticals, Essex, UK), was also tested for its ability to inhibit LPCAT. CI-976 
was added to cells, ranging from 0 to 50 µM for 30 minutes prior to co-culture with 
or without LPS. However, cell viability data demonstrated that even at low 
concentrations (10 µM) this inhibitor was toxic to cells, so CI-976 was not used in 
further experiments. 
 
 
CI-976       HETP 
 
 
2.4 Cell Stimulants 
Experiments to determine the inhibitor concentration were stimulated with 100 ng/ml 
Escherichia coli 0111:B4 lipopolysaccharide (LPS). As well as TLR4 ligand, LPS, 
further experiments used TLR2 ligands; 10 µg/ml Staphylococcus aureus  
lipoteichoic acid (LTA), 10 µg/ml S. aureus  peptidoglycan (PG) (all from Sigma, 
Poole, UK) and 1.0 µg/ml N-palmitoyl-S-dipalmitoylglyceryl (Pam3) Cys-Ser-
(Lys)4trihydrochloride (Pam3CSK4) (a synthetic lipohexapeptide analog of the 
immunologically active portion of bacterial lipoprotein) (Merck Chemicals Ltd. 
Nottingham UK). Recombinant human Interferon gamma (IFN-γ) (R&D Systems, 
Oxford, UK) was used at 10 µg/ml (250 units/ml) to prime cells before stimulation, 
and enhance inflammatory responses, as previously shown with LPS (Neville et al., 
2005). 
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2.5 Assessment of LPCAT inhibition on inflammatory responses to TLR ligands 
by ELISA 
2.5.1 Co-culture of Cells for Cytokine secretion analysis by ELISA 
For standard analysis of cytokine production by ELISA, cells were cultured in 1 ml of 
media in 12 well plates. Selected cells were then incubated with or without IFN-γ for 
16 hours. The cells were then treated with or without HETP for 30 minutes prior to 
co-culture with or without LPS, LTA, PG or Pam3CSK4. The negative controls were 
cell alone. One plate was co-cultured for 6 hours (to analyse TNF-α concentrations) 
and the other for 24 hours (to analyse IL-6 and IL-8 concentrations), then 1 ml 
samples were collected, centrifuged (2000 rpm, 5 minutes) and two 300 µl samples of 
supernatant were collected, for later detection of cytokine production, and stored at -
80°C. 
 
2.5.2 Detection of Cytokine secretion by ELISA 
The cell supernatants collected from the 6 hour culture were probed for human TNF-
α/TNFSF1A and the cell supernatants collected from the 24 hour culture were probed 
for human IL-6 and CXCL8/IL-8 using DuoSet ELISA kits (R&D Systems, Oxford, 
UK) and KPL Sureblue TMB Microwell Peroxidise Substrate (Insight Biotechnology 
Ltd, Wembley, UK). A set of seven 2-fold serial dilutions of the standard provided in 
the kit, was generated for each assay. Each standard, control, and sample in the assay 
was tested and applied in triplicate to the 96 well plate and the method continued 
according to the manufacturer’s protocol. The plate was analysed using an Anthos II 
Optical Absorbance microplate reader set to 450 nm, with correction wavelength 540 
nm. The optical density data was analysed with a linearized plot of log of the cytokine 
concentrations versus the log of the optical density. If the optical density value of 
sample fell outside of the standard plot, samples were diluted accordingly and the 
assay repeated. 
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2.6 Assessment of LPCAT inhibition on inflammatory responses to TLR ligands 
by qPCR 
2.6.1 Co-culture of Cells for Cytokine Analysis by qPCR 
For standard analysis of mRNA expression by qPCR, cells (3×10
6
) were set up 3 ml 
of media in 6 well plates. Selected cells were incubated with or without IFN-γ for 16 
hours, or directly treated with or without HETP for 30 minutes (post IFN-γ 
incubation) prior to co-culture with or without LPS, LTA, PG or Pam3CSK4. The 
negative controls were cell alone.  The plate was co-cultured for 4 hours and then the 
cells were collected and centrifuged (5 minutes, 2000 rpm). Total RNA isolation was 
achieved using an acid guanidinium thiocyanate-phenol-chloroform extraction 
method.  
 
2.6.2 Total RNA isolation 
Briefly, 500 μL of denaturing solution was added directly to the cell pellet and 
allowed to stand for 15 minutes. The following was then sequentially added to cell 
lysates: 50 μL of 2 M sodium acetate, pH 4, mixed thoroughly; 500 μL water 
saturated phenol, mixed thoroughly; 100 μL of chloroform: isoamyl alcohol (49:1) 
and shake vigorously by hand for 10 seconds. The samples were then cooled on ice 
for 15 minutes and centrifuged for 20 minutes at 15000×g at 4°C. The upper aqueous 
phase, which contains mostly RNA, was transferred to a new RNase- and DNase-free 
eppendorf tube, containing 500 μL of isopropanol to precipitate the RNA. Samples 
were left to incubate overnight at -20°C and then centrifuged for 20 minutes at 
15000×g at 4°C. The gel-like precipitate, which is RNA, was kept and the 
supernatant discarded. The RNA pellet was dissolved with 300 μL of denaturing 
solution and 300 μl of isopropanol. The sample was incubated for 30 minutes at -
20°C and then centrifuged for 10 minutes at 15000×g at 4°C. The supernatant was 
discarded and the RNA pellet resuspended with 500 μL of 75 % ethanol. The samples 
were vortex for 10 seconds and incubated for 15 minutes at room temperature to 
dissolve residual guanidinium thiocyanate. Once again, the samples were centrifuged 
for 10 minutes at 15000×g at 4°C, supernatant discarded and the RNA pellet left to 
air-dry for 5 minutes at room temperature. Finally, the RNA was dissolved in RNase- 
and DNase-free water and incubated for 15 minutes at 60°C to ensure complete 
solubilisation. The RNA was then stored at -80°C for reverse transcription. 
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2.6.3 RNA quantification and integrity 
The RNA was quantified using a Nanodrop 1000 Spectrophotometer (Thermo Fisher 
Scientific, Loughborough, UK) and the RNA integrity was calculated using an 
Agilent RNA 6000 Nano kit and Agilent 2100 bioanalyser (Agilent Technologies 
Ltd, Stockport, UK). RNA with an integrity number (RIN) less than 8 were not used 
and the majority of samples had a RIN of 9 or 10.  
 
2.6.4 Reverse Transcription 
Reverse transcription was carried out according to manufacturer’s protocol using 
Superscript II Reverse Transcriptase and Oligo (dT)12-18 (Invitrogen, Paisley, UK). 
Briefly, 2 µg of total RNA and 0.1 ng of RuBisCo mRNA (plant mRNA spike used as 
an internal control) was added to 1 µl of dNTP mix (10mM each) and made up to 13 
µl with sterile water. This mixture was heated to 65°C for 5 minutes in a PTC-200 
Peltier Thermal Cycler (MJ Research), to denature RNA tertiary structure and then 
chilled on ice. Next 4 µl of 5× first strand buffer and 2 µl of DTT (0.1M) was added 
and the mixture heated to 42°C for 2 minutes. Finally, 1 µl of Superscript II RT was 
added, mixed and incubated at 42°C for 1 hour 30 minutes. The reaction was then 
inactivated by heating at 70°C for 15 minutes. For internal control RuBisCO mRNA 
sequence see appendix 4. 
 
2.6.5 qPCR 
Real time PCR was performed in triplicate using SYBR GreenER qPCR SuperMix 
(Invitrogen, Paisley, UK) for the iCycler (Bio-Rad, Hertfordshire, UK) according to 
manufacturer’s protocols. Briefly, 10 µl of SYBR GreenER, 400 nM of forward and 
reverse primers and 5 µl of cDNA (diluted between 1:50-1:100 from RT to achieve 
approximately 30 µg per reaction) was used in each reaction in a total volume of 20 
µl. For specific primer sequences see appendix 4. 
 
2.6.6 Agarose gel for electrophoresis of PCR products 
A 2 % agarose gel was made with TRIS Borate–EDTA buffer (TBE) and 0.5 µg/ml 
ethidium bromide. The gel was set aside to solidify for at least 30 minutes before 
removing the comb. qPCR samples were mixed with loading buffer before adding to 
the wells and DNA Hyperladder V  (Bioline Ltd, London, UK) was loaded to the 
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outer well to assist base-pair separation. The agarose gel was run in TBE at 120V for 
1 hour. 
 
2.7 Assessment of human primary monocyte responses to TLR ligands  
2.7.1 Isolation of Peripheral Blood Mononuclear Cells 
Briefly, 50 ml of human donor blood was diluted with an equal volume of sterile 
PBS. The blood sample was then overlaid on equal volume of LymphoPrep (Axis-
shield, Cambridgeshire, UK) and centrifuged at 2,900 rpm for 30 minutes at room 
temperature with no brake. The buffy coat layer was carefully removed and placed 
into clean tubes with PBS for cell washing (2,400 rpm, 15 minutes). The PBMC 
pellets were then combined and washed in sterile water (1,300 rpm, 10 minutes). The 
PBMCs were resuspended in 20 ml of ×1 red blood cell lysis buffer and left at room 
temperature for 10 minutes. The cells were then washed twice in PBS (1,300 rpm, 10 
minutes) and prepared for culture or monocyte isolation.  
 
2.7.2 Isolating an Enriched Monocyte Population 
Enrichment of human monocytes from donor PBMCs, involved the trialling of three 
methods following manufacturer’s instruction; the first followed the adherent method 
as used by Schmid et al. (2003), the second required separation of monocytes from a 
leukocyte-rich plasma by flotation through a discontinuous iodixanol gradient using 
OptiPrep (Axis-shield, Cambridgeshire, UK) (Graziani-Bowering et al., 1997) and 
the third comprised of an indirect magnetic labelling system (MACS monocyte 
isolation kit II; Miltenyi Biotec Ltd, Surrey, UK) which was subsequently use in 
additional experiments. 
 
2.7.3 Adherence method by Schmid et al. (2003) 
Following isolation of PBMCs, cells were washed twice with NaCl/Pi RPMI 1640 
medium without additives to give a cell density of 5×10
6
/ml. To each well of a 24-
well plate, 400 µl of the cell suspension was added and incubated at 37°C for 2 h. The 
monolayer was washed thrice with warm RPMI 1640 medium. 1 ml fresh complete 
RPMI 1640 medium (with all additives detailed above) was added and the cells 
incubated at 37°C.  
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2.7.4 OptiPrep™ (Axis-Sheild) 
This method separated monocytes from a leukocyte-rich plasma by flotation through 
discontinuous iodixanol gradient (Axis-Sheild Cell Application Sheet C09). Briefly, 
two solutions of 1.068 g/ml and 1.084 g/ml were prepared by mixing OptiPrep™ and 
a solution containing 1.0 % (w/v) NaCl, 1 mM EDTA, 10 mM Hepes-NaOH, pH 7.4 
and 0.5 % (w/v) bovine serum albumin. After isolation of PBMCs, cells were mixed 
with OptiPrep™(10 ml + 4 ml, respectively) and overlaid with 7.5 ml of the 1.084 
g/ml solution and 20.0 ml of the 1.068 g/ml solution. Finally a small volume (approx. 
0.5 ml) of Hepes-buffered saline was layered on top. The discontinuous gradient was 
centrifuged at 600-800×g in a swinging-bucket rotor for 20-25 min at 20°C. 
 
2.7.5 MACS monocyte isolation kit II (Axis-shield) 
The indirect magnetic labelling system isolated untouched monocytes and was used 
according to the manufacturer’s guidelines. In summary, PBMCs were resuspended in 
30 µl of PBS buffer/107 cells, 10 µl of FcR blocking reagent/107 cells and 10 µl /107 
cells of biotin conjugated antibodies against CD3, Cd7, Cd16, CD19, Cd56, Cd123 
and CD235a and cells were incubated for 10 minutes at 4°C. 30 µl PBS buffer/107 
cells and 20 µl of anti-biotin microbeads/107 cells were subsequently added and 
incubated for an additional 15 minutes at 4°C. Following washing with PBS buffer, 
cells were resuspended in 500 µl /108 cells and applied to a 3 ml LS MACS separator 
column, where unlabelled cells passed through and effluent was collected. This cell 
suspension represented an enriched population of monocytes.  
 
2.7.6 Assessment of enriched cell population purity by flow cytometry 
PE Mouse anti-human CD14 antibody (BD Bioscience, Oxford, UK) was used to 
assess the percentage of monocytes in PBMCs before isolation and to check the 
purity of the enriched monocyte population by flow cytometry. Cells were blocked 
with BSA for 10 minutes at RT prior to staining with conjugated CD14-PE antibody 
at 1 µg /106 cells for 40 minutes. For the iso-type control, cells from each treatment 
were incubated with PE secondary antibody for 40 minutes. All cell samples and 
treatments were then analysed using Accuri C6 Flow Cytometer. Cell debris and dead 
cells are excluded from the analysis based on scatter signals and fluorescence.  
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2.8 Analysis of LPCAT and TLR2 protein expression by western blot 
2.8.1 Co-culture of cells for analysis by western blot 
For standard analysis of protein expression by western blot, cells (6×10
6
) were set up 
3 ml of supplemented RPMI media in 6 well plates. Selected cells were incubated 
with or without IFN-γ for 18 hours, or directly treated with or without HETP for 30 
minutes (post IFN-γ incubation) prior to co-culture with or without LPS, LTA, PG or 
Pam3CSK4. The plate was co-cultured for 1 hour and then the cells were collected and 
centrifuged (5 minutes, 2000 rpm). The negative controls were cell alone.   
 
2.8.2 Preparation of total cell lysate 
Following incubation, cells were harvested, washed twice with ice cold PBS and 
centrifuged at 1500 rpm, for 5 minutes at 4°C. Cells were lysed in 300 µl of ice cold 
Triton X extraction buffer for 1 hour at 4°C and sonicated on ice to homogenize the 
lysate in 4×11 second bursts and reduce sample viscosity. Complete lysis of cells was 
checked using light microscopy, before centrifuging the samples at 2,500×g at 4°C 
for 5 minutes to remove cell debris and retain protein in the supernatant. 
 
2.8.3 Quantification of Total Protein  
Protein quantification of cell lysate was determined using Pierce BCA microplate 
Protein assay kit (Thermo Fisher Scientific, Loughborough, UK). This method 
combines the well-known reduction of Cu+2 to Cu+1 by protein in an alkaline 
medium (the biuret reaction) with the highly sensitive and selective colorimetric 
detection of the cuprous cation (Cu+1) using a unique reagent containing 
bicinchoninic acid. 
 
2.8.4 Western blot method 
Equal volumes of each lipid fractions or 20 µg of total cell lysate were mixed with the 
same volume of ×2 LDS sample buffer and heated at 95°C for 5 minutes before being 
loaded onto Criterion XT Precast (4-12 %) Bis-Trisgels (Bio-Rad, Hertfordshire, 
UK). Biotinylated Protein ladder (New England Biolabs, Hertfordshire, UK) and see 
blue plus 2 pre-stained standard (Invitrogen, Paisley, UK) were loaded at either end 
of the gel to aid identification of proteins and assess the progress of the separation. 
The gels were run in a Criterion Electrophoresis Tankat 100V for 1.5 hours in the 
presence of XT-MOPS running buffer.  
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The gel was then transferred onto Hybond-C Extra nitrocellulose membrane 
(Amersham via GE Healthcare, Buckinghamshire, UK)using a Criterion blotter at 
50V for 1 hour at 4°C in the presence of transfer buffer. After transfer the membrane 
was washed with TBS-T (two 5 minute washes) and left for 1 hour in blocking 
solution (5 % low fat dried milk dissolved in TBS-T), to block non specific binding 
sites, then washed with TBS-T (three 5 minute washes). Membranes were probed 
with the appropriate dilution of primary antibody in blocking solution overnight at 
4°C, including; IMGENEX monoclonal mouse anti-human TLR2 and anti-human 
CD71 (transferrin receptor) (Cambridge Bioscience, Cambridge, UK), mouse anti-
human RNF40 polyclonal antibody  (Abnova distributed by Novus Biologicals Ltd, 
Cambridge, UK), rabbit anti-human polyclonal  LPCAT1 and LPCAT2 (ProteinTech, 
Manchester, UK), mouse anti-human monoclonal GAPDH (0411) antibody (Santa 
Cruz, CA, USA). 
 
Overnight incubation was followed by three 5 minute washes in TBS-T. Membranes 
were then incubated for 1 hour with HRP-conjugated anti-biotin antibody to detect 
biotinylated protein markers, and the appropriate dilution of HRP-conjugated 
secondary antibody in blocking buffer (either anti-mouse or anti-rabbit IgG) (Cell 
Signalling Technology, supplied by New England Biolabs, Hertfordshire, UK). After 
extensive washing with TBS/T to remove excess antibody, the antigen was visualised 
using Amersham ECL Plus Western Blotting Detection Reagents (GE Healthcare, 
Buckinghamshire, UK) according to the manufacturer’s instructions. Re-probing of 
membranes was achieved by stripping the membrane in 1M sodium hydroxide for 7 
minutes, followed by extensive washing with PBS and TBS/T and repeating the 
above process from the blocking step. The electrophoresis gel was also fixed and 
stained with a Brilliant Blue G-Colloidal mix to confirm successful transfer of 
proteins. 
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2.9 Determining TLR translocation into lipid raft domains 
2.9.1 Preparation of Total Cell Lysate 
MonoMac-6 cells (3×10
6
) were incubated with or without IFN-γ for 18 hours and 
then treated with or without HETP for 30 minutes prior to co-culture with or without 
LPS, LTA, PG or Pam3CSK4. The negative controls were cell alone.  The plate was 
co-cultured for 45 minutes and then the cells were collected and centrifuged (2000 
rpm, 5 minutes). Cells were lysed in 300 µl of ice-cold extraction buffer containing 1 
% Triton X-100 and 1 tablet of Complete Mini EDTA-free protease inhibitor cocktail 
(Roche, Hertfordshire, UK), for 1 hour on ice. The cell lysate was sonicated for four 
11 second bursts to homogenize the lysate, shear DNA and reduce sample viscosity. 
Complete lysis was checked using light microscopy. Lysates were centrifuged at 2000 
rpm for 5 minutes to remove the nuclei and cell debris and the supernatant transferred 
and stored at -80°C for later use. 
 
2.9.2 Isolation of Lipid Fractions 
The lipid raft domains were isolated from cells as described by Triantafilou et al. 
(2004) with slight modifications. MonoMac-6 cells (1×10
7
) were incubated with or 
without IFN-γ for 18 hours and then treated with or without HETP for 30 minutes 
prior to co-culture with or without LPS, LTA, PG or Pam3CSK4. The negative 
controls were cell alone.  The plate was co-cultured for 45 minutes and then the cells 
were collected and centrifuged (2000 rpm, 5 minutes). Cells were lysed in 500 µl of 
MES buffered saline (MBS) containing 1 % Triton X-100 (a detergent that facilitates 
the separation of soluble and insoluble fractions) and 1 tablet of Complete Mini 
EDTA-free protease inhibitor cocktail (Roche, Hertfordshire, UK), to inhibit 
proteolytic activity, for 1 hour on ice. The cell lysate was sonicated for four 11 
second bursts to homogenize the lysate and reduce sample viscosity. The cell lysate 
was then mixed with an equal volume of 90 % sucrose in MBS and placed at the 
bottom of a centrifuge tube. The sample was overlaid with 5.5 ml of 30 % sucrose 
and 4.5 ml of 5 % sucrose in MBS and centrifuged at 100,000×g for 16 hours (4°C) 
using SW40Ti rotor on Beckman Coulter Optima L-100XP Ultracentrifuge. This 
allowed the membrane microdomains, rich in sphingolipids and cholesterol, to be 
separated out based on their insolubility in Triton X-100 and by low buoyant density 
in sucrose gradients. Twelve membrane fractions (1 ml each) were then gently 
removed from the top of the gradient and n-Octyl-β-D-glucopyranoside (Sigma, 
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Poole, UK) added to each fraction (60 µM final concentration) to solubilise the lipid 
fractions. These were stored at -80°C for later use. 
 
2.9.3 Assessment of lipid raft isolation by Dot Blot 
To determine which fractions contained the lipid raft, samples (5 µl) from each of the 
twelve fractions were taken and left to dry on nitrocellulose membrane for 1 hour. 
The membrane was then probed for GM1 (a ganglioside receptor prevalent in lipid 
rafts) with 1:1000 dilution of HRP-conjugated cholera-toxin β-subunit (which 
specifically binds to GM1) (Sigma, Poole, UK) for 1 hour in blocking buffer (5 % 
low fat dried milk dissolved in TBS, 0.1 % Tween 20). The membrane was washed 
with 15 ml washing buffer, TBS +0.1 % Tween 20 (TBS-T), four 5 minute washes 
and two 2 minute washes in water,to remove any excess antibody. The antigen was 
then visualised using Amersham ECL Plus Western Blotting Detection Reagents (GE 
Healthcare, Buckinghamshire, UK) according to the manufacturer’s instructions. 
 
2.9.4 Protein concentration  
Concentrating protein from cell lysate fractions following lipid raft isolation, 
involved the trialling of three methods; methanol/chloroform precipitation (Wessel 
and Flugge, 1984), acetone precipitation (Pierce Biotechnical Inc, USA) and 
phenol/ether precipitation (Sauvé et al., 1995). Following extensive experimental 
optimisation and analysis, it was evaluated that the phenol/ether precipitation method 
was the most proficient at recovering protein from the samples. 
 
2.9.5 Methanol/chloroform precipitation 
The original method by methanol/chloroform precipitation Wessel and Flugge (1984) 
was optimised to incorporate a large volume of sample. Briefly, 700 µl of methanol 
was added to 300 µl of sample and mixed before the addition of 400 µl of 
chloroform. Samples were mixed well by vortexing, then 200 µl of de-ionised water 
was added to assist phase separation. Samples were centrifuged at 13,000×g for 15 
minutes at 4°C. The top aqueous phase was removed and discarded, whilst the 
organic phase was dissolved in 800 µl methanol. Samples were centrifuged at 
13,000×g for 30 minutes at 4°C and the supernatant was removed, subsequently 
leaving the protein pellet to air dry before being resuspended in SDS buffer. 
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2.9.6 Acetone precipitation 
Modifications to the original protocol by Pierce Biotechnical Inc. included an 
additional precipitation cycle necessary to completely remove the interfering sucrose 
as follows; chilled acetone (-20°C) was added at four times the sample volume and 
incubate for 60 minutes at -20°C. Samples were centrifuged at 13,000×g for 15 
minutes at 4°C before removal of the supernatant. A second precipitation cycle was 
repeated with samples incubating with acetone at -20°C for an additional 20 minutes. 
The acetone was allowed to evaporate from the uncapped sample at room temperature 
for 30 minutes prior to dissolving the protein pellet in SDS buffer. 
 
2.9.7 Phenol/ether precipitation 
The use of the rapid method for concentration of protein based on extraction with 
phenol and ether, as described by Sauvé et al. (1995), was used in subsequent 
experiments. In summary, an equal volume of phenol for each sample was added and 
mixed thoroughly by vortexing. Samples were centrifuged at 13,000×g for 5 minutes 
at 4°C before removal of the upper phase. Two times the volume of ether was added 
to the phenol phase, mixed and centrifuged as above. The upper phase was again 
discarded and the previous step repeated with the addition of twice the volume of 
ether. The lower aqueous phase was dried by vacuum centrifugation prior to 
solubilising the protein pellet in SDS buffer. 
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2.10 Data analysis 
Independent experiments were performed on separate dates with distinctive cells or 
progressive cell passage numbers. Statistical comparisons among groups were 
analysed using a two-tailed, paired t-test. Minitab software Version 15 (Minitab Inc., 
UK) was used for all analyses. The paired t-test compares the mean of the two sets of 
data and produces a probability, or P value, that the difference between the two sets 
of data is likely to be due to chance. Paired t-test results were interpreted depending 
on whether the P value was small or large. If P>0.05, then it was more than likely 
that the two sets of data were the same and that any differences were due to chance. If 
P<0.05, then it was more than likely that the two sets of data were significantly 
different and that the differences were due to treatment. Assumptions of the t-test are 
that both sets of data follow normal distribution, which was confirmed with a 
Kolmogorov–Smirnov normality test. 
 
2.10.1 ELISA data analysis 
Cell supernatants were tested for the presence of human TNF-α, IL-6 and IL-8 using 
DuoSet ELISA kits (R&D Systems, Oxford, UK). Each standard, control and sample 
was tested in triplicate and the average optical density of the triplicate readings was 
used to calculate the resulting concentration. The average optical density for the zero 
standards was then subtracted from each sample. A seven point standard curve using 
2-fold serial dilutions of the standard was generated for each set of samples assayed. 
Then a linearized plot of the log of the cytokine concentrations versus the log of the 
optical density of the standards was produced. The best fit line was determined by 
regression analysis and used to calculate cytokine concentrations from the optical 
density data. Where samples were diluted, the concentration read from the linearized 
plot was multiplied by the dilution factor. 
 
Statistical comparisons among groups were determined by calculating a P value. For 
assessment of multiple concentration comparisons of pharmacological inhibitors a 
one-way analysis of variance (ANOVA) was performed. For all other ELISA data 
analysis, a two-tailed, paired t-test was used to compare treatments. Data from cells 
stimulated with a microbial ligand were paired with the data from cells, in the same 
independent experiment, also treated with the inhibitor, HETP. 
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2.10.2 qPCR data analysis 
Real-time PCR data for assessment of cytokine expression were analysed using 2
-ΔΔCT 
and relative gene expression methods (Livak and Schmittgen, 2001) by normalizing 
data to the housekeeping gene, GAPDH, and then calculating the relative fold 
difference against untreated cells as a reference. For analysis of endogenous LPCAT 
expression in different cell types, all cells were untreated, therefore expression levels 
were relative to each other. The data are presented as the mean fold change in mRNA 
expression, normalized to GAPDH and relative to MM6 cells for comparison. 
Statistical comparisons among groups were analysed using a two-tailed, paired t-test. 
 
2.10.3 Western blot data analysis 
Protein expression of LPCAT1 and LPCAT2 in different cells was determined via 
western blot. Protein band intensity was measured using ImageJ software and used as 
a qualitative measure of protein expression (Abramoff et al., 2004). 
 
2.10.4 Flow cytometry data 
Human blood monocytes extracted using the monocyte indirect magnetic labelling 
system were analysed by flow cytometry using Accuri C6 Flow Cytometer. Cell 
debris and dead cells are excluded (gated) from the analysis based on scatter signals 
and fluorescence and 10, 000 events recorded. 
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3.1 INTRODUCTION 
LPCAT enzymes are potential targets for the regulation of inflammatory responses. 
Previous studies have examined the effect of a specific inhibitor for LPCAT on LPS 
induced cytokine production in human monocytic cells; the inhibitor 5 hydroxyethyl 
5,3’ thiophenyl pyridine (HETP or YM 50201) was shown to reduce TNF-α secretion 
induced by LPS in MonoMac6 (MM6) cells (Schmid et al., 2003) and subsequent 
investigation observed that this inflammatory response was largely mediated by 
signalling through TLR4 (Jackson et al., 2008). The work presented in this chapter 
details experiments that assess the effect of LPCAT inhibitors on TLR2 mediated 
responses to determine if LPCAT has a key role in the regulation of Gram-positive 
bacterial induced inflammatory responses in monocytes. This will ascertain whether 
the inhibitory effects of HETP observed in LPS induced cells are either general to 
surface TLRs or associated with TLR4 specifically. 
  
The lungs are in constant contact with the external world of commensals and 
pathogens and therefore they are organs that are always under some condition of 
damage and danger. Lung tissues are delicate and have designated functions to 
perform, thus they cannot allow themselves to be overly infiltrated with immune cells 
that might destroy them or their function in the process of fighting infection. In this 
chapter, the effect of LPCAT inhibitors on TLR2 mediated responses in lung 
epithelial cells will be assessed to establish if the inflammatory responses are as 
sensitive as those observed in monocytes. 
 
Gram positive bacterial components, LTA, PG and Pam3CSK4 were chosen to 
stimulated TLR2 responses because of the diversity of signalling pathways they 
provide; LTA through TLR2/TL6,  Pam3CSK4 through TLR2/TLR1 and PG possibly 
through the TLR2/TL6 heterdimer or intracellular NODs (Nod1/Nod2) (Travossos et 
al., 2004: O’Neill et al., 2013). 
 
3.2 AIMS 
The key aim of this chapter was to assess the effect of LPCAT inhibition on TLR2 
and TLR4 ligand-mediated inflammatory responses in human monocyte and lung 
epithelial cells. 
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3.3 METHODS 
Following Schmid et al. (2003), experiments in this study used MM6 cells, which are 
phenotypically and functionally similar to mature monocytes, to investigate the role 
of LPCAT in inflammatory signalling processes. Unless specified otherwise, “cells” 
refers to the MM6 cell line. 
 
3.3.1 Toxicity assessment for LPCAT inhibitors  
A toxicity assay was performed in parallel to dose response assays in order to assess 
the effectiveness of the LPCAT inhibitors and ensure that selected inhibitors 
exhibited no cell toxicity. MM6 cells (5×10
5
) were co-cultured with a specified 
concentration of either HETP (15-100 µM) or CI-976 (10-50 µM) alone or 30 
minutes prior to stimulation with 100 ng/ml E. coli LPS and incubated for 24 hours. 
After culture, the cells were gently resuspended and a cell viability count performed 
using the Typan blue dye exclusion method.  
 
3.3.2 Determination of IC50 
Under identical conditions and in parallel to the toxicity assay, the effect of LPCAT 
inhibitors on cytokine secretion were assessed by dose response experiments. After 6 
or 24 hours culture, cell supernatants were collected and tested for the presence of 
TNF-α, IL-6 and IL-8 by ELISA. The concentrations of secreted cytokines were 
analysed to determine the respective IC50 for each inhibitor and inhibitor 
concentrations for further work were selected on the basis of these results and cell 
toxicity assays. 
 
3.3.3 Assessment of the effects of HETP on inflammatory responses to TLR ligands 
Cultures of MM6 cells (5×10
5
) were incubated in the presence or absence of 50 μM 
HETP, 30 minutes prior to stimulation with either 100 ng/ml E. coli O111:B4 
lipopolysaccharide (LPS), 10 µg/ml S. aureus  lipoteichoic acid (LTA), 10  µg/ml  S. 
aureus  peptidoglycan (PG) or 1.0 µg/ml Pam3CSK4 and subsequently co-cultured for 
6 or 24 hours. The concentrations of three cytokines central to inflammation, TNF-α, 
IL-6 and IL-8, were then determined using specific ELISAs. 
  
Jenny Hughes       Chapter 3: Results and Discussion 
 61 
 
3.3.4 Assessment of human primary monocyte responses to TLR4 and TLR2 
ligands and the effects of HETP 
To confirm that MM6 cells were a good model for human monocytes, human primary 
monocyte cells were obtained from healthy volunteer PBMCs using three isolation 
methods and the purity of each enriched monocyte population was assessed by 
staining with anti-human CD14 antibody (BD Bioscience, Oxford, UK) and flow 
cytometry.  
 
Monocytes were purified by several methods including the adherence method as used 
by Schmid et al. (2003), a floatation method using OptiPrep discontinuous gradients 
(Axis-shield, Cambridgeshire, UK) (Graziani-Bowering et al., 1997) and a monocyte 
indirect magnetic labelling system (MACS monocyte isolation kit II; Miltenyi Biotec 
Ltd, Surrey, UK). However the first two methods were not considered to be viable 
options due to low recovery, therefore the magnetic labelling system was used in 
further experiments.  
 
All experiments were completed in the presence of human serum, since it is well 
documented that serum increases responsiveness of monocytes to LPS due to the 
availability of soluble CD14, a key factor in the inflammatory responses (Kreutz et 
al., 1997; Adib-Conquy et al., 2002; Schmid et al., 2003). Peripheral blood 
monocytes were incubated under the same conditions as the experiments with MM6 
cells (section 3.3.3) to confirm that the results observed with MM6 cells were 
representative of human monocytes.  
 
3.3.5 Efficacy of HETP to inhibit inflammatory cytokine mRNA expression 
qPCR was used to determine the influence of HETP on cytokine mRNA to establish 
if cytokine inhibition at a protein level was caused by changes at the transcriptional 
level. MM6 cells (2.2×10
6
) were treated for 4 hours in the presence of a TLR ligand 
or with prior inhibition by addition of HETP (50 µM), before total RNA isolation by 
acid guanidinium thiocyanate, phenol, chloroform extraction. Using qPCR, the 
mRNA of inflammatory cytokines, TNF-α, IL-6, IL-8, were normalized with 
housekeeping gene, GAPDH, and the fold difference calculated using untreated cells 
as a reference (2
-ΔΔCT 
method).  
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3.3.6 Determination of interactions between IFN priming of cells and HETP, and 
the effect on cellular responses to TLR4 and TLR2 ligands 
Experiments were performed to examine the effect of IFN-γ priming on monocyte 
cytokine secretion in response to TLR4 and TLR2 ligands and the potential of HETP 
to down-regulate cytokine secretion. MM6 cells (5×10
5
) were pre-incubated with 250 
U/ml IFN-γ for 16 hours, as was optimal for LPCAT activity in previous studies 
(Neville et al., 2005), prior to treatment with HETP (50 µM) and TLR ligand 
stimulation, then co-cultured for 6 or 24 hours. As described previously (section 
3.3.3), concentrations of inflammatory cytokine secretion were determined by 
ELISA. 
 
3.3.7 Assessment of the effects of HETP on inflammatory responses to TLR4 and 
TLR2 ligands in broncho-epithelial cells 
BEAS-2B cells were maintained in media supplemented with 5 % (v/v) foetal calf 
serum, however, these cells were initially unresponsive to microbial stimulants under 
these culture conditions. Further experimental investigation found that lung epithelial 
cells required human serum components to respond to LPS-induced activation, 
supporting the findings of Schulz et al. (2002). 
 
BEAS-2B cells (1×10
5
) were cultured in 12 well plates for 2 days to reach 
confluency, before changing to serum free media overnight. For the cytokine 
experiments, fresh media supplemented with 2 % pooled human serum (HS), required 
for a low concentration LPS induced inflammatory response, was added. BEAS-2B 
cells were treated with or without HETP prior to stimulation with TLR4 and TLR2 
ligands, as with previous experiments and concentrations of inflammatory cytokines 
were determined by ELISA (section 3.3.3). 
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3.4 RESULTS 
3.4.1 Pharmacological LPCAT inhibitors show differences in cellular toxicity  
Viability experiments were performed using a range of inhibitor concentrations, 
either in the presence or absence of LPS. With the specific LPCAT inhibitor, HETP, 
cell viability was over 80 % using a concentration up to 50 μM in the presence of 
LPS (Figure 1.1Table 4.1). However, cell viability significantly deteriorated with 100 
μM HETP, demonstrating that higher concentrations of this inhibitor were toxic to the 
cells. Conversely cell viability was significantly impaired using even low 
concentrations (10 μM) of the non-specific inhibitor, CI-976. This reduction in 
viability is likely a result of CI-976 inhibiting multiple membrane trafficking steps, 
including those required for cells to survive (Brown et al., 2008). 
 
3.4.2 Pharmacological inhibitors of LPCAT reduce cytokine secretion in a dose-
dependent manner 
Alongside the toxicity assay, TNF-α, IL-6 and IL-8 secretions were measured using 
ELISA to determine the IC50 for each inhibitor. Figure 3.1 shows that although both 
LPCAT inhibitors reduce individual cytokine secretion in a dose dependant manner, 
50 % inhibition across all three cytokines can be achieved using 50 μM HETP and 25 
μM CI-976. However, at this concentration, CI-976 was shown to be toxic to the cells 
and thus this inhibitor was excluded from further studies. Future experiments, 
therefore, were completed using the specific LPCAT chemical inhibitor, HETP, at a 
concentration of 50 μM to maintain significant cytokine inhibition and cell viability 
over 80 %. Statistical analysis of control cells co-cultured with 50 μM HETP was 
found not to significantly (P>0.1) effect cytokine secretion when compared to 
endogenous cytokine levels secreted by MM6 cells (Figure 3.2). 
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HETP concentration 
(μM) 
MM6 cell viability (%) 
Without LPS With LPS 
0 94.7 ± 2.3 84.6 ± 5.1 
25 92.4 ± 2.1 93.0 ± 1.8 
50 86.7 ± 3.3 83.0 ± 4.3 
100 75.4 ± 4.6 62.7 ± 8.6 
 
 
CI-976 concentration 
(μM) 
MM6 cell viability (%) 
Without LPS With LPS 
0 94.7 ± 2.3 84.6 ± 5.1 
10 81.6 ± 7.9 76.2 ± 4.6 
25 77.9 ± 5.3 56.3 ± 10.2 
50 23.2 ± 12.4 0.00 
 
 
 
Table 4.1 The effect of CI-976 and HETP concentration on MM6 cell viability. 
MM6 cells were cultured with a specified concentration of either HETP (25-100 µM) 
or CI-976 (10-50 µM) for 24 h alone or with 100 ng/ml E. coli LPS. After culture the 
cells were gently suspended and a cell viability count performed using the Typan blue 
dye exclusion method. Results are a mean percentage ± S.D. of viable cells from 3 
independent experiments.  
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(a) (b) 
 
 
 The effect of pharmacological LPCAT inhibitors on TNF-α, IL-6 Figure 3.1
and IL-8 secretion in LPS stimulated MM6 cells. 
MM6 cells were treated for 6 or 24 h with 100 ng/ml E. coli LPS alone or together 
with LPCAT inhibitor, HETP (15-100 µM) or CI-976 (10-50 µM). After culture cell, 
supernatants were collected and tested for the presence of each cytokine by ELISA. 
Results are a percentage of the value obtained with cells stimulated with LPS and are 
the mean  +/- S.E.M of 5 independent experiments. The red dashed line represents 
IC50 of HETP (a) and CI-976 (b). These data were analysed for significance by 
ANOVA (see 2.10.1 for details).  
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(a) Not significant, P>0.05, n=5  (b) Not significant, P>0.05, n=5 
 
 
(c) Not significant, P>0.05, n=5 
 
 
 
 Control cells - LPCAT inhibitor, HETP, has no significant effect on Figure 3.2
TNF-α, IL-6 and IL-8 secretion in MM6 cells. 
The supernatants from MM6 cells alone or after incubation with LPCAT inhibitor, 
HETP (50 µM) for 30 minutes were collected and tested for the presence of (a) TNF-
α, (b) IL-6 or (c) IL-8 by ELISA. Results represent the intrinsic level of cytokine 
secretion by control cells and are the mean cytokine concentration +/- S.E.M of 5 
independent experiments. These data were analysed for significance by paired t-test.  
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3.4.3 MM6 cells treated with HETP have reduced inflammatory response on 
stimulation with TLR2 ligands  
As observed previously, HETP demonstrated an ability to significantly reduce 
secretion of inflammatory cytokines TNF-α, IL-6 and IL-8 in cells stimulated with 
TLR4 ligand LPS, suggesting that LPCAT has a role in TLR4 initiated cytokine 
responses. In order to determine if a similar effect could be reproduced in cells 
stimulated with TLR2 ligands, experiments were conducted with PG, LTA and the 
synthetic tripalmitoylated lipopeptide, Pam3CSK4. Concentrations of inflammatory 
cytokine secretion were determined as previously by ELISA. 
 
E. coli LPS was employed as a positive control for cytokine stimulation and induced 
a mean of 320 pg/ml TNF-α in MM6 cells (Figure 3.3a). A significant reduction in 
the concentration of TNF-α produced by these cells was seen with pre-incubation of 
HETP (50 µM) to a mean of 150 pg/ml, inhibiting TNF-α secretion by 53 % 
(P<0.01). 
 
In cells stimulated with LTA, the LPCAT inhibitor reduced TNF-α secretion by 22 % 
to a mean concentration of 109 pg/ml (Figure 3.3b). Although this was to a lesser 
extent when compared to LPS stimulated cells, the inhibition was still significant 
(p=0.04). LTA alone induced TNF-α secretion to a mean of 140 pg/ml, approximately 
half the concentration as seen with LPS stimulation. This may indicate that LTA is 
not as proficient as LPS in inducing TNF-α secretion in MM6 cells. 
 
Pre-incubation with HETP in PG stimulated MM6 cells also displayed significant 
cytokine inhibition; a 51 % reduction (p=0.02) of secreted TNF-α (264 pg/ml) was 
observed (Figure 3.3c). Interestingly, stimulation with TLR2 ligand PG alone 
produced higher concentrations of TNF-α compared to LPS; inducing a mean of 533 
pg/ml in these cells.  
 
In spite of the minimal TNF-α concentration that Pam3CSK4 alone induced (58 
pg/ml), the largest suppression of TNF-α secretion by HETP was seen in cells 
stimulated with this ligand (Figure 3.3d). Results displayed a significant 54 % 
reduction (p=0.03) of secreted TNF-α to a mean of 27 pg/ml.  
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(a) ** P<0.01, n=7  (b) * P<0.05, n=5  
 
 
        
 
(c) * P<0.05, n=5  (d) * P<0.05, n=6 
 
 
Key:
 
 
 The effect of HETP on TNF-α secretion in MM6 cell stimulated with Figure 3.3
LPS, LTA, PG or Pam3CSK4. 
MM6 cells were treated for 6 hours with (a) 100 ng/ml LPS, (b) 10 µg/ml LTA, (c) 10 
µg/ml PG or (d) 1.0 µg/ml Pam3CSK4 alone or with prior inhibition by addition of  
HETP (50 µM). After culture cell supernatants were collected and tested for the 
presence of TNF-α by ELISA. Results represent the TNF-α concentration from at 
least 5 independent experiments and the mean TNF-α concentration. Control cells 
with HETP only were also run alongside experiments (Figure 3.2). These data were 
analysed for significance by paired t-test. 
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The next inflammatory cytokine studied, IL-6, expressed a similar trend to TNF-α. 
LPS induced a mean of 3.1 ng/ml in MM6 cells (Figure 3.4a) and IL-6 secretion was 
significantly supressed with pre-incubation of HETP to a mean of 736 pg/ml; 
equivalent to 76 % inhibition (p=0.01). LTA induced strong IL-6 secretion (Figure 
3.4b), comparable in concentration to the LPS positive control stimulus (2.6 ng/ml). 
This IL-6 secretion was significantly inhibited by 45 % (p=0.02) when cells were 
stimulated with LTA in the presence of the LPCAT inhibitor (1.4 ng/ml).  
 
Similarly, PG induced high levels of IL-6, displaying a mean of 3.8 ng/ml (Figure 
3.4c). Pre-incubation with HETP in PG stimulated MM6 cells also displayed 
significant cytokine inhibition; a 69 % reduction (p=0.04) of secreted IL-6 to 1.1 
ng/ml was observed. Comparable to TNF-α concentrations, Pam3CSK4 alone induced 
minimal mean concentrations of IL-6 (246 pg/ml) in these cells. However, in the 
presence of HETP (Figure 3.4d) this IL-6 secretion was strongly inhibited by 80 % 
(P<0.01) to a mean of 49 pg/ml. 
 
Notably, IL-8 data followed a similar trend to that seen with both TNF-α and IL-6. 
LPS induced a high concentration of IL-8 (8.0 ng/ml) (Figure 3.5a) and in the 
presence of HETP this cytokine secretion was supressed by 49 %, to a mean of 4.0 
ng/ml (p=0.05) in MM6 cells. LTA induced an equivalent inflammatory response to 
LPS stimulated cells, secreting a mean concentration of 7.8 ng/ml IL-8 (Figure 3.5b). 
LPCAT inhibitor HETP, was shown to significantly reduce (P<0.01) IL-8 secretion 
by 41 % to 4.6 ng/ml in MM6 cells. 
 
Compared with LPS and the other TLR2 ligands, PG consistently induced the highest 
secretion of all the inflammatory cytokines studied, with a mean of 11.5 ng/ml IL-8 
being secreted by MM6 cells (Figure 3.5c). As seen previously, a significant 42 % 
reduction (P<0.01) in IL-8 was observed with pre-incubation of HETP, 
demonstrating that LPCAT plays a key role in PG induced inflammatory responses.  
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(a) ** P<0.01, n=4  (b) * P<0.05, n=4  
 
  
 
 
(c) * P<0.05, n=4  (d) ** P<0.01, n=4 
 
  
Key: 
 
 
 The effect of HETP on IL-6 secretion in MM6 cell stimulated with Figure 3.4
LPS, LTA, PG or Pam3CSK4. 
MM6 cells were treated for 24 hours with (a) 100 ng/ml LPS, (b) 10 µg/ml LTA, (c) 
10 µg/ml PG or (d) 1.0 µg/ml Pam3CSK4 alone or with prior inhibition by addition of 
HETP (50 µM). After culture cell supernatants were collected and tested for the 
presence of IL-6 by ELISA. Results represent the IL-6 concentration from 4 
independent experiments and the mean IL-6 concentration. Control cells with HETP 
only were also run alongside experiments (Figure 3.2). These data were analysed for 
significance by paired t-test. 
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(a) * P<0.05, n=4    (b) ** P<0.01, n=5  
 
   
 
 
(c) ** P<0.01, n=5   (d) ** P<0.01, n=7 
 
 
Key:
 
 
 
 The effect of HETP on IL-8 secretion in MM6 cell stimulated with Figure 3.5
LPS, LTA, PG or Pam3CSK4. 
MM6 cells were treated for 24 hours with (a) 100 ng/ml LPS, (b) 10 µg/ml LTA, (c) 
10 µg/ml PG or (d) 1.0 µg/ml Pam3CSK4 alone or with prior inhibition by addition of 
HETP (50 µM). After culture cell supernatants were collected and tested for the 
presence of IL-8 by ELISA. Results represent the IL-8 concentration from at least 4 
independent experiments and the mean IL-8 concentration. Control cells with HETP 
only were also run alongside experiments (Figure 3.2). These data were analysed for 
significance by paired t-test. 
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IL-8 concentrations in Pam3CSK4 stimulated MM6 cells followed the same trend as 
observed with TNF-α and IL-6. Although, in comparison to the other ligands, 
Pam3CSK4 induced a low concentration of IL-8 (1.5 ng/ml), a significant 70 % 
reduction of IL-8 (P<0.01) was seen in HETP treated cells (Figure 3.5d). Under these 
conditions, Pam3CSK4 stimulated MM6 cells consistently displayed the greatest 
cytokine reduction with the LPCAT inhibitor compared to the cytokine inhibition 
observed with the other stimulants. 
 
In summary, HETP has shown to significantly inhibit cytokine secretion in the MM6 
cell line, irrespective to the size of the inflammatory response, when cells are 
simulated with LPS, LTA, PG or Pam3CSK4, thus suggesting that LPCAT has a role 
in regulating normal inflammatory responses. 
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3.4.4 Pre-incubation with HETP reduces cytokine secretion in primary human 
monocytes  
To confirm that MM6 cells were a good model for human monocytes, human primary 
monocyte cells were obtained from healthy volunteer PBMCs. The enriched 
monocyte population produced by magnetic labelling system was assessed by 
staining with anti-human CD14 antibody (BD Bioscience, Oxford, UK) and flow 
cytometry and was consistently >74 % CD14+ and  <24 % CD3+ T cells (Figure 3.6).  
Subsequently, experiments were performed on the enriched CD14+ culture to confirm 
that the results observed with MM6 cells were representative of human monocytes 
and thus the peripheral blood monocytes were incubated under the same conditions as 
the experiments with MM6 cells. 
 
Results are expressed as cytokine concentration from 3 healthy donors obtained as 
previously by ELISA and stimulated with the corresponding microbial ligand. Actual 
levels of TNF-α secretion from donor monocytes challenged with LPS were 
comparable to that observed in MM6 cells: a mean of 253 pg/ml compared to 320 
pg/ml TNF-α (Figure 3.7a). However, when compared to MM6 cells, donor 
monocytes produced 2 fold lower concentrations of TNF-α with Pam3CSK4 
stimulation (24 pg/ml), 3 fold lower with PG stimulation (154 pg/ml) and 4 fold 
lower with LTA stimulation (34 pg/ml), which may indicate that human blood 
monocytes are not as proficient at secreting this inflammatory cytokine (Figure 3.7).  
 
Despite the lower production of TNF-α from LTA and Pam3CSK4 induced donor 
cells, pre-incubation with HETP significantly supressed TNF-α secretion by 61 % 
(P<0.05) and 62 % (P<0.01), respectively. Similarly, as seen with LPS-induced 
MM6 cells, the LPCAT inhibitor reduced TNF-α secretion by 46 % to a mean 138 
pg/ml and by 45 % in PG stimulated donor cells to a mean of 85 pg/ml, although the 
neither reduction was statistically significant (P>0.10). 
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(a) (b) 
  
 
(c) (d) 
  
  
 
 CD3+ and CD14+ cell population percentages of enriched donor Figure 3.6
cells 
Human blood monocytes were extracted using the monocyte indirect magnetic 
labeling system and assessed by flow cytometry, collecting 10, 000 events per 
sample. (a) Unlabelled enriched monocyte population control cells. (b) Cell debris 
and dead cells are excluded (gated) from further the analysis based on scatter signals 
and fluorescence (c) Conjugated CD3 (c) and CD14 (d) antibodies were used to 
assess the (gated) enriched monocyte population. 
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(a) NS= not significant, P>0.05, n=3   (b) * P<0.05, n=3  
 
 
(c) NS= not significant, P>0.05, n=3   (d) ** P<0.01, n=3  
 
Key:   
 
 The effect of HETP on TNF-α secretion in human blood monocytes Figure 3.7
stimulated with LPS, LTA, PG or Pam3CSK4 
Human blood monocytes were extracted using the monocyte indirect magnetic 
labeling system and the enriched monocyte population were treated for 6 hours with 
100 ng/ml LPS, 10 µg/ml LTA, 10 µg/ml PG or 1.0 µg/ml Pam3CSK4 alone or with 
prior inhibition by addition of HETP (50 µM). After culture cell supernatants were 
collected and tested for the presence of TNF-α by ELISA. Results represent the TNF-
α concentration from 3 healthy donors and the mean TNF-α concentration. These data 
were analysed for significance by paired t-test. 
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The next inflammatory cytokine studied, IL-6, showed equivalent concentrations to 
those seen with MM6 cells stimulated with LPS, LTA or PG. LPS induced a mean of 
3.6 ng/ml, LTA induced a mean of 1.7 ng/ml and PG induced a mean of 3.5 ng/ml in 
donor monocytes (Figure 3.8a-c). Unexpectedly, Pam3CSK4 induced 8 fold higher IL-
6 concentrations, a mean of 2.0 ng/ml (Figure 3.8d), in these donor cells in contrast to 
the MM6 cell line (246 pg/ml). In comparison to MM6 cells, the efficacy of HETP to 
inhibit IL-6 secretion upon stimulation was considerably decreased in donor 
monocytes. The LPCAT inhibitor reduced the secreted IL-6 concentration by 21 % 
(p=0.07) to a mean of 2.8 ng/ml when challenged with LPS and by 51 % (p=0.24) to 
a mean of 846 pg/ml when challenged with LTA. However these data were not found 
to be statistically significant by paired t-test thus differences in the concentrations 
observed with HETP are more likely to be random variability in the data than actual 
inhibition. 
 
In contrast, treatment with HETP in donor monocytes stimulated by PG reduced IL-6 
concentration by 17 % (p=0.01) to a mean of 2.9 ng/ml and with Pam3CSK4 
stimulation, IL-6 levels reduced by 27 % (p=0.03) to a mean of 1.5 ng/ml. Whilst the 
cytokine reduction with these stimulants was not as profound as seen in the MM6 
cells (a reduction of 69 % and 80 %, respectively), the inhibitions are statistically 
significant demonstrating that the LPCAT inhibitor has some effect on IL-6 
production in human monocytes. 
 
In donor monocytes stimulated with LPS alone an increased concentration of IL-8 
(18.0 ng/ml) was observed (Figure 3.9a); over twice that seen in MM6 cells. A 
similar trend was seen with the other microbial stimulants, where LTA and PG both 
induced 2.5 fold higher concentrations of IL-8 (19.1 ng/ml and 18.6 ng/ml, 
respectively), but most significantly in Pam3CSK4 induced over 10 fold higher (16.2 
ng/ml) than MM6 cells. This suggests that human monocytes are prolific IL-8 
secreting cells and that perhaps this cytokine induction pathway may be more 
sensitive to microbial stimuli than the other inflammatory cytokines. Due to these 
large increases in IL-8 concentrations, the effectiveness of HETP to inhibit cytokine 
production was impeded. In the presence of HETP, the stimulant induced IL-8 
secretion by donor monocyte cells could only be inhibited to a small extent, 
observing a reduction of 9 % to a mean of 16.3 ng/ml with LPS challenge, 13 % to a 
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mean of 16.6 ng/ml with LTA challenge, 13 % to a mean of 15.9 ng/ml with PG 
challenge and 8 % to a mean of 14.0 ng/ml with Pam3CSK4. However, these 
reductions in IL-8 secretion were found to be statistically insignificant by paired t-test 
(P>0.08) thus likely not to be due to the LPCAT inhibitor.  
 
Overall, in comparison to MM6 cells, human donor monocytes secreted TNF-α at 
lower levels, IL-6 at equivalent levels and IL-8 at higher levels when induced with 
either TLR4 stimulant LPS or the TLR2 stimulants studied. A noteworthy 
observation in human monocytes was the amplified secretion of both IL-6 and IL-8 
with Pam3CSK4 stimulation, suggesting that this synthetic tripalmitoylated 
lipopeptide is an effective inflammatory cytokine inducer in these cells. However, 
unlike MM6 cells, the efficacy of HETP to inhibit secretion was impeded because of 
the vast IL-8 concentrations secreted. Conversely, in most cases TNF-α and IL-6 
inhibition was seen with HETP treatment, although it was not always statistically 
significant suggesting natural variability between the donor cells. 
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(a) NS= not significant, P>0.05, n=3   (b) NS= not significant, P>0.05, n=3 
   
 
(c) ** P<0.01, n=3   (d) * P<0.05, n=3   
  
Key:   
 
 The effect of HETP on IL-6 secretion in human blood monocytes Figure 3.8
stimulated with LPS, LTA, PG or Pam3CSK4 
Human blood monocytes were extracted using the monocyte indirect magnetic 
labeling system and the enriched monocyte population were treated for 24 hours with 
100 ng/ml LPS, 10 µg/ml LTA, 10 µg/ml PG or 1.0 µg/ml Pam3CSK4 alone or with 
prior inhibition by addition of HETP (50 µM). After culture cell supernatants were 
collected and tested for the presence of IL-6 by ELISA. Results represent the IL-6 
concentration from 3 healthy donors and the mean IL-6 concentration. These data 
were analysed for significance by paired t-test. 
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(a) NS= not significant, P>0.05, n=3   (b) NS= not significant, P>0.05, n=3  
   
 
(c) NS= not significant, P>0.05, n=3   (d) NS= not significant, P>0.05, n=3 
   
Key:   
 
 The effect of HETP on IL-8 secretion in human blood monocytes Figure 3.9
stimulated with LPS, LTA, PG or Pam3CSK4 
Human blood monocytes were extracted using the monocyte indirect magnetic 
labeling system and the enriched monocyte population were treated for 24 hours with 
100 ng/ml LPS, 10 µg/ml LTA, 10 µg/ml PG or 1.0 µg/ml Pam3CSK4 alone or with 
prior inhibition by addition of HETP (50 µM). After culture cell supernatants were 
collected and tested for the presence of IL-8 by ELISA. Results represent the IL-8 
concentration from 3 healthy donors and the mean IL-8 concentration. These data 
were analysed for significance by paired t-test. 
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3.4.5  HETP inhibits inflammatory cytokine mRNA expression 
HETP was shown to significantly reduce secretion of inflammatory cytokines TNF-α, 
IL-6 and IL-8 in cells stimulated with both TLR4 and TLR2 ligands. In order to 
establish if this was caused by changes at the transcriptional level, qPCR was used to 
determine the influence of HETP on cytokine mRNA. Real time PCR of MM6 cell 
RNA was completed under similar experimental conditions to those used in the 
inflammatory cytokine ELISA detection experiments, but with a shorter incubation 
time of 4 hours, as per studies by Jackson et al. (2008).  
 
Data was normalized using the housekeeping gene, GAPDH, and the relative 
difference calculated using untreated cells as a reference. Levels of TNF-α mRNA 
expression were comparable between LPS, LTA and PG stimulated cells (Figure 
3.10a) whilst the previous trend for Pam3CSK4 to induce a lower TNF-α 
concentration was apparent at the mRNA level. Results show significantly reduced 
mRNA in cells stimulated with LPS and PG in the presence of HETP reaching 
approximately 85 % decrease in mRNA fold expression in both cases (P<0.05). IL-6 
mRNA expression was considerably higher than observed with TNF-α and IL-8 
mRNA with all microbial stimulants; 3 to 4 times greater, suggesting that IL-6 has a 
central role in inflammatory responses (Figure 3.10b). HETP significantly inhibited 
induction of IL-6 mRNA expression, irrespective of the microbial stimulant. IL-8 
mRNA expression followed a similar trend to IL-6, although to a lesser degree 
(Figure 3.10c). LTA stimulated the highest IL-8 mRNA expression, which was 
considerably inhibited, by 85 % (P<0.01), in the presence of HETP.  
 
Overall, qPCR results show that LPS produced the most consistent mRNA inhibition 
across all cytokines in the presence of HETP. As with results obtained by ELISA, 
Pam3CSK4, induced the weakest mRNA expression. Interestingly, it was LTA which 
stimulated a highest IL-6 and IL-8 mRNA expression, and not PG, in contrast to 
ELISA results. These data suggest that, whilst LPCAT appears to regulate 
inflammatory cytokine mRNA expression in MM6 cells, there may be further 
regulatory mechanisms such as post-transcriptional modifications with cytokine 
mRNA that would account for the differences observed between mRNA expression 
and protein secretion, particularly with LTA and PG stimulated cells. 
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(a)  * P<0.05, NS= not significant, n=4 
 
(b)  ** P<0.01, * P<0.05, NS= not significant, n=4 
 
(c)  ** P<0.01, * P<0.05, NS= not significant, n=3 
 
 The effect of HETP on cytokine mRNA expression in MM6 cells. Figure 3.10
MM6 cells were treated for 4 hours in the presence of LPS (100 ng/ml), LTA (10 
µg/ml), PG (10 µg/ml) or Pam3CSK4 (1.0 µg/ml) alone or with prior inhibition by 
addition of HETP (50 µM), before total RNA extraction. Using qPCR, the mRNA of 
inflammatory cytokines, TNF-α (a), IL-6 (b), IL-8 (c), were normalized with 
housekeeping gene, GAPDH, and the fold difference calculated using untreated cells 
as a reference (2
-ΔΔCT 
method). The results represent the mean +/- S.E.M of 3 
independent experiments and analysed by paired t-test.  
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3.4.6 IFN- primed MM6 cells are inhibited by HETP 
In previous studies, (Jackson et al., 1992; Darmani et al., 1993) IFN-γ was shown to 
significantly up-regulate monocyte LPCAT activity thus significantly modifying the 
phospholipid composition of monocyte plasma membranes. In 2003, Schmid and 
colleagues primed MM6 cells with IFN-γ prior to stimulation with LPS and 
demonstrated that IFN-γ amplified the release of inflammatory cytokine TNF-α. 
Moreover, Schmid found that LPCAT inhibitor, HETP, could decrease cytokine 
release to a greater degree in IFN-γ primed monocytes than in unprimed cells 
(Schmid et al., 2003). These results suggest that whilst IFN-γ primes monocytes for 
subsequent challenge with LPS, LPCAT may regulate the consequential release of 
cytokines associated with sepsis. However it is not clear if other inflammatory 
cytokines are also regulated in the same way or if a similar mechanism exists for 
monocytes challenged with TLR2 ligands. 
 
As per Schmid et al. (2003), in this study MM6 cells were co-cultured with 250 U/ml 
IFN-γ for 16 hours prior to treatment with HETP and stimulation with LPS, LTA, PG 
or Pam3CSK4.  This examined the effect of IFN-γ on monocyte cytokine secretion in 
response to TLR2 ligands and the potential of HETP to down-regulate cytokine 
secretion, as determined by ELISA. Results are expressed as cytokine concentration 
from independent experiments and are analysed by paired t-test for significance. 
 
Results show that addition of IFN-γ alone did not elicit an inflammatory response, but 
rather primed the monocytes to respond to microbial stimuli, in most instances 
leading to increased cytokine production. LPS induced a mean of 789 pg/ml TNF-α in 
MM6 cells (Figure 3.11a), over twice that previously seen in unprimed cells. With 
pre-incubation of HETP, a significant reduction in TNF-α secreted was observed, 
with a mean inhibition of 44 % (P<0.01). This suggests that, although priming cells 
with IFN-γ extensively increases the concentration of cytokine secreted, the cell 
inflammatory processes could still be considerably inhibited by HETP. LTA induced 
the highest TNF-α secretion in IFN-γ primed MM6 cells to a mean concentration of 
1.2 ng/ml (Figure 3.11b), nearly 10 fold higher than unprimed cells. LPCAT inhibitor 
HETP reduced TNF-α secretion to a lesser extent when compared to the LPS positive 
control stimulus, by a mean of 12 %, but the reduction was still significant (P<0.01). 
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(a) ** P<0.01, n=4  (b) ** P<0.01, n=3  
  
 
 
(c) ** P<0.01, n=4  (d) * P<0.05, n=3  
  
Key: 
 
 
 The effect of HETP on TNF-α secretion in IFN-γ primed MM6 cell Figure 3.11
stimulated with LPS, LTA, PG or Pam3CSK4 
MM6 cells were primed with IFN-γ for 16 hours prior to treatment with (a) 100 ng/ml 
LPS, (b) 10 µg/ml LTA, (c) 10 µg/ml PG or (d) 1.0 µg/ml Pam3CSK4 for 6 hours 
alone or with prior inhibition by addition of HETP (50 µM). After culture cell 
supernatants were collected and tested for the presence of TNF-α by ELISA. Results 
represent the TNF-α concentration from at least 3 independent experiments and the 
mean TNF-α concentration. These data were analysed for significance by paired t-
test. 
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Stimulation with PG induced comparable concentrations of TNF-α compared to LPS, 
with a mean of 876 pg/ml in primed cells (Figure 3.11c). In the presence of HETP, 
significant cytokine inhibition was observed (P<0.01), but this was noticeably less 
compared to the unprimed PG stimulated cells; a mean of 27 % suppression in 
contrast to 50 %, respectively. Interestingly, in IFN-γ primed cells stimulated with 
Pam3CSK4, TNF-α secretion (Figure 3.11d) was equivalent to that observed in 
unprimed cells; a mean of 54 pg/ml. This may suggest that IFN-γ plays a lesser role 
in the regulation of TNF-α production with this microbial stimulant. However, HETP 
significantly reduced TNF-α secretions by a mean of 28 % (P<0.05) confirming the 
role of LPCAT in this inflammatory process. 
 
The next inflammatory cytokine studied, IL-6, was highly secreted by IFN-γ primed 
MM6 cells in response to the microbial stimulants, but most noticeably with LTA and 
Pam3CSK4 where nearly double IL-6 (a mean of 4.4 ng/ml and 590 pg/ml, 
respectively) was produced (Figure 3.12a-d) compared to that observed for unprimed 
cells. IL6 concentrations were significantly reduced in the presence of LPCAT 
inhibitor, regardless of the stimulant, with the most prominent inhibition occurring for 
Pam3CSK4 stimulated cells (a mean inhibition of 66 %, P<0.05) (Figure 3.12d). 
 
A similar trend to IL-6 was observed in IL-8 secretion by IFN-γ primed MM6 cells, 
with Pam3CSK4 and LTA inducing the highest inflammatory responses (Figure 3.13a-
d). Pam3CSK4 induced a mean of 3.7 ng/ml (Figure 3.13d) and LTA 11.9 ng/ml 
(Figure 3.13c), twice that seen with unprimed cells. IFN-γ primed cells stimulated 
with PG induced comparable levels of IL-8 seen with unprimed cells, however, 
LPCAT inhibition of cytokine secretion was still statistically significant (a mean 
inhibition of 18 %, P<0.01). The level of cytokine was considerably supressed with 
pre-incubation of HETP across the stimulants, with Pam3CSK4 induced IFN-γ primed 
cells being largely inhibited by a mean of 54 % (P<0.01). 
 
These results demonstrate that, although priming cells with IFN-γ increases the 
concentration of cytokine secreted in most instances, the cell inflammatory processes 
could still be consistently inhibited by HETP. This suggests that, even where IFN-γ 
promotes the monocytes to secrete an exaggerated level of inflammatory cytokines, 
LPCAT has an important role in regulation and subsequent release. 
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(a) ** P<0.01, n=6  (b) ** P<0.01, n=4  
 
 
 
(c) ** P<0.01, n=5  (d) * P<0.05, n=4  
 
Key: 
 
 
 The effect of HETP on IL-6 secretion in IFN-γ primed MM6 cell Figure 3.12
stimulated with LPS, LTA, PG or Pam3CSK4 
MM6 cells were primed with IFN-γ for 16 hours prior to treatment with (a) 100 ng/ml 
LPS, (b) 10 µg/ml LTA, (c) 10 µg/ml PG or (d) 1.0 µg/ml Pam3CSK4 for 24 hours 
alone or with prior inhibition by addition of HETP (50 µM). After culture cell 
supernatants were collected and tested for the presence of IL-6 by ELISA. Results 
represent the IL-6 concentration from at least 4 independent experiments and the 
mean IL-6 concentration. These data were analysed for significance by paired t-test. 
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(a) ** P<0.01, n=7  (b) ** P<0.01, n=6  
 
 
 
(c) ** P<0.01, n=6  (d) ** P<0.01, n=7  
 
Key: 
 
 
 
 The effect of HETP on IL-8 secretion in IFN-γ primed MM6 cell Figure 3.13
stimulated with LPS, LTA, PG or Pam3CSK4 
MM6 cells were primed with IFN-γ for 16 hours prior to treatment with (a) 100 ng/ml 
LPS, (b) 10 µg/ml LTA, (c) 10 µg/ml PG or (d) 1.0 µg/ml Pam3CSK4 for 24 hours 
alone or with prior inhibition by addition of HETP (50 µM). After culture cell 
supernatants were collected and tested for the presence of IL-8 by ELISA. Results 
represent the IL-8 concentration from at least 6 independent experiments and the 
mean IL-8 concentration. These data were analysed for significance by paired t-test. 
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3.4.7 The effect of LPCAT inhibition in BEAS-2B cells on inflammatory responses 
to TLR ligands 
Human airways regularly come into contact with pathogenic components making 
respiratory epithelium an important environmental interface. Although at different 
levels, like monocytes, epithelial cells express TLR4 on their surface, enabling LPS 
to induce an inflammatory response. Human broncho-epithelial cell line (BEAS-2B) 
display TLR1-6 expression demonstrating that they have the receptors required for a 
response to a range of microbial ligands and have previously been used to study 
LPCAT initiated synthesis of surfactant protein DPPC (Schulz et al., 2002). In this 
study BEAS-2B cells were used to investigate if LPCAT has a role in regulating 
inflammatory responses in broncho-epithelial cells.  
 
Initial results showed that BEAS-2B basal cytokine expression in serum free 
conditions were negligible, although PG and (synthetic lipopeptide) Pam3CSK4 
induced minimal concentrations of IL-6 and IL-8 (Figure 3.14 & Figure 3.15). 
Cytokine release in BEAS-2B cells was substantially activated by the presence of 2 % 
pooled human serum (HS) when compared to serum free concentrations. 
 
LPS induced a mean of 1.5 ng/ml IL-6 in BEAS-2B cells (Figure 3.14a) and IL-6 
secretion was only slightly supressed with pre-incubation of HETP to a mean of 1.2 
ng/ml; equivalent to 12 % inhibition, however this was not statistically significant 
(P>0.05). In contrast, LTA induced lower levels of IL-6, displaying a mean of 653 
pg/ml (Figure 3.14b). Pre-incubation with HETP in LTA stimulated BEAS-2B cells 
displayed significant cytokine inhibition; a 25 % reduction (p=0.02) of secreted IL-6 
to 493 pg/ml, less than that induced by the presence of HS, was observed. 
Comparable in concentration to LPS, PG induced IL-6 secretion (Figure 3.14c) to a 
mean of 1.5 ng/ml. This IL-6 secretion was not significantly inhibited in the presence 
of the LPCAT inhibitor (P>0.05), but secretion was suppressed by an average of 29 
%. Pam3CSK4 induced strong concentrations of IL-6 (2.0 ng/ml) and in the presence 
of HETP (Figure 3.14d) IL-6 secretion was significantly inhibited by 10 % (p=0.04) 
to a mean of 1.8 ng/ml. 
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(a)  NS= not significant, n=4 
 
(b)  * P<0.05, n=4 
 
(c)  NS= not significant, n=4  
 
(d)  * P<0.05, n=4 
 
 The effect of HETP on IL-6 secretion in BEAS-2B cells stimulated Figure 3.14
with LPS, LTA, PG or Pam3CSK4 
BEAS-2B cells were incubated alone or with 2 % pooled human serum (HS) and 
treated for 24 hours with (a) 100 ng/ml LPS, (b) 10 µg/ml LTA, (c) 10 µg/ml PG or 
(d) 1.0 µg/ml Pam3CSK4 alone or with prior inhibition by addition of HETP (50 µM). 
After culture cell supernatants were collected and tested for the presence of IL-6 by 
ELISA. Results represent the IL-6 concentration from 4 independent experiments and 
the mean IL-6 concentration. Data were analysed for significance by paired t-test.  
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As anticipated, IL-8 data followed a similar trend to that seen with IL-6 in BEAS-2B 
cells. LPS induced a high concentration of IL-8 (3.1 ng/ml) (Figure 3.15a) and in the 
presence of  HETP this cytokine secretion was supressed, although not significantly 
(P>0.05), by 17 % to a mean of 2.6 ng/ml.  
 
As observed for IL-6 secretions in BEAS-2B cells, LTA induced a lower 
inflammatory response than LPS stimulated cells, secreting a mean concentration of 
2.1 ng/ml IL-8 (Figure 3.15b). However, most noticeably, LPCAT inhibitor HETP 
was shown to significantly reduce (p=0.02) IL-8 secretion by 54 % in BEAS-2B cells, 
below that induced by HS alone. PG induced a mean of 3.5 ng/ml IL-8 in BEAS-2B 
cells (Figure 3.15c) and pre-incubation with HETP displayed significant cytokine 
inhibition; a 15 % reduction (P<0.01) of secreted IL-8 to 2.9 ng/ml. 
 
BEAS-2B cells were more immunologically responsive to Pam3CSK4, where it 
consistently induced the highest secretion of inflammatory cytokine, with a mean of 
3.8 ng/ml IL-8 (Figure 3.15d). As seen previously with IL-6, a small reduction (13 %) 
in IL-8 was observed when cells were pre-incubated with HETP. 
 
Under these conditions, Pam3CSK4 stimulated BEAS-2B cells to consistently secrete 
the largest cytokine concentrations, indicating that perhaps this synthetic lipopeptide 
is a more prolific stimulant in lung epithelial cells than the other TLR ligands. This is 
in contrast to observations in the monocyte (MM6) cell line, where PG induced the 
highest levels of cytokine secretion. These data may suggest that Pam3CSK4 is a 
better immunological stimulus for inflammatory mediated responses by lung 
epithelial cells. 
 
Inhibition of LPCAT demonstrated a reduction in cytokine secretion by BEAS-2B 
cells; however in some cases this was not statistically significant, highlighting that 
LPCAT’s involvement in these inflammatory mechanisms, is not as predominant as 
in monocyte cells. 
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(a)  NS= not significant, n=4 
 
(b)  * P<0.05, n=4 
 
(c)  ** P<0.01, n=4 
 
(d)  NS= not significant, n=4 
 
 The effect of HETP on IL-8 secretion in BEAS-2B cells stimulated Figure 3.15
with LPS, LTA, PG or Pam3CSK4 
BEAS-2B cells were incubated alone or with 2 % pooled human serum (HS) and 
treated for 24 hours with (a) 100 ng/ml LPS, (b) 10 µg/ml LTA, (c) 10 µg/ml PG or 
(d) 1.0 µg/ml Pam3CSK4 alone or with prior inhibition by addition of HETP (50 
µM). After culture cell supernatants were collected and tested for the presence of IL-8 
by ELISA. Results represent the IL-8 concentration from 4 independent experiments 
and mean IL-8 concentration. Data were analysed for significance by paired t-test.   
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3.5 DISCUSSION 
In this study, a specific inhibitor to LPCAT, 5 hydroxyethyl 5,3’ thiophenyl pyridine 
(HETP), was shown to reduce inflammatory cytokine secretion induced not only by 
LPS, as observed by Schmid et al. (2003), but also by LTA, PG and Pam3CSK4. This 
perhaps suggests that LPCAT enzymes are potential targets in the regulation of 
inflammatory responses.  
 
Schmid et al. (2003) evaluated chemical inhibition of LPCAT and found that only 20 
µM of HETP was required for an IC50 of TNF-α in LPS-stimulated MM6 cells; in this 
report an increased concentration of 50 µM HETP was required to reach levels of 
inhibition, which may be due to batch-to-batch variation that occurs in its production. 
 
The finding that HETP significantly inhibited TNF-α, IL-6 and IL-8 cytokine 
secretion in MM6 cells stimulated with TLR2 ligands adds weight to the theory that 
LPCAT may be involved in TLR2 activation and signalling. On treatment with 
HETP, a reduction in all cytokines secreted was observed (≥50 %), and was 
significant for all conditions (P value <0.05 or <0.01). Furthermore, qPCR data added 
evidence that LPCAT inhibition occurred at the mRNA level, subsequently affecting 
the level of TNF-α, IL-6 and IL-8 cytokine mRNA expression in MM6 cells. This 
strongly suggests that LPCAT controls cytokine secretion by altering transcription of 
the gene or mRNA stability, rather than affecting translational or post-translational 
events. 
 
In agreement with findings in this report, Jackson et al. (2008) found LPS to be more 
potent than Pam3CSK4 in stimulating inflammatory cytokine secretion in MM6 cells, 
supporting the evidence that MM6 cells are not as responsive to this synthetic 
lipopeptide compared to the other TLR ligands studied here. However, irrespective to 
the size of the inflammatory response, MM6 cells stimulated with Pam3CSK4 
consistently displayed the greatest cytokine reduction with the LPCAT inhibitor, 
suggesting that this inflammatory mechanism is most noticeably regulated by 
LPCAT. 
 
To confirm that MM6 cells are representative of human monocytes, the same 
experimental conditions were used on an enriched population of peripheral blood 
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monocytes. In agreement with results obtained from MM6 cells, LPS was found to be 
the most potent mediator to stimulate inflammatory cytokine secretion in this 
population of donor monocytes. Kreutz et al. (1997) found that Salmonella LPS and 
(50 ng/ml) Pam3-Cys-Ala-Gly (500 ng/ml) greatly induced cytokine responses in 
monocytes isolated from human PBMCs, reporting IL-6 and IL-8 concentrations on 
average 10 times higher than levels seen in the present study.  
 
Schmid et al. (2003) also studied the TNF-α and IL-6 secretion in isolated peripheral 
blood monocytes challenged with LPS. Schmid found that LPS induced double the 
TNF secretion in donor monocytes to that seen in the present study. In contrast, LPS 
stimulation of donor monocytes in the present study induced 70 fold more IL-6 
compared to the concentrations Schmid reported. The variance between reported data 
may be due to basal differences in cytokine secretion between donor PBMCs, 
differences in experimental isolations of peripheral blood monocytes and source of 
the stimulants and stimulant concentrations used.  
 
A noteworthy observation in the enriched population of human monocytes was the 
amplified (10 fold) secretion of both IL-6 and IL-8 with Pam3CSK4 stimulation 
compared to the MM6 cell line, suggesting that this synthetic tripalmitoylated 
lipopeptide is a prolific inflammatory cytokine inducer in donor monocytes. The 
culture of donor monocytes in the presence of human serum may have some influence 
on this observation, as Pam3CSK4 is not dependent on co-receptor CD36, but an 
increased concentration of CD36 (as is likely to be in human serum) has been shown 
to increase monocytes responsiveness (Jin et al., 2007: Triantafilou et al., 2006). This 
also suggests that the MM6 cell line is less sensitised to Pam3CSK4-induced 
inflammatory responses which may be linked to the stimulants signalling pathway via 
a TLR2/TLR1 heterodimer. 
 
Although large discrepancies can be observed between the concentration of cytokines 
secreted by donor monocytes by Schmid and the present study, the inhibitory effects 
of HETP on TNF-α and IL-6 upon LPS stimulation were comparable. The findings in 
this report indicate that LPCAT has a crucial role in regulating the release of 
inflammatory cytokines in enriched populations of donor peripheral blood 
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monocytes, supporting the theory that the MM6 cell line provides model cells to 
conduct this study. 
An important contribution to the pathogenesis of LPS-induced septic shock is the 
priming of monocytes/macrophages with IFN-γ, leading to an increased inflammatory 
responsiveness to LPS. IFN-γ has previously been shown to induce hypersensitivity 
to LPS by up regulating monocyte LPCAT activity (Jackson and Parton, 2004), 
inducing increased plasma membrane fluidity through altering phospholipid 
composition (Darmani et al., 1993) and by increasing expression of TLR4 and LPS 
binding sites (Remick, 2003).  It was, therefore, of interest to study the effect of IFN-
γ primed MM6 cells on the secretion of inflammatory cytokines. 
 
In agreement with other studies (Neville et al., 1997: Schmid et al., 2003) IFN-γ was 
found not to elicit an inflammatory response alone, but rather primed the monocytes 
to respond to microbial stimuli, leading to increased production of inflammatory 
cytokines. On average the size of the inflammatory response in IFN-γ primed 
monocytes was twice that seen in unprimed cells, with LTA and Pam3CSK4 
stimulation providing the most consistent up-regulation. Schmid et al. (2003) found 
that the secretion of TNF-α and IL-6 was five times greater in MM6 cells primed with 
IFN-γ than unprimed on stimulation with LPS, in contrast to the present study. 
 
Inhibition of LPCAT activity, with HETP, also significantly blocked the secretion of 
TNF-α, IL-6 and IL-8 in not only LPS stimulated IFN-γ primed MM6 cells (as 
previously reported by Schmid), but also LTA, PG and Pam3CSK4 stimulated, primed 
MM6 cells. When LPCAT activity was inhibited, a significant (P value <0.01) 
reduction in the cytokines secreted was seen, however, the reduction was not as 
sizeable as Schmid reported (90 % inhibition).  
 
In short, these findings indicate that LPCAT plays a crucial role in regulating the 
release of inflammatory cytokines upon microbial stimulated, in both unprimed and 
IFN-γ primed monocytes, suggesting that LPCAT is involved in the activation of 
monocytes possibly at the level of the TLR or subsequent signalling pathways. 
 
Although monocytes and macrophages are important producers of cytokines involved 
in the pathophysiology of bacterial sepsis, lung epithelium also provides an important 
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interface between the environment and host and may play a role in immune 
regulation. Lung epithelium are constantly exposed to environmental microbial 
PAMPs, so mechanisms to limit activation of uncontrolled inflammatory responses to 
inhaled bacteria must exist. Mayer et al. (2007) found BEAS-2B cells expressed 
lower levels of TLR2 than MM6 cells and were missing expression of co-receptor 
CD36, which restricts TLR2 signalling pathways. Thus the differences between 
bronchial epithelial and monocytic immune responses and the influence LPCAT may 
have on these responses were of interest to study. 
 
In comparison to monocytes, BEAS-2B cells secreted a lower concentration of 
inflammatory cytokines, though LPCAT inhibition was still able to impede cytokine 
secretion. Inhibition by LPCAT was not as substantial as for the monocyte cell line, 
varying from 10 to 20 %, but was found to be significant in some cases. Interestingly, 
Pam3CSK4 stimulated BEAS-2B cells to secrete IL-6 concentrations 8 fold higher 
than seen in MM6 cells and comparable to that observed in the enriched populations 
of donor monocytes. These data may indicate that the synthetic lipopeptide is a more 
prolific stimulant and that LPCAT may therefore also have an important role in 
regulating inflammatory responses in epithelial cells, though perhaps to a lower 
extent than seen in monocytes. Unfortunately, no other studies on lung epithelial cells 
stimulated with TLR2 ligands are available to compare these results with, as lung 
epithelial cells are principally used to investigate environmental particle 
inflammatory effects (Verath et al. 2008). 
 
Interestingly, Schulz et al. (2002) discovered that, in the presence of a low 
concentration of LPS (10 ng/ml), BEAS-2B cells do not respond as efficiently to LPS 
if serum is substituted with sCD14 and suggested that BEAS-2B cells require an 
alternative serum signalling molecule other than CD14 in order to elicit an 
inflammatory response to LPS (Schulz et al., 2002). This information may help to 
explain the increased cytokine secretion on incubation with HS, which appears to be 
dependent on the presence and concentration of these factors. Literature methods are 
widely variable for the best culture of BEAS-2B cells and the current conditions may 
not be optimal for the assay. 
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Recent studies have characterized the expression of LPCAT like acyltransferases in 
diverse cell types and it has been suggested different iso-forms of LPCAT exist 
(Shindou and Shimizu, 2009; Agarwal et al., 2007; Hishikawa et al., 2008; Chen et 
al., 2006; Shindou et al., 2007; Zhao et al., 2008; Cao et al., 2008). An important 
difference between lung epithelial cells and monocytes inflammatory responses could 
be as a result of contrasting LPCAT isoform expression levels which may regulate 
these mechanisms. It is now of interest to explore the endogenous LPCAT expression 
and the effect of TLR ligands on LPCAT expression in monocytes and bronchial 
epithelial cell, as determined in the next chapter. 
 
  
 
  Chapter 4
 
 
RESULTS AND DISCUSSION 
 
EXPRESSION LEVELS OF 
LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASES 
IN DIFFERENT CELL TYPES 
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4.1 INTRODUCTION 
Current literature describes the identification of 5 LPCATs that have been shown to 
incorporate acyl-CoA into lysoPC, reacylating it to PC (Shindou et al., 2007; 
Nakanishi et al., 2006; Harayama et al., 2009; Chen et al., 2006; Agarwal et al.,  
2007). The literature describes the LPCATs in terms of preference for the donor fatty 
acid and the lysoPC acceptor, and has determined mRNA expression levels in a 
variety of mouse, rat and human tissues or cell lines. However, very little research 
about the inflammatory role of these LPCAT-like enzymes has been published. 
LPCAT1 is thought to be most notably expressed in lung tissue, where it plays a role 
in producing DPPC (Agarwal et al., 2010) whilst LPCAT2 is reported to play a 
constitutive role in inducible PC remodelling pathways in response to external stimuli 
in mouse peritoneal macrophages (Shindou et al. 2005). To consolidate findings that 
LPCAT2 is the major remodelling enzyme involved in inflammatory pathways, the 
expression levels of LPCAT2 were investigated in part of the study. 
 
4.2 AIMS 
Monocytic and lung epithelial cell lines were examined to ascertain if they have 
differential expression of the LPCATs between cell types, which may help to explain 
the altered inhibitory effects that HETP treatment produces on inflammatory cytokine 
expression in different cell types. A further aim was to investigate whether LPCAT 
expression can induced by TLR4 or TLR2 ligands and if a correlation exists between 
increased inflammatory cytokine secretion and LPCAT expression. Additionally 
LPCAT mRNA and protein levels were examined to determine how IFN-γ 
stimulation alters expression. 
 
4.3 METHODS 
qPCR and western blot analysis were used to determine the endogenous mRNA and 
protein expression of the LPCATs in a panel of different cell types. LPCAT mRNA 
and protein expression levels were also further examined following treatment with 
TLR ligands. 
 
4.3.1 Relative quantification of LPCAT mRNA expression 
Following total RNA extraction from MM6, BEAS-2B, A549, HepG2 and 
Hek293cells (3×10
6
) with an acid guanidinium thiocyanate-phenol-chloroform 
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extraction method, RNA was quantified and the integrity checked using an Agilent 
RNA 6000 Nano kit (Agilent Technologies Ltd, Stockport, UK). The Agilent 
bioanalyser assesses the intactness of RNA by showing a detailed picture of the size 
distribution of RNA fragments. RNA degradation is a gradual process, where a 
decrease in the 18S and 28S ribosomal band ratio occurs and the bioanalyser uses 
software algorithms to produce the RNA Integrity Number (RIN). Samples with 
significantly degraded RNA, with an integrity number (RIN) less than 8, were 
discarded. The results from a processed Agilent chip can be viewed in Figure 4.1 and 
is representative of the data analysed. 
 
The RNA samples were spiked prior to reverse transcription with 0.1ng of Senecio 
vulgaris ribulose-1,5-bisphosphate carboxylase oxygenase (RuBisCO) small subunit 
mRNA. This plant cDNA was then used as an internal control to validate the reverse 
transcription process and GAPDH was the assumed house-keeping gene for all cells 
tested. First strand cDNA was synthesized from 2 µg total RNA and real time PCR 
completed in triple technical replicates using SYBR GreenER qPCR SuperMix 
(Invitrogen, Paisley, UK) for the iCycler (Bio-Rad, Hertfordshire, UK) according to 
manufacturer’s protocols.  
 
Three sets of primers for each of the 5 LPCATs mentioned in the introduction were 
designed using Primer-BLAST Primer design software (NCBI database), the 
information from the reviewed literature and BLAST database searches to ensure 
each primer’s specificity (Figure 1.1Table 4.1).  
 
Real-time PCR results were analysed using 2
-ΔΔCT 
and relative gene expression 
methods (Livak and Schmittgen, 2001). Relative quantification relates the PCR signal 
of the target transcript to that of another sample, such as an untreated control. This 
report set out to analyse the endogenous expression of different cell types. All cells 
were untreated, therefore, expression levels were relative to each other. The data are 
presented as the mean fold change in mRNA expression, normalized to GAPDH and 
relative to MM6 cells for comparison. 
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 Representative Agilent chip Figure 4.1
RNA integrity was calculated using an Agilent RNA 6000 Nano kit and Agilent 2100 
bioanalyser (Agilent Technologies Ltd, Stockport, UK). (a) is the results from a 
processed chip which is representative of the qPCR data analysed. (b) is an 
electropherogram of the ladder – RNA Area: 83.9, RNA Concentration: 150 ng/μL. 
(c) is an electropherogram of Sample 1 –RNA Area: 364.9, RNA Concentration: 652 
ng/μL, rRNA Ratio [28s / 18s]: 1.7, RNA Integrity Number (RIN): 9.4.  
(a) 
(b) (c) 
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Table 4.1 Primer sets of LPCAT-like acyltransferases. 
LPCAT primer RNA sequences. Details on how the primer sequence span across 
each LPCAT mRNA and how they compare to sequences used in literature, can be 
found in Appendix 1. 
LPCAT1 (AYTL2: AGPAT9) 
  Chromosome 5 Gene ID: 79888 mRNA sequence: NM_024830.3 
PRIMER 5' to 3’ Forward primer  3’ to 5’ Reverse Primer 
Product 
length 
Primer 1 sequence LA1F  CCAGCCTGTGGTTTTACGAT LA1R TCCTCCTCAGAAGGGCTGTA 156 bp 
Primer 2 sequence LB1F AGATATTCCGAGGGAAGGGA LB1R AAGTCGCCACGAAGAGAAAA 168 bp 
Primer 3 sequence LC1F GGTGTGAACTCAAGGGCCTA LC1R TATCCAACCTCGGACTGGAG 159 bp 
LPCAT2 (LysoPAFAT: AYTL1: AGPAT11) 
  Chromosome 16 Gene ID: 54947 mRNA sequence: NM_017839.4 
PRIMER 5' to 3’ Forward primer 3’ to 5’ Reverse Primer 
Product 
length 
Primer 1 sequence LD1F  TGTGCAACCAGTTTTGGTGT LD1R TGGAACTCCTGGAATGAAGG 184 bp 
Primer 2 sequence LE1F GAAATAGCCCAAGGGGACTC LE1R TGCTTTTCAGGGCTGACTTT 182 bp 
Primer 3 sequence LF1F ACATTGCCTATGGAAGCTGG LF1R GGCGAATTCTTCAATTCCAA 150 bp 
LPCAT3 (MBOAT5) 
  Chromosome 12 Gene ID: 10162 mRNA sequence: NM_005768.5 
PRIMER 5' to 3’ Forward primer 3’ to 5’ Reverse Primer 
Product 
length 
Primer 1 sequence LG1F  GCCACATCTTCTTCCTGAGC LG1R GCTGTGAAAAGGGAGACGAG 154 bp 
Primer 2 sequence LH1F CTCTCGTTGCTATTCCTGGC LH1R GAGCCAGTGGATGGTCTGTT 198 bp 
LPCAT4 (MBOAT2) 
  Chromosome 2 Gene ID: 129642 mRNA sequence: NM_138799.2    
PRIMER 5' to 3’ Forward primer 3’ to 5’ Reverse Primer 
Product 
length   
Primer 1 sequence LL1F  ATGGGCCATTTTTACCACAA LL1R AGGAGGTACAATCTGGGGCT 153 bp 
Primer 2 sequence LM1F CAGGCCCACTTTGCTCTTAC LM1R AACAAGGACAGCCCACAAAC 169 bp 
Primer 3 sequence LN1F GTTTGTGGGCTGTCCTTGTT LN1R AGCTAGCGTCCATGCAAAAT 171 bp 
LPEAT2 (AGPAT7: AYTL3) 
  Chromosome 15 Gene ID: 254531 mRNA sequence: NM_153613.2 
PRIMER 5' to 3’ Forward primer 3’ to 5’ Reverse Primer 
Product 
length 
Primer 1 sequence LI1F  ATTGGAGCCCTTCTTCGATT LI1R AGCAAAGCCTTCTTGTTGGA 167 bp 
Primer 2 sequence LJ1F CCGGTCTTAGTGAGGAGCAG LJ1R TGGGGTCAAAGAAAGTGGAG 198 bp 
Primer 3 sequence LK1F TCTGGGAACTGGGAAAAGTG LK1R CTGCTGGAAGTAGCCAAAGG 167 bp 
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4.3.2 Protein expression profile of LPCAT1 and LPCAT2 
Western blot analysis was used to examine the endogenous protein expression of 
hLPCAT1 and hLPCAT2 in MM6, A549, BEAS-2B, HepG2, Hek293 and mouse 
Raw26.7 cell lines. Equal volumes and concentrations of protein (20 µg of protein per 
lane) were loaded and 5 µl of biotinylated protein ladder was loaded in lane 1 to aid 
identification of proteins on nitrocellulose membranes. Commercially designed anti-
human polyclonal LPCAT1 and LPCAT2 antibodies (ProteinTech, Manchester, UK) 
were used to detect protein expression of hLPCAT1 and hLPCAT2.   
 
4.3.3 Effect of IFN- γ and LPS on LPCAT mRNA expression  
Cells (3×10
6
) were incubated either with IFN-γ (250 units/ml) or Escherichia coli 
O111:B4 LPS (100 ng/ml) for 18 or 4 hours, respectively. Following total RNA 
extraction, first strand cDNA was synthesized and qPCR completed in triple technical 
replicates as described previously (section 4.3.1). Results were analysed using 2
-ΔΔCT 
and are presented as the fold change in mRNA expression normalized to GAPDH and 
relative to the corresponding untreated cell. 
 
4.3.4 Effect of TLR4 and TLR2 ligand stimulation on LPCAT1 and LPCAT2 
protein expression 
Western blot analysis was used to examine the effect of TLR4 and TLR2 ligands, and 
the influence of HETP, on LPCAT protein expression in MM6 cells. Cultures of 
MM6 cells (6×10
6
) were incubated for 30 minutes in the presence or absence of 
50μM HETP, prior to stimulation with LPS (100 ng/ml), LTA (10 µg/ml) PG (10 
µg/ml) or Pam3CSK4 (1.0 µg/ml) and further co-culture for 24 hours. As for previous 
experiments, equal volumes and concentrations of protein were loaded. Membranes 
were then striped and re-probed with hGADPH antibody to aid densitometry analysis. 
 
4.3.5 Effect of IFN- γ on LPCAT1 and LPCAT2 protein expression  
MM6 cells (6×10
6
) were co-cultured with IFN-γ (250 units/ml) for 18 hours prior to 
incubation with HETP and treatment with TLR4 and TLR2 ligands. As with previous 
experiments, western blot analysis was used to determine the effect of IFN-γ on 
LPCAT1 and LPCAT2 expression.  
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4.4 RESULTS 
4.4.1 LPCAT mRNA expression varies among cell types 
Figure 4.2 shows the expression of LPCAT1, LPCAT2, LPCAT3, LPEAT2 and 
LPCAT4 in lung epithelial A549 cells relative to MM6 cells. The results suggest that 
A549 cells express LPCAT1, 2, 3 and LPEAT2 mRNA at equivalent levels to MM6 
cells.  Conversely A549 cells were observed to have significantly more LPCAT4 
expression (85 fold) than MM6 cells, which did not appear to express any detectable 
LPCAT4. 
 
LPCAT expression in BEAS-2B cells followed a similar trend to that seen with A549 
cells (Figure 4.3); BEAS-2B cells expressed comparable mRNA levels of LPCAT1, 
LPCAT2, LPCAT3 and LPEAT2 to MM6 cells, but like A549 cells, highly expressed 
LPCAT4, indicating that LPCAT4 is likely to be of importance in lung epithelial cells 
regulatory pathways. 
 
The human embryonic kidney cell line Hek293 has been reported to be the cell of 
choice to analyse LPCAT1 (Chen et al., 2006) and LPCAT3 over-expression (Zhao et 
al., 2008) as well as siRNA knockdown of LPCAT2 (Shindou et al., 2007) and of 
LPEAT2 (Cao et al., 2008). Liver tissue and hepatocyte cell lines have also displayed 
high expression of LPCATs therefore offering a reliable means for the investigation 
of expression levels (Agarwal et al., 2007; Hishikawa et al., 2008). Thus the mRNA 
from both HepG2 and Hek293, were analysed by the same method to provide a 
positive comparison for the qPCR experiments.  
 
Relative expression of LPCAT1 and LPEAT2 in HepG2 cells were of comparable 
levels to MM6 cells (Figure 4.4), but LPCAT2 and LPCAT3 appear to be elevated, at 
2.5 and 1.5 fold higher than MM6 cells (respectively). However, in contrast to the 
lung epithelial cells, expression of LPCAT4 in HepG2 was comparable to MM6; 
below the limit of detection. 
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 Intrinsic expression of LPCAT-like acyltransferases in A549 cells Figure 4.2
Intrinsic LPCAT expression of A549 cells, presented as the mean mRNA expression normalized to GAPDH and relative to MM6 cells. Results 
are the mean +/- S.E.M of 3 independent experiments. 
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 Intrinsic expression of LPCAT-like acyltransferases in BEAS-2B cells Figure 4.3
Intrinsic LPCAT expression of BEAS-2B cells, presented as the mean mRNA expression normalized to GAPDH and relative to MM6 cells. 
Results are the mean +/- S.E.M of 3 independent experiments. 
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 Intrinsic expression of LPCAT-like acyltransferases in HepG2 cells Figure 4.4
Intrinsic LPCAT expression of HepG2 cells, presented as the mean mRNA expression normalized to GAPDH and relative to MM6 cells. Results 
are the mean +/- S.E.M of 3 independent experiments. 
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Since Hek293 cells are widely used to study LPCAT, it was not surprising to observe 
that the preliminary data for the intrinsic LPCAT expression in Hek293 cells was the 
highest across the cells studied (Figure 4.5). Expression of all the LPCAT genes were 
substantially increased in comparison to MM6 expression; most notably LPCAT2 
expression (21 fold more) and LPCAT4 (over 2000 fold more). However, although 
the expression level of LPCAT4 was significantly increased, it is worth noting that 
results are displayed relative to MM6 (not actual quantities) and MM6 cells did not 
appear to express any LPCAT4 which may account for the sizeable difference. Initial 
results may suggest that LPCAT4 is crucial to Hek293 cell functions, although data 
was observed from one sample and further replicates are required in order to 
consolidate these findings. 
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 Intrinsic expression of LPCAT-like acyltransferases in Hek293 cells Figure 4.5
Preliminary data for intrinsic LPCAT expression of Hek293 cells, presented as 
mRNA expression normalized to GAPDH and relative to MM6 cells. Results are 
preliminary from a single sample of mRNA, with qPCR. 
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4.4.2 Endogenous LPCAT1 and LPCAT2 protein expression is highest in BEAS-
2B, HepG2 and Hek293 cells 
Since LPCAT1 and LPCAT2 mRNA was detected in all the cell lines studied, the 
LPCAT protein level in these cells was examined. Protein bands at the corresponding 
molecular mass to hLPCAT1 and hLPCAT2 were identified in each cell line (Figure 
4.6). Strong LPCAT1 bands appeared in protein from the metabolically active cells, 
HepG2 and Hek293. However, bronchial epithelial cell protein was shown to have 
stronger LPCAT2 signals than both HepG2 and Hek293 cells. MM6 cells on the other 
hand, display a low intensity of both LPCAT1 and LPCAT2.  
 
Noticeably, the anti-human LPCAT2 antibody appears to have identified two bands 
of slightly different molecular mass in the MM6 cell protein. Whilst it must be noted 
that the antibodies are polyclonal, this second band may suggest that an isoform of 
LPCAT2 protein exists as suggested by NCBI database / UniProtKB (GenBank 
accession number Q7L5N7) and have been found in mice (Shindou et al.,  2007; 
Soupene et al., 2008) or alternatively that the antibody is detecting one of the other 
LPCATs. This may also explain the large band observed in BEAS-2B cells when 
probed with anti-human LPCAT2 antibody. In 2009, Harayama et al. showed that 
antiserum against mouse LPCAT1 could also detect human LPCAT1, supporting the 
evidence of high amino acid homology that exists between species. On this basis, 
murine macrophage, RAW 264.7 cell lysate was also examined with anti-human 
LPCAT1 and LPCAT2 antibodies. The antibodies not only had cross-reactivity with 
the mouse cell lysate, but showed a strong signal with anti-human LPCAT2. 
 
Although the protein levels analysed by western blot were not quantified by 
comparison to a known concentration of LPCAT protein, the results show some 
similarities to the qPCR data. HepG2 and Hek293 expressed the highest levels of 
LPCAT1 and LPCAT2 mRNA (relative to MM6) which is also implied in the 
western blots. However, BEAS-2B cell protein appears to have the highest LPCAT2 
protein signal, in contrast to the qPCR data. Without standards and loading controls, 
however, these observations must be considered with caution. 
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 Expression profile of LPCAT1 and LPCAT2 in various cell lines. Figure 4.6
The endogenous expression of hLPCAT1and hLPCAT2 in MM6, A549, BEAS-2B, 
HepG2, Hek293 and mouse cell line Raw26.7 as determined by western blot. 20 µg 
of protein cell lysate was loaded per lane and probed using anti-hLPCAT1 and anti-
hLPCAT2 antibodies. Arrowhead indicates bands of expected molecular mass 
(≈59kDa) for LPCAT1 and (≈53kDa) for LPCAT2. Results are representative of 2 
identical experiments 
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4.4.3 LPS and IFN-γ do not significantly affect the mRNA expression levels of 
LPCATs 
LPCAT regulates the increased inflammatory cytokine production from IFN-γ primed 
and microbial induced cells, as described in Chapter 3. IFN-γ has also been observed 
to up-regulate LPCAT activity and significantly modify the phospholipid composition 
of monocytes (Schmid et al., 2003). Shindou and colleagues (2005) observed 
LPCAT2 activity to double in LPS induced mouse peritoneal macrophages, 
confirming the crucial role that LPCAT plays in regulating inflammatory responses. It 
was therefore of interest to study the effects of IFN-γ and LPS on LPCAT mRNA 
expression in MM6 and BEAS-2B cells. 
 
Following qPCR, results were analysed using 2
-ΔΔCT 
and are presented as the fold 
change in mRNA expression normalized to GAPDH and relative to the corresponding 
untreated cell. No significant changes in mRNA expression of LPCAT 1, 2, 3, 4 or 
LPEAT2 (Table 4.2) were observed with LPS stimulation in MM6 or BEAS-2B cells. 
Preliminary experiments with IFN-γ treatment (Table 4.3) also found that neither 
MM6 nor BEAS-2B mRNA displayed any significant changes in expression of the 
LPCATs. This is suggestive that changes in the two sets of data are due to random 
variability and not influenced by treatment, however, this data should be viewed 
cautiously as only one IFN-γ experiment was completed and the characteristic of 
qPCR is to study one specific time point in the experiment, which perhaps need 
optimising. 
 
  
Jenny Hughes       Chapter 4: Results and Discussion 
 111 
 
(a)  (b) 
 
Table 4.2 The effect of LPS stimulation on LPCAT mRNA expression in MM6 
and BEAS-2B cells. 
LPCAT mRNA expression of MM6 (a) and BEAS-2B (b) cells treated with LPS, 
normalized to GAPDH and relative to untreated cells, presented as the mean fold 
change in mRNA expression. One primer set for each LPCAT was selected and 
displays the representative expression. Results are the mean +/- SEM of 3 
independent experiments. 
 
 
(a)  (b) 
 
Table 4.3 The effect of IFN-γ treatment on LPCAT mRNA expression in 
MM6 and BEAS-2B cells. 
LPCAT mRNA expression of MM6 (a) and BEAS-2B (b) cells treated with IFN-γ, 
normalized to GAPDH and relative to untreated cells, presented as the fold change in 
mRNA expression. The same primer set for each LPCAT (as above) was selected and 
displays the representative expression. Results are preliminary data of one 
experiment. 
BEAS-2B mean expression change with LPS 
treatment 
Primer 
Mean 2-
ΔΔCT 
S.E 
LPCAT 1 (LA) 1.2 0.1 
LPCAT 2 (LD) 1.7 0.0 
LPCAT 3 (LH) 1.0 0.0 
LPEAT 2 (LJ) 1.0 0.1 
LPCAT 4 (LM) 1.5 0.1 
MM6 mean expression change with LPS 
treatment 
Primer 
Mean 2-
ΔΔCT 
S.E 
LPCAT 1 (LA) 0.5 0.0 
LPCAT 2 (LD) 0.5 0.1 
LPCAT 3 (LH) 0.8 0.1 
LPEAT 2 (LJ) 0.3 0.0 
LPCAT 4 (LM) 0.8 0.2 
MM6 expression change with  
IFN-γ treatment 
Primer  2-ΔΔCT 
LPCAT 1 (LA) 1.2 
LPCAT 2 (LD) 0.8 
LPCAT 3 (LH) 0.9 
LPEAT 2 (LJ) 1.0 
LPCAT 4 (LM) 0.5 
BEAS-2B expression change with  
IFN-γ treatment 
Primer  2-ΔΔCT 
LPCAT 1 (LA) 0.7 
LPCAT 2 (LD) 1.0 
LPCAT 3 (LH) 1.4 
LPEAT 2 (LJ) 1.0 
LPCAT 4 (LM) 1.2 
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4.4.4 LPCAT protein is up-regulated with PG stimulation 
Whilst LPCAT mRNA expression appears unaffected by interactions with TLR4 
ligand LPS and IFN-γ, it was of interest to study their effects on LPCAT protein 
expression. Western blot analysis was used to show the protein expression of 
LPCAT1 and LPCAT2 in MM6 cells stimulated with TLR4 and TLR2 ligands, and to 
assess its reduction in expression after treatment with HETP. LPCAT band intensity 
was measured using ImageJ software and used as a qualitative measure of protein 
expression (Abramoff et al., 2004). 
 
Detection using hLPCAT1 antibody revealed a protein band at approximately 59kDa 
in all the untreated and treated cell lysates which corresponds to the expected weight 
of LPCAT1 (Figure 4.7a). ImageJ analysis suggests that stimulation with LPS, LTA 
or Pam3CSK4 did not significantly affect expression of the 59kDa band (Figure 4.7b). 
However PG treatment resulted in a small, but significant (P<0.05), 2.5 fold increase 
in expression of LPCAT1. 
 
Similar findings were found using hLPCAT2 antibody. In all the untreated and 
treated cell lysates, a protein band at approximately 53kDa was identified which 
corresponds to the expected weight of LPCAT2 (Figure 4.8Error! Reference source 
not found.a). Comparable to results seen with LPCAT1 antibody, PG treatment 
resulted in a small, but significant (P<0.05), 3 fold increase in expression of 
LPCAT2, whereas stimulation with LPS, LTA or Pam3CSK4 did not significantly 
affect expression (Figure 4.8b). It was noted that in all experiments no reduction in 
LPCAT1 or LPCAT2 expression was observed in cells treated with HETP. 
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 Effect of TLR ligands on LPCAT1 protein expression in MM6 cells Figure 4.7
MM6 cells (3×106) were incubated in the presence or absence of 50μM HETP, 30 minutes prior to stimulation with LPS (100 ng/mL), LTA (10 
µg/mL) PG (10 µg/mL) or Pam3CSK4 (1.0 µg/mL) for 24 hours. An equal volume and concentration (20 µg) of cell lysate was loaded per lane. (a) 
Representative western blot probed with hLPCAT1antibody. Membranes were stripped and re-probed with GAPDH. (b) Densitometry data of 
western blots probed with LPCAT1antibody. Results are the mean +/- S.E.M of 3 independent experiments, normalized to GAPDH and relative to 
the untreated control.  
(b) 
59 kDa 
 
 
37 kDa 
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 Effect of TLR ligands on LPCAT2 protein expression in MM6 cells Figure 4.8
MM6 cells (3×106) were incubated in the presence or absence of 50μM HETP, 30 minutes prior to stimulation with LPS (100 ng/mL), LTA (10 
µg/mL) PG (10 µg/mL) or Pam3CSK4 (1.0 µg/mL) for 24 hours. An equal volume and concentration (20 µg) of cell lysate was loaded per lane. (a) 
Representative western blot probed with hLPCAT2antibody. Membranes were stripped and re-probed with GAPDH. (b) Densitometry data of 
western blots probed with LPCAT2antibody. Results are the mean +/- S.E.M of 3 independent experiments, normalized to GAPDH and relative to 
the untreated control. 
(b) 
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37 kDa 
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4.4.5 IFN-γ does not significantly affect LPCAT protein expression 
It was investigated if there was a correlation between increased inflammatory 
cytokine secretion in cells treated with IFN-γ (as seen in chapter 3) and the expression 
levels of LPCAT. Preliminary results suggest that IFN-γ does not induce a significant 
change in LPCAT mRNA expression, but it was of interest to investigate if IFN-γ 
alters expression at the protein level.  
 
As for previous experiments, ImageJ software was used to quantify protein LPCAT 
expression by measuring band intensity of western blots. Figure 4.9 and Error! 
Reference source not found. Figure 4.10 identified protein bands in all lanes to the 
corresponding molecular weights of LPCAT1 and LPCAT2. The protein bands 
detected in cell lysates treated with IFN-γ and/or TLR ligands revealed intensities 
equivalent (within 1 fold) to untreated MM6 cell lysate. 
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 Effect of IFN- γ on LPCAT1 protein expression in MM6 cells Figure 4.9
MM6 cells (3×106) were pre- incubated with IFN- γ for 18 hours prior to inhibition with of 50μM HETP for 30 minutes and stimulation with LPS 
(100 ng/mL), LTA (10 µg/mL) PG (10 µg/mL) or Pam3CSK4 (1.0 µg/mL) for 24 hours. An equal volume and concentration (20 µg) of cell lysate 
was loaded per lane. (a) Representative western blot probed with hLPCAT1antibody. Membranes were stripped and re-probed with GAPDH. (b) 
Densitometry data of western blots probed with LPCAT1antibody. Results are the mean +/- S.E.M of 3 independent experiments, normalized to 
GAPDH and relative to the untreated control. 
(b) 
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  Effect of IFN- γ on LPCAT2 protein expression in MM6 cells Figure 4.10
MM6 cells (3×106) were pre- incubated with IFN- γ for 18 hours prior to inhibition with of 50μM HETP for 30 minutes and stimulation with LPS 
(100 ng/mL), LTA (10 µg/mL) PG (10 µg/mL) or Pam3CSK4 (1.0 µg/mL) for 24 hours. An equal volume and concentration (20 µg) of cell lysate 
was loaded per lane. (a) Representative western blot probed with hLPCAT2 antibody. Membranes were stripped and re-probed with GAPDH. (b) 
Densitometry data of western blots probed with LPCAT2antibody. Results are the mean +/- S.E.M of 3 independent experiments, normalized to 
GAPDH and relative to the untreated control. 
59 kDa 
 
 
37 kDa 
(b) 
Jenny Hughes       Chapter 4: Results and Discussion 
 118 
 
4.5 DISCUSSION 
4.5.1 Expression of LPCAT is ubiquitous, but LPCAT4 is highly in lung epithelial 
cells. 
Many groups have published findings on the expression levels of acyltransferases 
with LPCAT activity in human and mouse tissue panels; Nakanishi et al. (2006) 
reported the highest mLPCAT1 expression in mouse lung tissue. Harayama et al. 
(2009) also observed hLPCAT1 expression to be highest in the lung, then spleen and 
leukocytes confirming these findings. Furthermore, rat alveolar type II cells were 
isolated and found to be enriched with LPCAT1, where surfactant proteins are 
secreted (Chen et al., 2006). In agreement with these studies, Agarwal and co-
workers (2007) showed the expression of hAGPAT9/hLPCAT1 to be highly 
expressed in lung tissue. In comparison, leukocytes expressed approximately 3 fold 
less and liver tissue expressed 40 fold less than lung tissue (Agarwal et al., 2007). 
Furthermore, alveolar type II cells were found to express the majority of LPCAT2 
observed in total lung tissue.  
 
Literature would therefore suggest that hLPCAT1 is most notably expressed in lung 
tissue, where it plays a role in producing DPPC, with leukocytes expressing a little 
less (Nakanishi et al., 2006). Results from the present study show comparable mRNA 
expression of LPCAT1 between lung epithelial and monocytic cell lines, supporting 
this observation. The liver hepatocyte cell line HEPG2 was also found to have similar 
expression of LPCAT1 in contrast to the significantly reduced expression observed 
by Agarwal et al. (2007) in primary liver tissue. This discrepancy could be due to 
HepG2 being a transformed cell line, possibly expressing more LPCAT1 mRNA than 
primary hepatocytes. 
 
LPCAT2 shows significant amino acid sequence homology to LPCAT1 (Shindou et 
al., 2007) and it may therefore not be surprising that LPCAT2 has been reported to 
also have the highest expression in lung tissue and leukocytes (Agarwal et al., 2010). 
In fact Shindou et al. (2007) found the highest expression level of mLPCAT2 in 
resident macrophages (230 arbitrary units) and a low level seen lung tissue (12 
arbitrary units), suggesting that LPCAT2 has an important role to play in mouse 
macrophages. Shindou et al. (2005) reported LPCAT2 to play a constitutive role in 
inducible PC remodelling pathways in response to external stimuli in mouse 
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peritoneal macrophages. Thus initial thoughts are that LPCAT2 is the major 
remodelling enzyme involved in inflammatory pathways. 
 
However, a discrepancy is observed in the literature as this is inconsistent to the 
findings of Agarwal et al. (2010) who reported that leukocyte expression of 
hLPCAT2 was identical to expression in lung tissue. Results from the current study 
revealed that hLPCAT2 mRNA expression is alike in lung and monocyte cell lines in 
agreement with the observations made by Agarwal et al. (2010). Although mouse 
LPCAT2 was reported to have 88.4 % amino acid sequence homology to human 
LPCAT2 (Shindou et al., 2007), perhaps the discrepancy seen in the literature 
highlights the difference between the role of mouse LPCAT2 and human LPCAT2 in 
macrophages. As shown with LPCAT2 siRNA, human LPCAT2 actually appears to 
be the principal enzyme for PAF production in HEK293 cells (Shindou et al., 2007) 
which supports the high expression levels found in the present study. 
 
Mouse LPCAT3 (MBOAT5) has been detected ubiquitously amongst metabolically 
active tissue, with abundant expression levels in testis, liver and kidney tissues, 
compared to very low expression in both lungs and macrophages (Hishikawa et al., 
2008). Zhao, et al. (2008) supported these findings, observing high mLPCAT3 
expression in liver and pancreas tissue, suggesting it to be primarily responsible for 
hepatic LPCAT activity, but very low expression in lung tissue. However, expression 
levels of human LPCAT3/MBOAT5, is currently unreported in the literature. The 
present study found the mRNA levels of LPCAT3 comparable between A-549, 
BEAS-2B and MM6 cell lines. In contrast, HEPG2 mRNA expression of LPCAT3 
was observed to be 1.5 fold more than LPCAT3 expression in monocytes, similar to 
the increased level observed in liver tissue as published, indicating LPCAT3 as a 
principal enzyme in the regulation of the remodelling pathway. 
 
Contrasting to LPCAT3, LPEAT2 has been reported virtually undetectable in human 
lung and liver tissues, and was primarily expressed in both human and mouse brain 
tissue (Cao et al., 2008; Ye et al., 2005). As reported here, very low mRNA 
expression levels of LPEAT2 were seen across the panel of cell lines tested, 
suggesting that LPEAT2 has greater importance in modulating brain phospholipid 
composition, than in lungs, liver or monocytes. 
Jenny Hughes       Chapter 4: Results and Discussion 
 120 
 
Finally LPCAT4 (MBOAT2) mRNA was observed to have a remarkably high 
expression in both lung epithelial cell lines (Figure 4.2 and Figure 4.3) in the present 
study. In contrast, low expression of mLPCAT4 was detected in lung tissue by 
Hishikawa et al. (2008) who revealed that mLPCAT4 is predominantly expressed in 
mouse epididymis, brain and testis tissue, playing a constitutive role in membrane 
biogenesis. It may be that this variation exists because no LPCAT4 mRNA was 
detected in monocytes, to which the expression level of LPCAT4 in A-549 and 
BEAS-2B cells was relative. However, even the equivalent CT values display an 
enlarged expression of LPCAT4 in these lung cells (data not shown).  
 
It is possible that each LPCAT performs a unique function within different cell types 
in mice and humans, either maintaining cellular membrane structure and /or 
producing specific phospholipid signalling molecules. As such LPCAT expression 
observed in mice may not be representative of human expression. Nevertheless, data 
from the present study indicates that LPCAT4 may have a function in regulating the 
phospholipid remodelling pathway in lung epithelial cells.  
 
4.5.2 Expression of LPCAT is unaffected by stimulation and priming 
The present study has demonstrated that inhibition of LPCAT down-regulates 
inflammatory cytokine production in monocytes and epithelial cells. Jackson et al. 
(2008) discovered that this observation was due the inhibition of LPCAT preventing 
translocation of TLR4 into membrane lipid raft domains. These observations 
demonstrated a regulatory mechanism that can facilitate innate immune responses to 
microbial derived stimuli, but the specific LPCAT responsible remains unknown. 
 
In 2005 Shindou and colleagues reported the existence of an LPS-inducible 
remodelling pathway in response to external stimuli, where LPS induced LPCAT2 
activity doubled in mouse peritoneal macrophages. Initially, this indicated that 
LPCAT2 might be the candidate enzyme to modulate the phospholipid remodelling 
pathway in innate immune cells, but also that it regulates the production of specific 
signalling molecules in response to microbial molecular patterns, such as those seen 
in sepsis.  
 
Jenny Hughes       Chapter 4: Results and Discussion 
 121 
 
It was believed that LPCAT2 could be the LPCAT responsible for regulating 
inflammatory responses in monocytes and thus it was hypothesised that LPCAT2 
could be highly expressed in these immune cells. However, endogenous mRNA 
expression of LPCAT2 was found to be no more than observed in lung epithelial 
cells. So LPS-induced LPCAT2 expression was then investigated. Conflicting to 
these ideas, data in this report suggests that LPS does not significantly change the 
expression of LPCAT2 or any of these LPCAT-like ATs in monocytes or alveolar 
epithelial cell lines. However, although PCR data should be viewed with caution as 
only one experiment was completed. Additionally, western blot analysis of MM6 cell 
lysate demonstrated no protein expression alterations with LPS treatment or any 
TLR2 ligand. Furthermore, prior treatment with LPCAT inhibitor, HETP, did not 
reduce LPCAT1 or LPCAT2 protein expression 
 
IFN-γ, found to increased inflammatory responsiveness to LPS, is an important factor 
in the development of LPS-induced biological activity and its presence is linked to 
the mortality of several forms of endotoxic shock (Car et al., 1994). Schmid et al. 
(2003) observed IFN-γ to up-regulate LPCAT activity and significantly modify the 
phospholipid composition of monocytes. In addition to this activity, it was of interest 
to ascertain if IFN-γ can increase the expression of LPCAT in monocytes. However, 
IFN-γ did not significantly change the mRNA expression of any monocytic, nor 
protein expression of LPCAT1 or LPCAT2, which was relative to the constitutive 
expression. 
 
Nevertheless, qPCR and western blot analysis only looks at a snapshot in the timeline 
of mRNA and protein expression and this report looked at expression levels after 18 
hours of incubation with IFN-γ, which in hindsight could have been too late to 
observe any increased expression. The same conclusion could be reached with TLR 
ligand induced LPCAT expression which was observed at 4 hours post stimulation 
for PCR and 24 hours for western blot analysis. It would be advantageous to study 
different incubation time points to demonstrate what effect this has on mRNA and 
protein expression.  
 
  
Jenny Hughes       Chapter 4: Results and Discussion 
 122 
 
Further investigation could reveal that timely post-transcriptional modifications occur 
and allow for increased production in LPCAT protein, or more likely that modulation 
of LPCAT’s activity rather than expression is influenced by TLR ligands and IFN-γ, 
as Schmid et al. (2003) observed. This may also help to reveal why the LPCAT 
inhibitor HETP did not affect LPCAT expression levels and perhaps suggests that 
HETP impedes LPCAT enzyme activity. 
  
  Chapter 5
 
 
RESULTS AND DISCUSSION 
 
TOLL-LIKE RECEPTOR 2 MEMBRANE 
TRANSLOCATION IN INFLAMMATORY RESPONSES  
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5.1 INTRODUCTION 
An accumulating body of evidence exits suggesting that TLR4 and TLR2 are not 
constitutively found in membrane lipid rafts, but are recruited into them only after 
microbial stimulation (Abate et al., 2010; Jackson et al., 2008; Triantafilou et al., 
2004). To date the receptor molecules that cluster within lipid rafts have been 
characterized and demonstrated to show that translocation of these molecules provide 
a focused signalling event (Triantafilou et al., 2004). Furthermore, LPCAT enzymes 
have been shown to modify the plasma membrane phospholipid microenvironment 
facilitating the recruitment of receptor proteins into lipid rafts for the assembly of 
receptor complexes (Darmani et al., 1993; Schmid et al., 2003).  
 
In 2008, research by Jackson et al. confirmed that membrane lysophospholipid 
metabolism facilitates TLR4 translocation and thus is involved in the regulation of 
inflammatory signalling responses. This discovery was achieved through blocking 
LPCAT activity with the specific LPCAT inhibitor, HETP, which demonstrated the 
subsequent inhibition of TLR4 translocation into the lipid raft domain of MM6 cell 
membranes following stimulation with LPS (Jackson et al., 2008). Consequently, the 
receptor complex was prevented from assembling and a significant reduction in 
inflammatory cytokine secretion was observed.  
 
In addition, Abate et al. (2010) examined the involvement of TLR4 translocation into 
lipid rafts in the induction of chemokine release by lung epithelial cells A549 cells by 
disrupting the raft microdomains with mycostatin. The disruption of the lipid rafts 
caused a dose-dependent inhibition of LPS-mediated IL-8 production, which 
suggested that raft microdomains are important in LPS signalling in lung epithelial 
cells. In a manner analogous to TLR4, TLR2 forms activation clusters with TLR1 or 
TL6 depending on the microbial ligand it is exposed to; diacylated lipoproteins, such 
as LTA, require TLR2/6 heterodimers for activation, whereas triacylated lipoproteins, 
such as Pam3CSK4, induce activation of the innate immune system mainly through 
TLR2/TLR1 heterodimers (Triantafilou et al., 2006). These clusters trigger signalling 
from the cell surface, activating an inflammatory response in a lipid-raft dependent 
pathway (Triantafilou et al., 2004).  
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5.2 AIMS 
The aim of this study was to assess whether LPCAT inhibition prevents TLR2 
translocation into the membrane lipid raft, thus preventing the subsequent formation 
of the receptor signalling complex. 
 
5.3 METHODS 
MM6 cell stimulation with TLR ligands 
MM6 cells (1×10
7
) were co-cultured with or without 50 µM HETP for 30 minutes 
prior to co-culture in the presence or absence of LTA (10 µg/ml), PG (10 µg/ml) or 
Pam3CSK4 (1.0 µg/ml) and further incubated for 45 minutes, as recommended by 
Triantafilou et al. (2006) and Jackson et al. (2008). Cells were lysed in a Triton X 
extraction buffer for 1 hour at 4°C and sonicated on ice to homogenize the lysate in 
4×11 second bursts and reduce sample viscosity. Complete lysis of cells was checked 
using light microscopy. 
 
5.3.1 Total lipid isolation  
Since membrane lipid rafts are enriched in cholesterol, sphingolipids and are 
detergent-insoluble, they can be separated from other plasma membrane components 
based upon their insolubility in Triton X-100 and by low buoyant density in sucrose 
gradients. To determine if inhibition of LPCAT affects translocation of TLR2 into the 
lipid raft domain of MM6 cell membranes in response to a microbial stimulant,  total 
lipid fractions were isolated from cell lysate using sucrose density gradient 
ultracentrifugation as described by Triantafilou et al. (2002). A total of twelve 1 ml 
membrane fractions (1-12) were then recovered from the gradient and taken forward 
for analysis. 
 
5.3.2 Assessment of lipid separation by dot blot analysis 
To determine which fractions contained the lipid raft, samples from each of the 
twelve fractions were probed for GM1, a ganglioside receptor prevalent in lipid rafts, 
with HRP-conjugated cholera-toxin β-subunit that specifically binds to GM1. The 
antigen was then visualised using Amersham ECL Plus Western Blotting Detection 
Reagents (GE Healthcare, Buckinghamshire, UK) in accordance with the 
manufacturer’s instructions. 
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5.3.3 Determining TLR translocation by western blot 
Western blot analysis was used to examine the location of TLR2 within the lipid raft 
fractions after microbial ligand stimulation. Equal volumes of protein (20 µl of 
sample per lane) were loaded and 5 µl of biotinylated protein ladder was loaded in 
lane 1 to aid identification of proteins on nitrocellulose membranes. Commercially 
designed hTLR2 antibody (Cambridge Bioscience, Cambridge, UK) was used to 
detect protein expression of TLR2. 
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5.4 RESULTS 
5.4.1 Assessment of lipid raft separation by dot blot analysis 
The dot blots in Figure 5.1 show the isolation of the total lipid fraction by sucrose 
density gradient ultracentrifugation (Figure 5.1a). GM1, a ganglioside receptor 
prevalent in lipid rafts, was used as a probe to identify those fractions containing lipid 
rafts. GM1 was detected in membrane fractions 5, 6 and 7 from unstimulated MM6 
total cell lysate, indicating the presence of lipid rafts (Figure 5.1b). MM6 cells 
stimulated with TLR2 ligand LTA (Figure 5.1c), and with prior treatment with HETP 
(Figure 5.1d) were also probed with GM1 and dot blots verify that the membrane 
lipid rafts remained in fractions 5, 6 and 7.  
 
5.4.2 Determining TLR2 translocation by Western blot analysis 
Western blot analysis was used to identify the location of TLR2 in the fractions of 
untreated MM6 cells in order to assess TLR2 translocation upon stimulation with 
TLR2 ligands and to determine the degree of inhibition of TLR2 translocation by 
HETP. Initially, 20 µl of each membrane fraction were applied onto the Bis-Tris gel 
(4-12 %). However, after probing the nitrocellulose membrane with hTLR2 antibody, 
sample protein concentrations from neat fractions were insufficient to visualise 
protein bands. Whilst significant protein concentration can be seen on western blots 
by Triantafilou et al. (2002) who also loaded equivalent portions of membrane 
fractions, Jackson et al. (2008) however, concentrated proteins in each fraction prior 
to western blot. Thus future experiments following this trial followed this model of 
concentrating proteins by methanol:chloroform precipitation as described by Wessel 
and Flugge (1984).  
 
Despite optimising the ratios of methanol and chloroform used for protein 
concentration by Wessel and Flugge (1984), concentrating the proteins from 
membrane fractions proved more challenging than expected. One specific issue was 
that sucrose was concentrated along with the protein in the fractions, which ultimately 
interfered with protein concentration assays. Problems were also encountered with the 
limitation of micro-centrifuge tube volumes so alternative protein concentration 
methods were investigated. 
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 Dot Blot of lipid (5-7) and non-lipid (1-4 and 8-12) fractions. Figure 5.1
Plasma membrane fractions were obtained through total cell lysate sucrose density 
gradient ultracentrifugation. (a) twelve 1 ml fractions were removed and probed for 
GM1, a lipid raft specific protein. The presence of GM1 was detected with HRP-
conjugated cholera-toxin and visualised using ECL procedure (Amersham). GM1 was 
found in fractions 5, 6 and 7 in (b) unstimulated MM6 cells, (c) LTA stimulated 
MM6 cells and (d) HETP and LTA treated MM6 cells, indicating that these fractions 
contain the total lipid from the cells, including the lipid rafts. These dot blots are 
representative of all total lipid isolations performed and all additional experiments 
revealed the lipids in the same fractions, 5-7.  
(b) MM6 Unstimulated  
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To this end, several other protein concentration methods were investigated, including 
trichloroacetate (TCA- Pierce Technical resources) and phenol/ether (Sauvé et al., 
1995) precipitation. Whilst these methods achieved high protein concentrations and 
recovery from standard cell lysate, difficulties were still experienced with proteins 
suspended in sucrose solutions; including increased sample viscosity, difficultly re-
solubilising the pellet or substance interference with protein quantification assays. It 
was therefore of interest to investigate dialysing or desalting methods to remove the 
undesirable sucrose from lipid samples. However, while both methods served to 
reduce sucrose content, neither concentrated the protein. 
 
After extensively investigating a variety of dialysing and desalting methods and 
protein concentration and quantification assays, the phenol/ether method 
concentration method offered the most potential to eradicate the problematic sucrose. 
This method was scaled up, optimised and used thereafter to concentrate proteins 
directly from each 1 ml membrane fraction. The resulting pellet was resuspended 
using ×2 LDS sample buffer compatible with protein quantification assays, 
supplemented with 2 % SDS to aid re-solubilisation. Protein concentrations were 
determined using Pierce BCA microplate Protein assay kit (Thermo Fisher Scientific, 
Loughborough, UK) and equal volumes and concentrations (20 µg) of each lipid 
fractions were then used for western blot analysis. 
 
Probing using hTLR2 antibody revealed a protein band at approximately 80 kDa, 10 
kDa lower than the expected molecular weight of TLR2 in the non-lipid fractions (11 
and 12) of both untreated and treated cell lysates (Figure 5.2). As these fractions were 
the last to be removed from the sucrose density gradient, they likely contained 
residual cell lysate; therefore the presence of TLR2 in these fractions was not 
unexpected. However, western blot analysis also identified the presence of TLR2 at 
low concentration in the lipid (fractions 5-7), in both unstimulated and treated MM6 
cells. Even after protein concentration, the TLR2 protein was expressed at a 
significantly lower amount in the lipid than seen in the reports by both Triantafilou et 
al. (2002) and Jackson et al. (2008). 
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 Expression of TLR2 in monocyte plasma membrane fractions. Figure 5.2
1 ml plasma membrane fractions were obtained through total cell lysate sucrose 
density gradient ultracentrifugation and concentrated. An equal concentration (20 µg) 
and volume of concentrated protein was loaded per lane. The nitrocellulose 
membrane was probed with hTLR2 antibody for expected protein bands of 90 kDa. 
This is a representative western blot analysis of TLR2 expression in (a) unstimulated, 
(b) LTA treated (10 µg/ml) and (c) HETP (50 µM) + LTA (10 µg/ml) treated cell 
membrane fractions. Similar results were found in two other identical experiments. 
 
Protein band intensities were analysed using ImageJ software. The intensity of the 80 
kDa band was measured in each fraction and displayed as a percentage of the total 
band intensity on each western blot. (d) Results determine protein band intensity 
found in total lipid fractions (including lipid rafts) or non-lipid fractions in 
unstimulated, LTA and HETP + LTA treated cells. 
 
 
Non-lipid Lipid 
Non-lipid, cell lysate 
fragments 
Treatment Fractions 1-4 Fractions 5-7 Fractions 8-12 
Untreated 1.5 % 11.4 % 87.1 % 
LTA 0.6 % 11.4 % 88.0 % 
HETP + LTA 6.0 % 27.8 % 66.2 % 
(a) Unstimulated MM6 
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(b) MM6 + LTA 
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(c) MM6 + HETP + LTA 
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To further assess whether TLR2 was being translocated into the lipid fractions after 
stimulation with LTA, the 80 kDa band intensity was measured using ImageJ 
software and used as a qualitative measure of protein expression. Analysis of western 
blot images using ImageJ calculated that stimulation with LTA did not significantly 
affect expression of the 80 kDa band in the lipid fractions (Figure 5.2d); in fact 11.4 
% of protein was found in the lipid fractions before and after stimulation with LTA. 
However a small increase in the percentage of protein expressed in lipid fractions was 
identified with HETP treatment.  Although it is worth noting that the overall protein 
intensity in this western blot, Figure 5.3c, was over 30 % less than observed in blot 
(a) and (b), which was reflected in the images. 
 
As TLR2 protein was expressed at a significantly lower amount in the lipid fractions 
than seen in the reports by both Triantafilou et al. (2002) and Jackson et al. (2008), an 
attempt to increase the sensitivity of protein detection by western blot was made. An 
alternative method to assess the cell lysate fractions, involved pooling the 
concentrated lipid fractions together, prior to loading equal volumes onto Bis-Tris 
gels. This gave the potential for any protein bands present in the lipid fraction to be 
identified. Furthermore, MM6 cells were stimulated with 10 µg/ml Pam3CSK4, a 
concentration 10 fold higher than used in previous assays, to investigate whether the 
TLR2/TLR1 ligand exhibited a greater capacity to influence translocation into the 
lipid raft domain. However, results indicate (Figure 5.3) that these modifications 
made no significant difference to the expression of the 80 kDa band in the lipid 
fractions. The protein band intensity identified in Pam3CSK4 stimulated cell lysate 
fractions were in fact comparable to both untreated cells and cells treated with HETP 
prior to stimulation. This may indicate that TLR2 translocation is not evident, 
although the protein concentration process may have masked slight but significant 
changes in expression. 
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 Figure 5.3: Western blot analysis of pooled, concentrated plasma Figure 5.3
membrane fractions 
1 ml plasma membrane fractions were obtained through total cell lysate sucrose 
density gradient ultracentrifugation and concentrated. An equal volume of 
concentrated lipid protein was loaded. Fractions were pooled into non-lipid (fractions 
1-4), lipid (fractions 5-7) and non-lipid membrane fragments (fractions 8-12). The 
nitrocellulose membrane was probed with hTLR2 antibody. (a)  a western blot 
analysis of TLR2 expression in unstimulated, Pam3CSK4 (10 µg/ml) treated and 
HETP (50 µM) + LTA (10 µg/ml) treated cell membrane fractions.  
 
(b) Protein band intensities from lipid fraction isolation western blots probed with 
TLR2 antibody were analysed using ImageJ software. The intensity of the 80 kDa 
band was measured in each fraction and displayed as a percentage of the total band 
intensity on each western blot.  
(b) Percentage of total protein band intensity in membrane fractions 
 
Non-lipid Lipid 
Non-lipid, cell lysate 
fragments 
Treatment Fractions 1-4 Fractions 5-7 Fractions 8-12 
Untreated 13.8 38.6 47.6 
Pam3CSK4 10.2 45.7 44.1 
HETP +  Pam3CSK4 10.7 44.2 45.1 
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5.5 DISCUSSION  
5.5.1 Assessment of TLR2 translocation 
In order to gain an insight into LPCAT’s function in TLR2 translocation as a 
response to microbial challenge, an attempt was made to study the protein expression 
in plasma membrane lipid raft fractions. Despite considerable efforts to identify 
detectable levels of TLR2 protein and to visualise TLR2 translocation via western 
blot analysis, the effect of LPCAT inhibitor, HETP, was unable to be adequately 
assessed.  
 
Total lipid isolation by sucrose density gradient ultracentrifugation was repeatedly 
successful, with GM1 being consistently detected membrane fractions 5, 6 and 7. 
However, neat protein from each fraction was at a low concentration and no protein 
could be detected when probed with TLR2 antibody. Whilst the methods of 
Triantafilou and colleagues (2004) had been followed as precisely as possible, further 
analysis revealed some discrepancies; for example, in 2002, where they studied TLR4 
translocation, they state to have only used 1×10
6
 MM6 cells, whereas in 2004, they 
processed 1×10
8
 from buffy coats to investigate TLR2 translocation from 12×1 ml 
fractions. The present study utilised1×10
7
 MM6 cells for cell lysate before lipid raft 
isolation following methods described by Jackson et al. (2008) and Abate et al. 
(2010).  
 
However, despite the differences in cell density which would have ultimately affected 
the resultant protein concentration, Jackson et al. (2008) concentrated lipid fractions 
by methanol precipitation as described by Wessel and Flugge (1984) before 
application to western blot. In the first approach this method was applied to 
membrane fractions, but it quickly became apparent that the concentration of sucrose 
was also increasing in the samples. Whilst there was no apparent reason for the 
accumulation of sucrose, one unavoidable technical difference was the volume 
limitations associated with the ultracentrifuge used in this study. Jackson et al. (2008) 
used the same density of MM6 cells, but a smaller total volume of 2.1 ml before 
ultracentrifugation. Unfortunately the smallest capacity that the current 
ultracentrifuge could contain was 12 ml; over 5 times larger volume, resulting in the 
use of a significantly greater volume of sucrose. 
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Whilst similar volumes were used by Triantafilou and colleagues (2004) and Olsson 
and Sundler (2006), in this study it led to the exploration of an assortment of protein 
concentration methods, with the aim to increase the assay sensitivity to TLR2 protein. 
Ultimately, the phenol/ether precipitation method (Sauvé et al., 1995) was used to 
increase protein concentration before western blot analysis since it removed the 
unwanted sucrose and did not interfere with downstream quantification assays.  
 
In spite of each lysate fraction undergoing protein concentration, western blot 
analysis of plasma membrane fractions in this report, revealed that TLR2 was present 
in low concentration in the non-lipid (fractions 8-12) of unstimulated MM6 cells, a 
finding that contradicts data reported in previous studies (Triantafilou et al., 2002; 
Triantafilou et al., 2004; Triantafilou et al., 2006). Similarly, TLR2 was also 
identified in the lipid fractions (5-7) of unstimulated cells, which is inconsistent with 
reports by Triantafilou and colleagues (2002) where TLR2 was only detected in lipid 
raft fractions after TLR2 ligand stimulation. Whilst it must not be ignored that there is 
a possibility the unstimulated MM6 cells were already stimulated, perhaps by a low 
level infection, this anomaly is most likely due to the broad concentration methods. 
Though each protein fraction needed to be concentrated for TLR2 detection by 
western blot, the consequence may have been that minor changes in protein 
expression were undetectable. 
 
Despite the presence of TLR2 in the lipid fractions of untreated cells, stimulation of 
MM6 cells with LTA and Pam3CSK4 was examined to determine if the concentration 
of TLR2 increased, as a result of membrane translocation. Unfortunately there was no 
significant change in TLR2 expression observed in all experiments. In the present 
study an incubation time of 45 minutes with either TLR2 stimulant was used as 
recommended by Triantafilou et al. (2004). However, dissimilarity between methods 
occurred; Triantafilou et al. (2004) stimulated human monocytes with 100mg/ml 
LTA, in contrast to the 10 µg/ml LTA used in the present study. This variation may 
account for the absence of elevated levels of TLR2 in the lipid fractions, suggesting 
that the detection of TLR2 translocation is dependent on the concentration of the 
stimuli. Thus these experiments warrant further investigation and optimisation to 
achieve give an insight into the effects of LPCAT inhibition on translocation. 
  
 
  Chapter 6
 
 
FINAL DISCUSSION AND CONCLUSIONS 
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6.1 SUMMARY 
Understanding the pathophysiology of sepsis is vital for successful therapeutic 
intervention. Recently a lysophospholipid metabolizing enzyme LPCAT 
(lysophosphatidylcholine acyltransferase) has been identified to play a significant role 
in regulating the inflammatory mediator expression of monocytes in response to LPS. 
It has previously been shown that phospholipid metabolism may influence cell 
activation and responses, since the clustering of the receptor molecules into 
membrane microdomains (lipid rafts) is required to trigger inflammatory responses. 
LPCAT therefore, may be a target for novel anti-sepsis therapies; thus its expression 
and activation in different cell types and the molecular mechanisms of its immune-
regulatory activity are being studied here. 
 
The aim of this study was to further investigate the effects of LPCAT phospholipid 
regulation on the expression of inflammatory mediators, in response to other bacterial 
stimuli in both monocytic and epithelial cells; including evaluating the influence of 
LPCAT to activate other receptor molecules into lipid rafts, and to characterise the 
expression of reported LPCATs in the same cell types. To firstly address the aims of 
this study, the immuno-regulatory properties of LPCAT were investigated in 
monocytes stimulated with TLR2 ligands. Subsequently a suitable in-vitro model was 
developed using HETP, a specific inhibitor to LPCAT, and measured inflammatory 
mediator expression from monocytes in response to microbial stimuli. 
 
The results of this study demonstrated that inhibition of LPCAT significantly reduced 
(≥50 %) the secretion of pro-inflammatory cytokines (TNF-α, IL-6 and IL-8) in 
response to a variety of TLR2 ligands. This was supported by evidence that cytokine 
reduction also occurred at the mRNA level, strongly suggesting that LPCAT controls 
cytokine secretion by altering transcription of the gene or mRNA stability and 
demonstrating that inflammatory response in monocytes are noticeably regulated by 
LPCAT. The findings in this report also indicate that LPCAT has a crucial role in 
regulating the release of inflammatory cytokines in enriched populations of donor 
peripheral blood monocytes, supporting the use of the monocytic cell line as a model 
for this investigation. 
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Neville et al. (1997) and Schmid et al. (2003) reported that IFN-γ increased 
monocytes inflammatory responsiveness to LPS and that this was as a result of 
increased phospholipid remodelling by LPCAT. The present study further 
investigated the role of LPCAT on inflammatory responses by IFN-γ primed 
monocytes via LPCAT inhibition prior to stimulation. A significant reduction in 
secreted cytokines was observed in response to all TLR2 ligands, indicating that 
LPCAT also plays a crucial role in the activation of primed monocytes, possibly at 
the level of the TLR or subsequent signalling pathways. 
 
In this report differences between LPCAT regulation of bronchial epithelial and 
monocytic immune responses were studied.  BEAS-2B cells were observed to secrete 
a lower concentration of inflammatory cytokines, in comparison to monocytes, 
although LPCAT inhibition still resulted in a reduced cytokine secretion, but to a 
lower extent than seen in monocytes. Whilst this may indicate that LPCAT also has a 
role in regulating inflammatory responses in epithelial cells, it should be noted the 
function of LPCAT within this cell type may predominately be for the production 
specific phospholipid molecules. 
 
Recent studies have characterized the expression of LPCAT like acyltransferases in 
diverse cell types and animal tissue, suggesting that different iso-forms of LPCAT 
exist with alternative functions (Shindou et al., 2007; Nakanishi et al., 2006; 
Harayama et al., 2009; Chen et al., 2006; Agarwal et al.,  2007). This study looked at 
the expression levels of these 5 enzymes within monocytic, lung epithelial and 
hepatocyte cell lines and aimed to evaluate the correlation between LPCAT isoform 
expression levels and the inflammatory response regulatory mechanisms in diverse 
cell types. 
 
Literature suggests that LPCAT1 is most notably expressed in lung tissue, in 
particular alveolar type II cells, where it plays a role in producing DPPC, a crucial 
surfactant protein (Nakanishi et al., 2006; Chen et al., 2006). Results from the present 
study however, did not observe increased LPCAT1 mRNA or protein expression in 
lung epithelial cells as might be expected. LPCAT2 has been reported to play a 
constitutive role in inducible PC remodelling pathways in response to external stimuli 
in mouse peritoneal macrophages (Shindou et al., 2007). Whilst this suggests that 
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LPCAT2 might be the candidate enzyme to modulate the phospholipid remodelling 
pathway in innate immune cells, results from this study revealed that hLPCAT2 
mRNA and protein expression was not increased in monocytes, but comparable 
across cell lines, and neither LPS nor IFN-γ significantly changed the expression of 
LPCAT2. Results from the present study did however confirm that human LPCAT2 
is highly expressed in HEK293 cells, where it appears to be the principal enzyme for 
PAF production (Shindou et al., 2007). 
 
In agreement with Hishikawa et al. (2008), LPCAT3 was detected with abundant 
mRNA expression levels in liver cells (HEPG2), suggesting it to be primarily 
responsible for hepatic LPCAT activity (Zhao, et al., 2008). In contrast, very low 
mRNA expression levels of LPEAT2 were seen across the panel of cell lines tested, 
supporting other studies that observed it to be virtually undetectable in human lung 
and liver tissues, and who reported LPEAT2 to have a greater importance in 
modulating  both human and mouse brain phospholipid composition (Cao et al., 
2008; Ye et al., 2005). LPCAT4 mRNA was observed to have a remarkably high 
expression in both lung epithelial cell lines; dissimilar to a previous study that 
reported low expression of mLPCAT4 in lung tissue (Hishikawa et al., 2008) and 
who discovered that mLPCAT4 plays a constitutive role in mouse epididymis, brain 
and testis tissue membrane biogenesis.  
 
Literature supports the belief that each LPCAT performs a unique function within 
different cell types, either maintaining cellular membrane structure and /or producing 
specific phospholipids as precursors to other inflammatory mediators. As such 
LPCAT expression observed in mice may not be representative of human expression. 
Whilst data in this report did not demonstrate one particular LPCAT iso-form to be 
highly expressed by monocytes, further investigation is need on LPCAT expression 
in human cell lines or tissues to consolidate the evidence that LPCAT2 might be the 
enzyme to modulate the inducible phospholipid remodelling pathways in innate 
immune cells. 
 
Jackson et al. (2008) observed that inhibition of LPCAT prevented translocation of 
TLR4 into membrane lipid raft domains, subsequently reducing down-stream 
inflammatory responses. This is the suggested mechanism that LPCAT elicits its 
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immuno-regulatory effect in response to microbial stimuli. Although the translocation 
of TLR2 into membrane lipid rafts has been examined (Triantafilou et al., 2004) and 
other raft-localised proteins identified (Olsson and Sundler, 2005), this study aimed to 
assess whether LPCAT inhibition could prevent TLR2 translocation, and thus prevent 
the subsequent formation of the receptor signalling complex. To achieve this aim, 
well characterized proteomic approaches were used however successful translocation 
of TLR2 was not achieved and so the effect of LPCAT inhibitor, HETP, was unable 
to be adequately assessed. Nonetheless this is the most likely mechanisms for LPCAT 
to down-regulate TLR2 induced inflammatory cytokine production in monocytes and 
epithelial cells as demonstrated by data in this report.  
 
The present study provided sufficient evidence that inhibiting LPCAT affects the 
complex network of cell signalling involved in microbial responses, underlying the 
importance of LPCAT, and potentially offering a target for novel anti-sepsis 
therapies. When considering LPCAT as a target for therapeautic intervention 
however, it must be taken into account that LPCAT is also essential for membrane 
biogenesis in many cell types and is fundamental for cell viability. Although the 
present study has underlined the importance of the enzyme in microbial induced 
cellular responses, inhibiting LPCAT may hence not be beneficial for the treatment of 
sepsis. Novel anti-sepsis treatment would become more feasible if tissue or cells 
specific isoforms of LPCAT were targeted, with the aim to reduce LPCAT activity 
rather than completely block it. With its central role in monocyte signalling, LPCAT 
would be investigated as a potential marker for patient susceptibility to sepsis. Further 
characterisation of LPCAT is thus required before contemplating it as a target for 
sepsis treatment, however this study has consolidated evidence that LPCAT as an 
important regulator of immunological responses. 
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6.2 FUTURE WORK 
The mechanism by which HETP inhibits LPCAT activity is unknown. Whilst the 
down-stream effects of LPCAT inhibition can be observed, HETP did not affect 
LPCAT mRNA or protein expression levels and this perhaps suggests that HETP 
impedes LPCAT enzyme activity.  
 
Enzyme activity assays, similar to those used by Schmid et al. (2003) and Neville et 
al. (2005), could be used to determine if LPCAT enzyme activity is inhibited by 
HETP. LPCAT enzyme activity is assessed in a radio-assay where a known amount 
of radiolabelled substrate is converted to labelled product; i.e. LPCAT incorporates a 
radioactive fatty acid into phosphatidylcholine. Preliminary enzyme assay were 
completed during this study, but were unsuccessful. 
 
To further consolidate evidence that inhibition of LPCAT down-regulates monocytic 
inflammatory responses, an LPCAT mRNA knockdown cell line was investigated to 
study the effects on inflammatory responses. Using small RNA interference 
technology, (siRNA) assays were extensively performed in a murine macrophage cell 
line (RAW 264.7) over a six month period during this study but were unsuccessful. 
Whilst complete knockout of LPCAT mRNA will almost certainly be lethal, another 
attempt to control attenuation of LPCAT mRNA levels should be attempted.  
 
If LPCAT knockdown cells are successful, there is the potential to reinvestigate all of 
the immune-regulatory effects seen in this study with HETP. Stimulation with TLR4 
and TLR2 ligands in knockdown cells would support LPCATs role in both signalling 
pathways. The potential down-regulation of TLR translocation into lipid rafts could 
also be investigated. 
 
Another attempt to optimise the lipid raft isolation assays should be made in future 
studies to repeat the findings of Jackson et al. (2008) and Abate et al. (2010), with 
TLR2 stimulants. TLR1 and TLR6 have also been shown to translocation into lipids 
rafts upon stimulation (Triantafilou et al., 2004), thus it would be interesting 
determine if LPCAT is involved. These finding would support the importance of 
LPCAT in regulating inflammatory responses, as found in this study. If lipid raft 
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assays are successful, future studies could investigate the location of LPCAT within 
the plasma membrane before and after stimulus. 
   
 
Mitogen-activated protein kinase (MAPKs) inflammatory signalling pathways such 
as p38 and p44/42 MAPK , can be activated in response to stimuli. Activation of 
MAPK is though phosphorylation, which subsequently activates transcription factors 
required to elicit production of cytokines. Preliminary data from this study suggests 
that LPCAT may regulate p38 phosphorylation when MM6 cells are stimulated with 
LPS. However further flow cytometry experimental replicates are required to clarify 
this potential relationship.  
 
To determine if LPCAT modulates inflammatory pathways other than those induced 
by TLR2 and TLR4 stimulants, an alternative ligand could be used to stimulate 
epithelial cells. Polyinosinic-polycytidylic acid (poly(I-C)) is a synthetic dsRNA 
analog, previously demonstrated to rely on TLR3 for recognition (Guillot et al., 
2005).  TLR3 is expressed in epithelial cells but does not seem present in monocytes 
or lymphocytes. Poly(I-C) has previously been shown to stimulate BEAS-2B cells to 
secrete high levels of IL-8, so this would be a good model to demonstrate the effect of 
LPCAT inhibition on TLR3 activation pathways. 
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APPENDIX 1 – qPCR primer sequences 
 
mRNA sequences below are displayed with the primers designed in this study and 
primers used in literature spanning across the mRNA. 
 
LPCAT1 (AYTL2: AGPAT9) 
Chromosome 5   
Gene ID: 79888   
mRNA sequence NM_024830.3 
 
Primers used in this study: 
Primer 1 sequence: LA1F and LA1R. Product length = 156 bp 
Primer 2 sequence: LB1F and LB1R. Product length = 168 bp 
Primer 3 sequence: LC1F and LC1R. Product length = 159 bp 
 
Primers used in literature: 
hLPCAT1 primer sequence; product length= 154 bp. Harayama et al., 2009. 
hAGPAT9 primer sequence; product length= 100 bp. Agarwal et al., 2007. 
 
GCCCGCTCCAGCCGCCGCGCATCCTCGGCCCGCGCCCCGAGACCCGCGCC
CAGCTAGCCCCGGCCCCGCTCGGCGCCCCAGGCAGCTCGGCTGCGCTCGC
CGCGGGACGGCGCGGCCATGAGGCTGCGGGGATGCGGACCCCGGGCCGC
CCCTGCCTCCAGCGCAGGGGCCAGCGACGCTCGGCTGCTGGCGCCCCCGG
GGCGGAACCCCTTCGTGCACGAGCTGCGCCTCAGCGCCCTGCAGAAGGCC
CAGGTGGCCCTCATGACACTGACGCTCTTCCCGGTCCGGCTCCTGGTTG
CCGCTGCCATGATGCTGCTGGCCTGGCCCCTCGCACTTGTCGCATCCCTGG
GCTCTGCGGAGAAGGAACCCGAGCAGCCCCCGGCCCTGTGGAGGAAGGT
TGTGGACTTCCTGCTGAAGGCCATCATGCGCACCATGTGGTTCGCCGGC
GGCTTCCACCGGGTGGCCGTGAAGGGGCGGCAGGCGCTGCCCACCGAGG
CGGCCATCCTCACGCTCGCGCCTCACTCGTCCTACTTCGACGCCATCCCTG
TGACCATGACGATGTCCTCCATCGTGATGAAGGCAGAGAGCAGAGACATC
CCGATCTGGGGAACTCTGATCCAGTATATACGGCCTGTGTTCGTGTCCCG
GTCAGACCAGGATTCTCGCAGGAAAACAGTAGAAGAAATCAAGAGACGG
GCGCAGTCCAACGGAAAGTGGCCACAGATAATGATTTTTCCAGAAGGAA
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CTTGTACAAACAGGACCTGCCTAATTACCTTCAAACCTGGTGCATTCATCC
CTGGAGCGCCCGTCCAGCCTGTGGTTTTACGATATCCAAATAAACTGGA
CACCATCACATGGACGTGGCAAGGACCTGGAGCGCTGGAAATCCTGTGGC
TCACGCTGTGTCAGTTTCACAACCAAGTGGAAATCGAGTTCCTTCCTGTGT
ACAGCCCTTCTGAGGAGGAGAAGAGGAACCCCGCGCTGTATGCCAGCA
ACGTGCGGCGAGTCATGGCCGAGGCCTTGGGTGTCTCCGTGACTGACTAC
ACGTTCGAGGACTGCCAGCTGGCCCTGGCGGAAGGACAGCTCCGTCTCCC
CGCTGACACTTGCCTTTTAGAATTTGCCAGGCTCGTGCGGGGCCTCGGGCT
AAAACCAGAAAAGCTTGAAAAAGATCTGGACAGATACTCAGAAAGAGCC
AGGATGAAGGGAGGAGAGAAGATAGGTATTGCGGAGTTTGCCGCCTCCC
TGGAAGTCCCCGTTTCTGACTTGCTGGAAGACATGTTTTCACTGTTCGACG
AGAGCGGCAGCGGCGAGGTGGACCTGCGAGAGTGTGTGGTTGCCCTGTCT
GTCGTCTGCCGGCCGGCCCGGACCCTGGACACCATCCAGCTGGCTTTCAA
GATGTACGGAGCGCAAGAGGACGGCAGCGTCGGCGAAGGTGACCTGTCC
TGCATCCTCAAGACGGCCCTGGGGGTGGCAGAGCTCACCGTGACCGACCT
ATTCCGAGCCATTGACCAAGAGGAGAAGGGGAAGATCACATTCGCTGAC
TTCCACAGGTTTGCAGAAATGTACCCTGCCTTCGCAGAGGAATACCTGT
ACCCGGATCAGACACATTTCGAAAGCTGTGCAGAGACCTCACCTGCGCC
AATCCCAAACGGCTTCTGTGCCGATTTCAGCCCGGAAAACTCAGACGCTG
GGCGGAAGCCTGTTCGCAAGAAGCTGGATTAGGACCCAGGGTTGCGGAG
AGACGCGGCCCCTCCCGCGTGGACATCACCGCCATGAGCCTCTTTGCGAG
TGACCTCTGGGCTCCGCTCCTCACTCCTGCTGTACAGGCACTGTCTTCAGC
CCGAGTTCCAGGGGCCTCGGGGGCTGTTTGTATCTTGTTCCTTTGTGAAGT
GTGTTGCAGAACCGACGCTTACTGTGCGAGAATCGGAGGGCGCGCACGC
GGATCCCCCGCCTGGCCTGGACCCCGTGGGGTCAGGTTCCCTGCCGGGCG
GGGGGCACCGGTGCCGCCCCGTGTTCTCCCACGGGGCCCTGGTTTCGAGT
CTCTGTCACAGCCTCTTCCGGCGGCAGCGTGCACCGGGCGGGCCTCCGTG
CACACTCAGCACACGCCTGCCACACAGCGTGCGCTTGCGTGTCACTCTGG
CACGAAACCTGTCTGCCTCTGTGGATCCACAGCCTGGCAGAGCCGAGCCG
TCACCTGATTTTTCAGTGTTTCTACCTGTGTGCTGGAGCTCATGAGTATTTT
ATAAACTCCATTTAGGTACTTCAGGAAACATGCAGCATTTTTTAAAAAAT
GAAAATTGTTTTTCTACTTCATTTTTCCTTTTAGAGTCAAAGGATATTTATT
TATAGGCCTTTTTTTTTTTAATATAGAATCTGAGGCTGTTTGGGCTTTGACT
TAAATTTCCATCAGGCCTCTCTCCAGCAGGTAATCCCTCTCCTTCCGCTGG
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GTCCCCTGGGGAGGTGTGAACTCAAGGGCCTAGCCCCAAAACACTTTTT
CTGCTTTTCTTAATCCTTTTCCAGTCCCCTCTTTTTTTATAAACGTTGGCAG
TTTGATGTTTCTGTTTCGGCATAACGTAATCCATTTCACTGTAGCCTAAAC
TCCAGTCCGAGGTTGGATATTGTTCAAATGAGCAGGGCCCGAGCTGGAA
GCGCAAGGCAGCCGCCGCCGTGCCGCTCCTCCCTTGCCCTCAGGCCAGGT
CCCTGCTGGAAGCGGCTGCATCTTCCTGTCAGCCCTGGTTTCCATGGTGAC
TGGCGTCACGCAGCCACCCGAGTATGGCTGACCTTCCTGCAGAGAGAGGA
GCCGCAGTCTTTTGCTTGTGGAAGGAGACGCTGGGCTGTGCGGTGCGGAG
GGTGATGAGGATGTCTGGTGACAGCCGTGCGGACACCACTCCTCTCTGCA
GCACTGCCTCCCAGCGCCAGGGTCGCGGGCACATCCCACTGAGAGCGGG
GGTCCTGCCCCATCTTAGAGTCAAAGGCAGAGGGGCTTCCAGGCCCTGGA
TGGGGTATTTTGGTGTCACCTGAAGTCCCTCTGACATCACCTTGTTTCATC
ATTTTTTATGACAGAATTAGAAACCCATCCTTCAAGCACAATAATCATCA
CAGACTTGAGTTTGCTTCCTAAAGCAAAGGCTCCGGGTTTGTTTGGAAAA
TTTTTTTGATTTCTGAAATGAATTGATTTTTATATTTGGGGCATCTCTATAG
AAAGTGACCACCAAGGCCAGTAAGTACGGGAAAAAATGTTTACTAACTTC
CTCAGAGATTCGTGATACGCGTTTCTCCACTGACAGACATTTAAAAACAA
CCTTCAGCTCCGTTTCAATCAATCACCTCGACTTGTTTTTTAGCATGGACA
CTGCCAGCAGGACAGACAGGGATGGAGTAAACCGAAGTCAATTTCAGGG
CTCTTGGCGTGTTGGACACAGAAGAAATCCTAGTGCAGCCTTTGGTAGCT
AACAGTCACTGATTTTATAATTGGAGAATGCGTAAAGATTCATTTTTCAA
GGAGAAGAGCCTGCAAATGGCCAATGAAGGAGGTAAATAAACTAAGATA
TTCCGAGGGAAGGGACCCAGGCCACCTCCCTTCCGCAGGTCTGCAGATG
AAGGGTTTTTTGAATGAAATGCCACTGTGCATTTTCAGAAAAAAAAATCT
CTGATAAACAGACTTTGAATGGATGTTTGTTCCTCCTGATTCTCTTTTCTC
TTCGTGGCGACTTAGAGTTGGCGGATATTCGGAACTGTGAATGTACATA
GCGTTGAGTTAAACCCCTTGTGTGTGAGACAGGACGCAGCGGGCCCCTGG
TGGCCTGGGGGCCAGACCCGTGGGCAGGTGGGGCATGGGCCCTGGCCTG
CGGGGACCTGCTGGGGTGTGAGGGCAGAGGGAGGGTTGCCATGAAGGAA
CTTGGGATTTTCAATGGAATAAGTAAAACATAAAGTCTATACTTGGGAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
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LPCAT2 (LysoPAFAT: AYTL1: AGPAT11) 
Chromosome 16  
Gene ID: 54947  
mRNA sequence: NM_017839.4 
 
Primers used in this study: 
Primer 1 sequence: LD1F and LD1R. Product length = 184 bp 
Primer 2 sequence: LE1F and LE1R. Product length = 182 bp 
Primer 3 sequence: LF1F and LF1R. Product length = 150 bp 
 
Primers used in literature: 
hAGPAT11 primer sequence; product length= 64 bp. Agarwal and Garg, 2010. 
lysoPAF-AT primer sequence; product length= 178 bp. Shindou et al., 2007. 
 
GCCTGGGGCGTGTCACAGCCGAAGGGGCAGGGCGGCAGCAGCAGGCGTC
TAAGTAACTTCAGCGCCTGCGCAGAGGCTCCCCAGCGTCGCCCTAGGCTG
GGACTCTAGTAGGTCTTCGGCTCAGTTTTGGCTGCAGCGCCCGCGTAGAT
CGCTTCGGCCGGGTTCTACGCCCGGCTCAACTATGAGCCGGTGCGCCCAG
GCGGCGGAAGTGGCGGCCACAGTGCCAGGTGCCGGCGTCGGGAACGTGG
GGCTGCGGCCGCCCATGGTGCCCCGTCAGGCGTCCTTCTTCCCGCCGCCG
GTGCCGAACCCCTTCGTGCAGCAGACGCAGATCGGCTCCGCGAGGCGGGT
CCAGATTGTCCTTCTTGGGATTATCTTGCTTCCAATTCGTGTCTTATTGG
TTGCGTTAATTTTATTACTTGCATGGCCATTTGCTGCAATTTCAACAGTAT
GCTGTCCTGAAAAGCTGACCCACCCAATAACTGGTTGGAGGAGGAAAATT
ACTCAAACAGCTTTGAAATTTCTGGGTCGTGCTATGTTCTTTTCAATGG
GATTTATAGTTGCTGTAAAAGGAAAGATTGCAAGTCCTTTGGAAGCACCA
GTTTTTGTTGCTGCCCCTCATTCAACATTCTTTGATGGAATTGCCTGTGTTG
TAGCTGGGTTACCTTCTATGGTATCTCGAAATGAGAATGCACAAGTCCCT
CTGATTGGCAGACTGTTACGGGCTGTGCAACCAGTTTTGGTGTCCCGTG
TAGATCCGGATTCCCGAAAAAACACAATAAATGAAATAATAAAGCGAAC
AACATCAGGAGGAGAATGGCCCCAGATACTAGTTTTCCCAGAAGGTACTT
GTACTAATCGTTCCTGTTTGATTACTTTTAAACCAGGAGCCTTCATTCCA
GGAGTTCCAGTGCAGCCAGTCCTCCTCAGATACCCAAACAAGCTGGATA
CTGTGACCTGGACATGGCAAGGATATACATTCATTCAGCTTTGTATGCTTA
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CTTTCTGCCAGCTCTTCACAAAGGTAGAAGTTGAGTTTATGCCAGTTCAAG
TACCAAATGATGAAGAAAAAAATGATCCTGTCCTTTTTGCCAATAAAGTC
CGGAATTTAATGGCAGAAGCTCTGGGAATACCAGTAACAGATCATACCTA
TGAAGACTGCAGATTGATGATTTCAGCAGGACAGCTAACATTGCCTATG
GAAGCTGGGCTGGTGGAATTTACTAAAATTAGCCGAAAATTGAAATTAG
ATTGGGATGGTGTTCGTAAGCATTTGGATGAATATGCATCTATTGCGAGTT
CCTCAAAAGGAGGAAGAATTGGAATTGAAGAATTCGCCAAGTATTTAA
AGTTGCCTGTTTCAGATGTCTTGAGACAACTTTTTGCACTCTTTGACAGG
AACCATGATGGCAGCATTGACTTCCGAGAGTATGTGATTGGCCTGGCT
GTCTTGTGCAACCCTTCCAACACAGAGGAGATCATCCAGGTGGCATTTAA
GCTGTTTGACGTTGATGAGGATGGCTACATAACGGAGGAAGAGTTCTCCA
CCATTCTACAGGCTTCCCTTGGAGTGCCTGACCTTGATGTTTCTGGTCTCT
TCAAGGAAATAGCCCAAGGGGACTCAATTTCCTATGAGGAATTTAAAAG
TTTTGCCTTAAAGCATCCAGAATATGCTAAGATATTTACAACATACCTAG
ACCTCCAGACGTGCCATGTGTTTTCATTACCAAAAGAAGTCCAGACAACC
CCCTCCACCGCCAGTAATAAAGTCAGCCCTGAAAAGCATGAAGAGAGTA
CCTCAGACAAAAAAGATGACTGAAAGCAGTATTTCCAATAAGGAAAACA
CAGTAGCTTTTGCTTGAAATTGTAAAGGCACTTATTGATAATACTTTTAAT
GTGTTGGTAATGATGTTTAAAATTGAAAGATTTTTAAAACAAAAATGATA
GATTTTCTTACTAAAAATGTTTTTATTAACCTTGCTTTTATTGGAAAAAAT
CAAGCAATATTTCGTTTTCTTTTGTGTTATATTGTACTTTACTGATTCATTT
ACTGGTGATACATATGTTTTTATGGATTTTCCAGTTTAATTTGCATATACA
AATGAATGCAATGGTCTATTGGTGAGCATTGAGCAACACTGTATAAAGTT
TTAAAAATGTAAACACTTTTTAATCTACTTTCCTCTAAAAATCAATAATAT
TCTATTATTTCTAATCCTTTTCCACTTGGGAAATAACAATGAAGAATCTGA
GAATTTGACATCTATAACTTTACAGATTCATTTTTCCATTTAAATTTCAGTT
TCTTGGATCACTGAATATGGGAAGGGAGAGCTTCACTAATTAGACGCAGC
TTCTTAAGAACTTATATTCTCTTTGACATACATCTCTATTGTAGTTTTTTGT
TTTGTTTTGTTTTTTGAGATGGAGTCTTGCTCTGTCACCCAGGCTGGAGTG
CAGTGGTGCAATCTCAGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGTG
ATTCTCGTACCTCAGACTCCCGAGTAGTTGGGATTACAGGTGCCCACCAC
CACACCCGACTAATTTTTGTATTTTTAGTAGCCATGTGGTTTTGCCATGTT
GGCCAGGCTGGTTTCGAACTCCTGACCTCAGGTGATCCACCCACCTCAGC
CTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACCGTTCCCGGCCTATTG
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TAGATTTTCTTAACTACTTGCTAAGGAAATCATATCCTTTTACATGAACTA
CAGGTTTAGAACTTGGTTTTAAGACAACTGCTATGGCCAGAAGGTAAATG
GGAATTGCCTTATTGAAGGTAACATTGATTGCCTAATAAGAAAATGAATT
GTTTGCCACAGAGTTGAATTTAATTTGAGTTAGATAGTTCAGAATGTAGC
ACTTGCCCTATAAATGAATCAGATTTGTTCTATTTATATAATATTAGAATT
AATATATTATCATGTAAGTGGGAATTTTATTTTGTTAAGTGGACTCTCAAA
TTTTAGAACTTGTGTGAAATATCTCCCAGAAAACACAAAAGGTTTCAAGG
TATCACCCAAAGCTAGGGAATCAACAAACGTACTTTATTAATGCAAGACC
ACAATTTAAGCCCCAGGCAGGAATCCAACAGTAACATTTTTCCTTTAGGT
TAAGCAGTAATTTTTTTGAATTGTCATTTTTAATGGGTCTCACACATGCAT
ATTGCTAATATCATTCATGTTTGAGGTTTTCAACAAAGAACCAATTTATTA
ATATAATGTACAAAAATAGTTGGTTCATTTTCTGAATTCAGTCTTTGAAAT
AAAACTCCTTGTTTTGGCCGTGTTTCTGAATGTATTGGTGATTCACCCCCA
AGCTAATTTTTTAAAGTCATTTTTGAAGTTGGGAAGTCTCATGAGAGATGT
TGAAGTATGTATTTAATCAAGAGTCATGATTTCAAACTAGTTTTACATATT
AAGCAGTTAGTGTTCTAATTTAATGGGTAAATGTGTGTTTGGATAAATATC
TGAAAATTTTATCCTTAAGTATATATAATTATTTGCCTCTTATATGTCTTAA
AGCTATTTAAACAAGGTGTTAAATGAGCCAAAACAATTAAGTAATTAGAA
CAGTACATTTTTATCAGAGTGTCTGTCATATGCAATGAATGTATGTAATAC
TAAAAAATCATGACTACTTTTATCAAAGAAAAACCACACATTAATCCTAT
TAATCATGAAAGCGTAGCATTGTAAATTAAAGGTTTTCTTTGAGGCTCTTG
AAAGTGATCCCATTGCTTTCCTGTTTTAAAAATATTTTATGCTCTTTATTTC
CACTTCTGTGAATGTGATATTTCTATTTTGTGATTATGTTACTGAATAAAC
AAACTTGCTACATAAAATTCTTAGCAATTAAAAAAATTCTGATTCTGCCAT
TTTGTCTCAAATGTAATATACCCTTTTAATATCATATGTTTACATATTTATG
AATGATTAATCATTTTTGTTTGCATTAAACTTTATGAAATGTCAGAAATGA
TTTTACTCTAATGAAACTCAAATTTTGCCCAAAGTAGCAATATTCTTAAAG
ATGTTGAATTTTGACTGGTTGAATTTTATATAGTAACACACAAGTCGTGAT
CATCAATATTATTGCAGACCAGGACTCTGCTTATATGCCTTGCTAACAAA
GATTTCTTTCACAGAGGCTTTTCTCCTCTCAAGACTTAAAGTAAGAATTAC
ATTTTATTAAGTCAGTTAAATGCACCATGGCTTCATATAGTAATATAAAA
AAACTCTTTGAAGTGAGAAATATTATATCCTAAAACCTCTAAACCACAAA
CATTCAATTGAAAGAGTTCTGTTGAAGGATAATGACATACTGACTGCTTA
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TAGAGCCTTGGAAGGCTAAGTGTGATAGTAATGCTAGCTCTAATGCATAT
TTAAAGGAGACTGCCTCGCTTTTAGAAGACATCTGGTCTGCTCTCTGCATG
AGGCACAGCAGTAAAGCTCTTTGATTCCCAGAATCAAGAACTCTCCCCTT
CAGACTATTACCGAATGCAAGGTGGTTAATTGAAGGCCACTAATTGATGC
TCAAATAGAAGGATATTGACTATATTGGAACAGATGGAGTCTCTACTACA
AAAGTCTTTGGGTATTTGTTTCTTACATAGAAAATGCTAACATGAATAGA
AAGATACTGGTGCAAGACCATTCCCGGGAAAGTAGACATACTTACATTTT
TTTCCTTTTCTGCTCATTTGAATGAACTCAATTTTATGTTAAATTGTTATAT
CAGAGTGACAAATAAGTGCTATGGCTTGATAGAAGTGAAGCTCTTCACAT
ATATTCAAAATACATATCACAAACTTTGGTAAATAGGATAGTAATCTGAA
GAACTTTTGCCCTTTTTACCCCATTTACTGTAACTCTTGTTTCTAGGTAATC
GTTCTCTCTCAACAAACTTCTCAAGCGTCTGTGTAACAAGCCACATGTTCT
AACAAATTGTCTCCATCGCACTTCAACAGCCAGGTCCCTATTTTTTATAAC
GTATTAACCTTATTATTTTCTTATTATTTTAAAAGAATCTATGCACATTAG
CAAAATTTAAAAGATAGAGAAAAATATAAACAGAAAAAATTATGTTTAC
TTCTACCACCCTAAATCAACTATTATCAATTTTATACATATTTTACTCCATC
TTTTTTCAAAGTTTCTTACATTTTCCAATGTCATTAAAATTCTCTGTGAATG
TAAATTTTAAAAACTGTACCTACTGTTTTTTGGAAATCTGTAACAAGCTAT
GTGTAATCATTCTTCTAATATTAAACATATTGTGTCCAGAATTTAAAAAAA
A 
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LPCAT3 (MBOAT5) 
Chromosome 12   
Gene ID: 10162  
mRNA sequence: NM_005768.5 
 
Primers used in this study: 
Primer 1 sequence: LG1F and LG1R. Product length = 154 bp 
Primer 2 sequence: LH1F and LH1R. Product length = 198 bp 
 
Primers used in literature: 
hLPCAT3 primer sequence; location 434. Product length = 91 bp. Matsuda et al., 
2008 
hLPCAT3 primer sequence; location 795. Product length = 125 bp. Zhao et al., 2008.  
hLPCAT3 primer sequence; Product length = 495bp. Gijón et al., 2008. 
 
AATGCGCACGCCGTGGGCGGGCCCCGAGCCGGAATTGGGGGTGAAGCGA
TAGCGTTTTGCCCGCATTCGGGGCGCGCGGAGCTGGGGGGTCCCTGTGGG
GCTCCCGGAGTTAAGATGGCGTCCTCAGCGGAGGGGGACGAGGGGACTG
TGGTGGCGCTGGCGGGGGTTCTGCAGTCGGGTTTCCAGGAGCTGAGCCTT
AACAAGTTGGCGACGTCCCTGGGCGCGTCAGAACAGGCGCTGCGGCTGAT
CATCTCCATCTTCCTGGGTTACCCCTTTGCTTTGTTTTATCGGCATTACCTT
TTCTACAAGGAGACCTACCTCATCCACCTCTTCCATACCTTTACAGGCCTC
TCAATTGCTTATTTTAACTTTGGAAACCAGCTCTACCACTCCCTGCTGTGT
ATTGTGCTTCAGTTCCTCATCCTTCGACTAATGGGCCGCACCATCACTGC
CGTCCTCACTACCTTTTGCTTCCAGATGGCCTACCTTCTGGCTGGATACTA
TTACACTGCCACCGGCAACTACGATATCAAGTGGACAATGCCACATTGT
GTTCTGACTTTGAAGCTGATTGGTTTGGCTGTTGACTACTTTGACGGAGGG
AAAGATCAGAATTCCTTGTCCTCTGAGCAACAGAAATATGCCATACGTGG
TGTTCCTTCCCTGCTGGAAGTTGCTGGTTTCTCCTACTTCTATGGGGCCTTC
TTGGTAGGGCCCCAGTTCTCAATGAATCACTACATGAAGCTGGTGCAGGG
AGAGCTGATTGACATACCAGGAAAGATACCAAACAGCATCATTCCTGCTC
TCAAGCGCCTGAGTCTGGGCCTTTTCTACCTAGTGGGCTACACACTGCTCA
GCCCCCACATCACAGAAGACTATCTCCTCACTGAAGACTATGACAACCAC
CCCTTCTGGTTCCGCTGCATGTACATGCTGATCTGGGGCAAGTTTGTGCTG
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TACAAATATGTCACCTGTTGGCTGGTCACAGAAGGAGTATGCATTTTGAC
GGGCCTGGGCTTCAATGGCTTTGAAGAAAAGGGCAAGGCAAAGTGGGAT
GCCTGTGCCAACATGAAGGTGTGGCTCTTTGAAACAAACCCCCGCTTCAC
TGGCACCATTGCCTCATTCAACATCAACACCAACGCCTGGGTGGCCCGCT
ACATCTTCAAACGACTCAAGTTCCTTGGAAATAAAGAACTCTCTCAGGGT
CTCTCGTTGCTATTCCTGGCCCTCTGGCACGGCCTGCACTCAGGATACC
TGGTCTGCTTCCAGATGGAATTCCTCATTGTTATTGTGGAAAGACAGGCTG
CCAGGCTCATTCAAGAGAGCCCCACCCTGAGCAAGCTGGCCGCCATTACT
GTCCTCCAGCCCTTCTACTATTTGGTGCAACAGACCATCCACTGGCTCTT
CATGGGTTACTCCATGACTGCCTTCTGCCTCTTCACGTGGGACAAATGGCT
TAAGGTGTATAAATCCATCTATTTCCTTGGCCACATCTTCTTCCTGAGCC
TACTATTCATATTGCCTTATATTCACAAAGCAATGGTGCCAAGGAAAGAG
AAGTTAAAGAAGATGGAATAATCCATTTCCCTGGTGGCCTGTGCGGGACT
GGTGCAGAAACTACTCGTCTCCCTTTTCACAGCACTCCTTTGCCCCAGA
GCAGAGAATGGAAAAGCCAGGGAGGTGGAAGATCGATGCTTCCAGCTGT
GCCTCTGCTGCCAGCCAAGTCTTCATTTGGGGCCAAAGGGGAAACTTTTTT
TTGGAGAAGGCGTCTTGCTTTGTCACCCACGCTGGAATGCAGTGGCGGGA
TCTCAGCTCACCGCAACCTCCACCTCCTGGGTTCAAGTGATTTTCCTGCCT
CAGCCTCCCAAGTAGCTGGGAATACAGGCACGCCACCATGCCCAGCTAAT
TTTTGTATTTTCAGTAGAAACGGGATTTCACCACGTTGGCCAGGCTGGTCT
CGAACTCCTGACCGCAAGTGATCCACCCGCCTCCGCCTCCCAAAGTGCTG
GGATTACAGGCGTGAGCCACCGTGCCCGGCCCAAAGGGGAAACTCTTGTG
GGAGGAGCAGAGGGGCTCACATCTCCCCTCTGATTCCCCCATGCACATTG
CCTTATCTCTCCCCATCTAGCCAGGAATCTATTGTGTTTTTCTTCTGCCAAT
TTACTATGATTGTGTATGTGCCGCTACCACCACCCCCCCCATGGGGGGGT
GGAGAGGGGTGCAAGGCCCTGCCTGCTCCACTTTTTCTACCTTGGAACTG
TATTAGATAAAATCACTTCTGTTTGTTCAGTTTTTCA 
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LPCAT4 (MBOAT2) 
Chromosome 2   
Gene ID: 129642  
mRNA sequence: NM_138799.2 
 
Primers used in this study: 
Primer 1 sequence: LL1F and LL1R. Product length = 153 bp 
Primer 2 sequence: LM1F and LM1R. Product length = 169 bp 
Primer 3 sequence: LN1F and LN1R. Product length = 171 bp 
 
Primers used in literature: 
hLPCAT4  Reverse primer sequence; Product length = bp. Gijón et al., 2008 
 
GGCCTTCCCCGCGCAGAGCTCCGACCGCGGGCGGCCCAGGGGCGGGCGC
GCCGCTGCATCCCCATCCTCGTCGTCGCCCGGCACAGCGCGAGCGGGCGA
GCGGCGCGGGCGGCCGGAGCGCCGAGGCCCGGCCATGGCCACCACCAGC
ACCACGGGCTCCACCCTGCTGCAGCCCCTCAGCAACGCCGTGCAGCTGCC
CATCGACCAGGTCAACTTTGTAGTGTGCCAACTCTTTGCCTTGCTAGCAGC
CATTTGGTTTCGAACTTATCTACATTCAAGCAAAACTAGCTCTTTTATAAG
ACATGTAGTTGCTACCCTTTTGGGCCTTTATCTTGCACTTTTTTGCTTTGGA
TGGTATGCCTTACACTTTCTTGTACAAAGTGGAATTTCCTACTGTATCATG
ATCATCATAGGAGTGGAGAACATGCACAATTACTGCTTTGTGTTTGCTCTG
GGATACCTCACAGTGTGCCAAGTTACTCGAGTCTATATCTTTGACTATGGA
CAATATTCTGCTGATTTTTCAGGCCCAATGATGATCATTACTCAGAAGATC
ACTAGTTTGGCTTGCGAAATTCATGATGGGATGTTTCGGAAGGATGAAGA
ACTGACTTCCTCACAGAGGGATTTAGCTGTAAGGCGCATGCCAAGCTTAC
TGGAGTATTTGAGTTACAACTGTAACTTCATGGGGATCCTGGCAGGCCCA
CTTTGCTCTTACAAAGACTACATTACTTTCATTGAAGGCAGATCATACCA
TATCACACAATCTGGTGAAAATGGAAAAGAAGAGACACAGTATGAAAGA
ACAGAGCCATCTCCAAATACTGCGGTTGTTCAGAAGCTCTTAGTTTGTGG
GCTGTCCTTGTTATTTCACTTGACCATCTGTACAACATTACCTGTGGAGT
ACAACATTGATGAGCATTTTCAAGCTACAGCTTCGTGGCCAACAAAGATT
ATCTATCTGTATATCTCTCTTTTGGCTGCCAGACCCAAATACTATTTTGCA
TGGACGCTAGCTGATGCCATTAATAATGCTGCAGGCTTTGGTTTCAGAG
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GGTATGACGAAAATGGAGCAGCTCGCTGGGACTTAATTTCCAATTTGAGA
ATTCAACAAATAGAGATGTCAACAAGTTTCAAGATGTTTCTTGATAATTG
GAATATTCAGACAGCTCTTTGGCTCAAAAGGGTGTGTTATGAACGAACCT
CCTTCAGTCCAACTATCCAGACGTTCATTCTCTCTGCCATTTGGCACGGGG
TATACCCAGGATATTATCTAACGTTTCTAACAGGGGTGTTAATGACATTA
GCAGCAAGAGCTATGAGAAATAACTTTAGACATTATTTCATTGAACCTTC
CCAACTGAAATTATTTTATGATGTTATAACATGGATAGTAACTCAAGTAG
CAATAAGTTACACAGTTGTGCCATTTGTGCTTCTTTCTATAAAACCATCAC
TCACGTTTTACAGCTCCTGGTATTATTGCCTGCACATTCTTGGTATCTTAGT
ATTATTGTTGTTGCCAGTGAAAAAAACTCAAAGAAGAAAGAATACACATG
AAAACATTCAGCTCTCACAATCCAAAAAGTTTGATGAAGGAGAAAATTCT
TTGGGACAGAACAGTTTTTCTACAACAAACAATGTTTGCAATCAGAATCA
AGAAATAGCCTCGAGACATTCATCACTAAAGCAGTGATCGGGAAGGCTCT
GAGGGCTGTTTTTTTTTTTTGATGTTAACAGAAACCAATCTTAGCACCTTT
TCAAGGGGTTTGAGTTTGTTGGAAAAGCAGTTAACTGGGGGGAAATGGAC
AGTTATAGATAAGGAATTTCCTGTACACCAGATTGGAAATGGAGTGAAAC
AAGCCCTCCCATGCCATGTCCCCGTGGGCCACGCCTTATGTAAGAATATTT
CCATATTTCAGTGGGCACTCCCAACCTCAGCACTTGTCCGTAGGGTCACA
CGCGTGCCCTGTTGCTGAATGTATGTTGCGTATCCCAAGGCACTGAAGAG
GTGGAAAAATAATCGTGTCAATCTGGATGATAGAGAGAAATTAACTTTTC
CAAATGAATGTCTTGCCTTAAACCCTCTATTTCCTAAAATATTGTTCCTAA
ATGGTATTTTCAAGTGTAATATTGTGAGAACGCTACTGCAGTAGTTGATGT
TGTGTGCTGTAAAGGATTTTAGGAGGAATTTGAAACAGGATATTTAAGAG
TGTGGATATTTTTAAAATGCAATAAACATCTCAGTATTTGAAGGGTTTTCT
TAAAGTATGTCAAATGACTACAATCCATAGTGAAACTGTAAACAGTAATG
GACGCCAAATTATAGGTAGCTGATTTTGCTGGAGAGTTTAATTACCTTGTG
CAGTCAAAGAGCGCTTCCAGAAGGAATCTCTTAAAACATAATGAGAGGTT
TGGTAATGTGATATTTTAAGCTTATTCTTTTTCTTAAAAGAGAGAGGTGAC
GAAGGAAGGCAGGAATGAAGAAGCACTGCGTGGCCTCCGGTGGAATGCA
CGGGGCACAGCCGCGACTCTGCAGGCAGCTTCCCCCCCATGCCAGGGCTC
TGCGCCGTCATGTGAGACTTAAAAAAAAAGTTGAATGACTTCGTGATACT
TTGGACTTCTAAATTAAATTTATCAGGCATAAATTATGTAGAATTAGAGG
CTTTGAAAATAATACTGGTAGGTTGCTCAAAGGTTTTGAAAGAGAAATCG
CTAGGTAGGTTACTATCTGGCTAATCCATTTCTTATCCTTGACAATTTAAT
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TCATATTTGGGAAACTTTTAGGGAAATGAAAAATAAAAGTCACTGAGTCT
GGGTGACATTTTTTAAGAATAATATAAATTCAGTTTCAAACTCTTCTCACA
TTAAAATTTTGCTGTGAACTCTTACTAAAATGAGTTTTAGGTTCTGTAAGT
GGAAAAATGTGCTTTTATTTTATGGGCCATTTTTACCACAACTAATCTTG
CCTTGGATTACTAAGCATCTCCTGCGATCCCACAGAGGACTGTGGTGGCC
ACAGGAGCTGAAAGCAGAAGAGTGGGATTTGATGCCAGGCAGTGGAGTG
GCCTCAGCCCCAGATTGTACCTCCTGCCCTGTAGGAGGGGAGGGGGCA
AAGCCTTCTGACTTCACCTTTGTTTGACCTATGTATGGAACTTACTTTTACT
TTTTGCCTTAAATTTTTAATGAAATGCAAATTTTCTGTGATGGGGTTCTCT
CTCTCTTTTTTTCGGGGGGTGGAGTCACTAATAAATTTGCAAATGAAGTTA
AAGACAAGGCAACCATCTGGCTTATGCTATATAATACTTCATTTAAAGAA
GAAAGGAAAAGCAAATGCACTTGCAGCTTTTGAGGTCTCAGCAAAAATG
GGCATGTGTCTTTTTTGAAGTTTAGAAATATCCTAATCTATTTTTATTTATC
TAAAAGTAAGTGTTTTCCGGCTGATAAGGCTAACCCTACCCAGGAAAGGA
TTGATAACTAAATAAATTTCCTCTGTTTTCCCATGCATTGAAATTATGTTG
GCTGAGCATGGTGGCTCACACCTGTAATCCTAGCACTTTGGGAGGCCGAG
GTGGGCGGATCACTTGAGGTCAGGAGTTGGAGACCAGCCTGGCCAACGT
GGTGAATCCCCGTCTCTACTGAAAACACAAAAATTAGACGGGCATGGTGG
CGCACACCTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATTGCT
TGAACCTGGGAGGTGGAGGTTGCAGTGAGCTAAAATTGTGCCACTGCACT
CCAGCCTGGGTGACAGAGGAAGACTCCGTCTCAC 
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LPEAT2 (AGPAT7: AYTL3) 
Chromosome 15   
Gene ID: 254531  
mRNA sequence: NM_153613.2 
 
Primers used in this study: 
Primer 1 sequence: LI1F and LI1R. Product length = 167 bp 
Primer 2 sequence: LJ1F and LJ1R. Product length = 198 bp 
Primer 3 sequence: LK1F and LK1R. Product length = 167 bp 
 
Primers used in literature: 
hLPEAT 2 primer sequence. Product length = 370 bp. Ye, Guang-Ming et al., 2005 
hLPEAT 2 primer sequence; location 212. Product length = 101 bp. Cao et al., 2008. 
 
AGCGCCGCCGCCGCCGCTGCTGCAGCAGCAGCTGCTCTGCAGAGTGGTGG
CCGGGGCCAGGGCCGGGGTGCCCTCCCTCCCACCTTCTCCCGCCATGAGC
CAGGGAAGTCCGGGGGACTGGGCCCCCCTAGATCCCACCCCCGGACCCCC
AGCATCCCCCAACCCCTTCGTGCATGAGTTACATCTCTCTCGCCTCCAGAG
GGTTAAGTTCTGCCTCCTGGGGGCATTGCTGGCCCCCATCCGAGTGCTTCT
GGCCTTTATCGTCCTCTTTCTCCTCTGGCCCTTTGCCTGGCTTCAAGTGGC
CGGTCTTAGTGAGGAGCAGCTTCAGGAGCCAATTACAGGATGGAGGAA
GACTGTGTGCCACAACGGGGTGCTAGGCCTGAGCCGCCTGCTGTTTTTCCT
GCTGGGCTTCCTCCGGATTCGCGTTCGTGGCCAGCGAGCCTCTCGCCTTCA
AGCCCCTGTCCTTGTTGCTGCCCCACACTCCACTTTCTTTGACCCCATTG
TTCTGCTGCCCTGTGACCTGCCCAAAGTTGTGTCCCGAGCTGAGAACCTTT
CCGTTCCTGTCATTGGAGCCCTTCTTCGATTCAACCAAGCCATCCTGGTA
TCCCGGCATGACCCGGCTTCTCGACGCAGAGTGGTGGAGGAGGTCCGAAG
GCGGGCCACCTCAGGAGGCAAGTGGCCGCAGGTGCTATTCTTTCCTGAGG
GCACCTGTTCCAACAAGAAGGCTTTGCTTAAGTTCAAACCAGGAGCCTT
CATCGCAGGGGTGCCTGTGCAGCCTGTCCTCATCCGCTACCCCAACAGTC
TGGACACCACCAGCTGGGCATGGAGGGGTCCTGGAGTACTCAAAGTCCTC
TGGCTCACAGCCTCTCAGCCCTGCAGCATTGTGGATGTGGAGTTCCTTCCT
GTGTATCACCCCAGCCCTGAGGAGAGCAGGGACCCCACCCTCTATGCCAA
CAATGTTCAGAGGGTCATGGCACAGGCTCTGGGCATTCCAGCCACCGAAT
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GTGAGTTTGTAGGGAGCTTACCTGTGATTGTGGTGGGCCGGCTGAAGGTG
GCGTTGGAACCACAGCTCTGGGAACTGGGAAAAGTGCTTCGGAAGGCT
GGGCTGTCCGCTGGCTATGTGGACGCTGGGGCAGAGCCAGGCCGGAGTC
GAATGATCAGCCAGGAAGAGTTTGCCAGGCAGCTACAGCTCTCTGATCCT
CAGACGGTGGCTGGTGCCTTTGGCTACTTCCAGCAGGATACCAAGGGTT
TGGTGGACTTCCGAGATGTGGCCCTTGCACTAGCAGCTCTGGATGGGGGC
AGGAGCCTGGAAGAGCTAACTCGTCTGGCCTTTGAGCTCTTTGCTGAA
GAGCAAGCAGAGGGTCCCAACCGCCTGCTGTACAAAGACGGCTTCAGCA
CCATCCTGCACCTGCTGCTGGGTTCACCCCACCCTGCTGCCACAGCTTTGC
ATGCTGAGCTGTGCCAGGCAGGATCCAGCCAAGGCCTCTCCCTCTGTCAG
TTCCAGAACTTCTCCCTCCATGACCCACTCTATGGGAAACTCTTCAGCACC
TACCTGCGCCCCCCACACACCTCTCGAGGCACCTCCCAGACACCAAATGC
CTCATCCCCAGGCAACCCCACTGCTCTGGCCAATGGGACTGTGCAAGCAC
CCAAGCAGAAGGGAGACTGAGTGCCTCAGCCTCTCACCCCCTCCTCCTC
AGGGCAGCGCTAGGGGCCTCCCCTATGCCTCAGCCCCATCTCTGCTCCTGT
TTGAATTTTGTTATTGTTGTTTGGTTGTTGTTTTTTTAAGTTGATTTTAATTT
TTTGTTTGGTTGATTTTTTTGTAAAAAACTATTTTATATATAAATATAAATC
TATATCTATATCTATTAAAAAAAATGAAGTCCAGTCATATTGATGTTACCA
TTA 
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RuBisCO 
Senecio Vulgaris Ribulose-1,5-bisphosphate carboxylase oxygenase (RuBisCO) small 
subunit mRNA sequence and primers. 
dbEST Id:       37236834   
EST name:       SV_CP_06_F12 
GenBank Acc:    DY664462    
GenBank gi:     89508666 
 
 
Primers used in this study: 
Primer sequence: RuBisCOF and RuBisCOR. Product length = 83 bp. 
 
TGGATCCCCCGGGCTGCAGGTAGAAGTCCATTCCTAAGTAACAACTACTA
AAATGGCTTCAATCTCTTCTTCCGCGGTCGCCACTGTTAGCAGGACCCCTG
CTCAAGCTAGCATGGTCGCTCCATTTACCGGTCTTAAGTCTAACGTCGCCT
TCCCAGTTACCAAGAAGGCTAACAATGACTTCTCCACCCTTCCCTCTAACG
GCGGAAGAGTCCAATGCATGAAGGTGTGGCCACCTTTGGGTTTGAAGAAG
TACGAGACCCTTTCATACCTTCCACCATTGACCGAAATCCAATTGGCTAA
GGAAGTCGACTACCTTCTCCGCAACAAGTGGGTTCCTTGTTTGGAATTCG
AAGTCGAGCACGGTTTCGTTTACCGTGAGCACGGCAACACCCCCGGATAC
TATGACGGAAGATACTGGACAATGTGGAAGTTGCCTATGTTCGGGTGCAC
CGACTCCGCTCAAGTGTTGAAGGAGCTAGCTGAGTGCAAGAAGGAGTA
CCCTGAGGCCTTCATCCGTATCATCGGATTCGACAACGTTCGTCAAGTG
CAATGTGTCAGTTTCATCGCCTCCAAGCCAGCTGGCTACTAAGCAACAAA
ATTTTCTATTTCTACCGGAACTTTCGATTAACCCACTTATAACGAGTAGGG
CTTACTTGAATGTTTAGGGTTTTGTTATATTTTTTTTTCGTTTTAAATTTAT
CATTTTCCTAATTGTCTTGTAATTCATTTCGTTGTTTGTTTTCGGATTTCCG
AT 
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APPENDIX 2 – Composition of buffers 
 
TRIS Borate–EDTA buffer (TBE) 
(pH 8.0) 
2 mM EDTA,  
90 mM Boric acid 
90 mM Tris-base 
 
Triton X-100 Extraction buffer 
(pH 7.6) 
10 mM Tris-base 
150 mM NaCl,  
1 mM EDTA  
1 mM EGTA 
1 % Triton X-100 
Protease inhibitor cocktail tablet 
 
MES buffered Saline (MBS) 
(pH 6.5) 
150 mM NaCl,  
20 mM MES 
1 % Triton X-100 
Protease inhibitor cocktail tablet 
 
XT-MOPS running buffer  
(pH 7.7) 
1 M MOPS 
1 M Tris-base 
69.3 mM SDS 
20.5 mM EDTA 
2L Transfer buffer  
(pH 7.2) 
6.06 g Tris-base 
28.8 g Glycine 
200 ml methanol 
 
Tris-buffered Saline (TBS) 
(pH 7.2-7.4) 
20 mM Tris-base 
150 mM NaCl 
For TBS-T add 0.1 % Tween 20  
 
Red Blood Cell Lysis buffer (x10) 
(pH 7.2-7.4) 
1.5 M NH4Cl 
100 nM KHCO3 
10 nM Na4EDTA 
 
50 ml Denaturing Solution 
25 g guanidinium thiocyante  
1.76 ml 0.75 M sodium citrate (pH 
7.0), 2.64 ml 10 % sarkosyl 
 
The working Denaturing solution can 
be prepared by adding 72 μL of 98 % 
2-mercaptoethanol to 10ml of stock 
solution 
 
 
 
 
